CA3236111A1 - Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide - Google Patents
Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide Download PDFInfo
- Publication number
- CA3236111A1 CA3236111A1 CA3236111A CA3236111A CA3236111A1 CA 3236111 A1 CA3236111 A1 CA 3236111A1 CA 3236111 A CA3236111 A CA 3236111A CA 3236111 A CA3236111 A CA 3236111A CA 3236111 A1 CA3236111 A1 CA 3236111A1
- Authority
- CA
- Canada
- Prior art keywords
- mosunetuzumab
- lenalidomide
- dosing
- dose
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229950009794 mosunetuzumab Drugs 0.000 title claims abstract description 726
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 title claims abstract description 457
- 229960004942 lenalidomide Drugs 0.000 title claims abstract description 451
- 201000003444 follicular lymphoma Diseases 0.000 title claims abstract description 267
- 238000011282 treatment Methods 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims description 344
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 186
- 239000003246 corticosteroid Substances 0.000 claims description 156
- 230000004044 response Effects 0.000 claims description 126
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 108
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 108
- 206010028980 Neoplasm Diseases 0.000 claims description 87
- 238000011342 chemoimmunotherapy Methods 0.000 claims description 71
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims description 68
- 208000004235 neutropenia Diseases 0.000 claims description 57
- 229960004641 rituximab Drugs 0.000 claims description 44
- 230000009467 reduction Effects 0.000 claims description 42
- 230000002195 synergetic effect Effects 0.000 claims description 41
- 229960003347 obinutuzumab Drugs 0.000 claims description 37
- 238000002560 therapeutic procedure Methods 0.000 claims description 35
- 238000002054 transplantation Methods 0.000 claims description 31
- 238000002659 cell therapy Methods 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 230000036961 partial effect Effects 0.000 claims description 24
- 238000009169 immunotherapy Methods 0.000 claims description 22
- 238000002591 computed tomography Methods 0.000 claims description 21
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 21
- 229960003957 dexamethasone Drugs 0.000 claims description 20
- 230000003902 lesion Effects 0.000 claims description 19
- 206010061818 Disease progression Diseases 0.000 claims description 17
- 230000005750 disease progression Effects 0.000 claims description 17
- 238000009121 systemic therapy Methods 0.000 claims description 17
- 230000000977 initiatory effect Effects 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 10
- 208000019420 lymphoid neoplasm Diseases 0.000 claims description 8
- 230000008520 organization Effects 0.000 claims description 8
- 230000003325 follicular Effects 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 60
- 239000003814 drug Substances 0.000 description 57
- 230000002411 adverse Effects 0.000 description 45
- 230000027455 binding Effects 0.000 description 44
- 238000004519 manufacturing process Methods 0.000 description 37
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 33
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 33
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 33
- 201000011510 cancer Diseases 0.000 description 31
- 208000035475 disorder Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 25
- 238000002648 combination therapy Methods 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 238000001990 intravenous administration Methods 0.000 description 20
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 19
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 238000009097 single-agent therapy Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229940127089 cytotoxic agent Drugs 0.000 description 15
- 230000002062 proliferating effect Effects 0.000 description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 13
- 206010025323 Lymphomas Diseases 0.000 description 13
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 12
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 description 11
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229960004618 prednisone Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 10
- 208000002633 Febrile Neutropenia Diseases 0.000 description 10
- 239000002050 international nonproprietary name Substances 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 208000037821 progressive disease Diseases 0.000 description 10
- 229960004397 cyclophosphamide Drugs 0.000 description 9
- 239000002254 cytotoxic agent Substances 0.000 description 9
- 231100000599 cytotoxic agent Toxicity 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229960004528 vincristine Drugs 0.000 description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 206010037868 Rash maculo-papular Diseases 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 231100000517 death Toxicity 0.000 description 8
- 238000009093 first-line therapy Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229960004679 doxorubicin Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229960003989 tocilizumab Drugs 0.000 description 7
- 208000003950 B-cell lymphoma Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 6
- 208000002151 Pleural effusion Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229940124572 antihypotensive agent Drugs 0.000 description 5
- 229950002826 canertinib Drugs 0.000 description 5
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 238000011284 combination treatment Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000009101 premedication Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000037922 refractory disease Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000010380 tumor lysis syndrome Diseases 0.000 description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 5
- 239000005526 vasoconstrictor agent Substances 0.000 description 5
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 4
- 208000037403 Blood and lymphatic system disease Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000010670 Hemic and Lymphatic disease Diseases 0.000 description 4
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 206010051792 Infusion related reaction Diseases 0.000 description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 208000025750 heavy chain disease Diseases 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 208000026278 immune system disease Diseases 0.000 description 4
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 4
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 206010043554 thrombocytopenia Diseases 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010003662 Atrial flutter Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 208000035451 General disorders and administration site conditions Diseases 0.000 description 3
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 3
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 208000019498 Skin and subcutaneous tissue disease Diseases 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 206010045169 Tumour flare Diseases 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960004584 methylprednisolone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 229950000578 vatalanib Drugs 0.000 description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 241000764238 Isis Species 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 208000029001 Mediastinal disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025316 Richter syndrome Diseases 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000690 anti-lymphoma Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000013059 antihormonal agent Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000009092 lines of therapy Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940060041 satralizumab Drugs 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 208000007617 thrombocytopenia 1 Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- JIZRGGUCOQKGQD-UHFFFAOYSA-N 2-nitrothiophene Chemical group [O-][N+](=O)C1=CC=CS1 JIZRGGUCOQKGQD-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- NFBCSWGEYDCCDW-UHFFFAOYSA-N 4-n-(3-methylphenyl)quinazoline-4,6-diamine Chemical compound CC1=CC=CC(NC=2C3=CC(N)=CC=C3N=CN=2)=C1 NFBCSWGEYDCCDW-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- RONQPWQYDRPRGG-UHFFFAOYSA-N 5,6-bis(4-fluoroanilino)isoindole-1,3-dione Chemical compound C1=CC(F)=CC=C1NC(C(=C1)NC=2C=CC(F)=CC=2)=CC2=C1C(=O)NC2=O RONQPWQYDRPRGG-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 description 1
- 108010093667 ALX-0061 Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 208000016403 Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 201000000439 HCL-V Diseases 0.000 description 1
- 208000035481 HHV-8-associated multicentric Castleman disease Diseases 0.000 description 1
- 208000010956 Hairy cell leukemia variant Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 208000036642 Metabolism and nutrition disease Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
- 101100523539 Mus musculus Raf1 gene Proteins 0.000 description 1
- 208000029027 Musculoskeletal and connective tissue disease Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000024588 Primary cutaneous follicle center lymphoma Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000011783 Splenic diffuse red pulp small B-cell lymphoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229940126624 Tacatuzumab tetraxetan Drugs 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 206010045171 Tumour pain Diseases 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- JZMHCANOTJFLQJ-IEQBYLOXSA-A affinitac Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JZMHCANOTJFLQJ-IEQBYLOXSA-A 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940044684 anti-microtubule agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- NMYKBZSMOUFOJV-FJSWQEPZSA-N aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229950002882 aselizumab Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960005522 bivatuzumab mertansine Drugs 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 208000011782 diffuse large B-cell lymphoma of the central nervous system Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002143 encouraging effect Effects 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229950004292 erlizumab Drugs 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950001563 felvizumab Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 229950004923 fontolizumab Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229940044700 hylenex Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- OMEUGRCNAZNQLN-UHFFFAOYSA-N isis 5132 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(S)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(O)C1 OMEUGRCNAZNQLN-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229940006990 lenalidomide 20 mg Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- 208000015325 multicentric Castleman disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- ZKKVUIPXPPDIRD-UHFFFAOYSA-N n-(3-chlorophenyl)quinazolin-4-amine Chemical compound ClC1=CC=CC(NC=2C3=CC=CC=C3N=CN=2)=C1 ZKKVUIPXPPDIRD-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- JZZFDCXSFTVOJY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide;hydron;dichloride Chemical compound Cl.Cl.C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 JZZFDCXSFTVOJY-UHFFFAOYSA-N 0.000 description 1
- YCKACRNXVWJWBX-UHFFFAOYSA-N n-phenyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical class N=1C=NC=2NC=CC=2C=1NC1=CC=CC=C1 YCKACRNXVWJWBX-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229950004406 porfiromycin Drugs 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000008518 pyridopyrimidines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- 229950009092 rovelizumab Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950005374 ruplizumab Drugs 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000006576 solitary osseous plasmacytoma Diseases 0.000 description 1
- 229950006551 sontuzumab Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229950001072 tadocizumab Drugs 0.000 description 1
- 229940121503 tafasitamab Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950004218 talizumab Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229950001802 toralizumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229950003364 tucotuzumab celmoleukin Drugs 0.000 description 1
- 108700008509 tucotuzumab celmoleukin Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229950007269 vobarilizumab Drugs 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having R/R FL by administering a combination of mosunetuzumab and lenalidomide.
Description
METHODS FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA WITH
MOSUNETUZUMAB AND LENALIDOMIDE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII
format and is hereby incorporated by reference in its entirety. Said ASCII
copy, created on October 29, 2021, is named 50474-262W02 Sequence Listing 10 28 21 ST25 and is 23,600 bytes in size.
FIELD OF THE INVENTION
The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to combination treatment of subjects having R/R FL, who may have received prior therapy with an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab) or other treatment, by administration of mosunetuzumab and lenalidomide.
BACKGROUND
Cancers are characterized by the uncontrolled growth of cell subpopulations.
Cancers are the leading cause of death in the developed world and the second leading cause of death in developing countries, with over 14 million new cancer cases diagnosed and over eight million cancer deaths occurring each year. Indolent cancers can also severely effect quality of life. Cancer care thus represents a significant and ever-increasing societal burden.
B cell proliferative disorders are a leading cause of cancer-related deaths.
For example, non-Hodgkin's lymphoma (NHL) advances quickly and is fatal if untreated. In the United States, B-cell lymphomas constitute approximately 80%-85% of all cases of NHL. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL accounting for approximately 30%-40% of all NHL diagnosis, followed by follicular lymphoma (FL; 20%-25% of all NHL
diagnosis) and mantle cell lymphoma (MCL; 6%-10% of all NHL diagnosis). B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with approximately 15,000 new cases per year in the United States (American Cancer Society 2015).
Lymphomas of B-cell origin constitute a diverse set of neoplasms within the larger context of non-Hodgkin lymphoma (NHL). Follicular lymphoma (FL) is the most common subtype of indolent NHL (Al-Hamandi et al. 2015). Regardless of the biologic and clinical heterogeneity of B-cell lymphomas, patients with advanced-stage B-cell malignancies are typically treated, initially, with intensive cytotoxic chemotherapy combined with monoclonal antibodies (mAbs) such as the anti-CD20 MAb, rituximab (Ri-ruxANO, MABTHERAO). Although durable responses can be achieved in some patients, the majority of patients will ultimately experience progressive or relapsed disease.
FL remains an incurable disease with currently available therapies. The addition of rituximab to commonly used induction chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); cyclophosphamide, vincristine, and prednisone (CVP);
fludarabine; or bendamustine (Zelenetz et al. 2014, Forstpointer et al. 2006), followed by rituximab maintenance therapy led to prolonged remission and improved patient outcomes. However, treatment with said therapies only result in partial, but not complete, responses in the majority of patients with relapsed or refractory (R/R) FL. As such, multiply relapsed FL remains a disease with a high, unmet medical need for which improved therapies are needed.
SUMMARY OF THE INVENTION
The present invention relates to methods of treating a subject having a relapsed and/or refractory folliouiar lymphoma (FL) by administration of rnosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a 11/F1 FL that is Rill to at least one prior syste,mic therapy which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g,, rituximab or obinutuzurnab) or other treatment.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen (e.g., R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone), R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP
(cyclophosphamide, vincristine, and prednisone), or BR (bendamustine and rituximab)) (e.g., at least one chemo-immunotherapy that included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab)).
In some embodiments, the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood.
2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy. In some embodiments, the subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014;
32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3
MOSUNETUZUMAB AND LENALIDOMIDE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII
format and is hereby incorporated by reference in its entirety. Said ASCII
copy, created on October 29, 2021, is named 50474-262W02 Sequence Listing 10 28 21 ST25 and is 23,600 bytes in size.
FIELD OF THE INVENTION
The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to combination treatment of subjects having R/R FL, who may have received prior therapy with an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab) or other treatment, by administration of mosunetuzumab and lenalidomide.
BACKGROUND
Cancers are characterized by the uncontrolled growth of cell subpopulations.
Cancers are the leading cause of death in the developed world and the second leading cause of death in developing countries, with over 14 million new cancer cases diagnosed and over eight million cancer deaths occurring each year. Indolent cancers can also severely effect quality of life. Cancer care thus represents a significant and ever-increasing societal burden.
B cell proliferative disorders are a leading cause of cancer-related deaths.
For example, non-Hodgkin's lymphoma (NHL) advances quickly and is fatal if untreated. In the United States, B-cell lymphomas constitute approximately 80%-85% of all cases of NHL. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL accounting for approximately 30%-40% of all NHL diagnosis, followed by follicular lymphoma (FL; 20%-25% of all NHL
diagnosis) and mantle cell lymphoma (MCL; 6%-10% of all NHL diagnosis). B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with approximately 15,000 new cases per year in the United States (American Cancer Society 2015).
Lymphomas of B-cell origin constitute a diverse set of neoplasms within the larger context of non-Hodgkin lymphoma (NHL). Follicular lymphoma (FL) is the most common subtype of indolent NHL (Al-Hamandi et al. 2015). Regardless of the biologic and clinical heterogeneity of B-cell lymphomas, patients with advanced-stage B-cell malignancies are typically treated, initially, with intensive cytotoxic chemotherapy combined with monoclonal antibodies (mAbs) such as the anti-CD20 MAb, rituximab (Ri-ruxANO, MABTHERAO). Although durable responses can be achieved in some patients, the majority of patients will ultimately experience progressive or relapsed disease.
FL remains an incurable disease with currently available therapies. The addition of rituximab to commonly used induction chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); cyclophosphamide, vincristine, and prednisone (CVP);
fludarabine; or bendamustine (Zelenetz et al. 2014, Forstpointer et al. 2006), followed by rituximab maintenance therapy led to prolonged remission and improved patient outcomes. However, treatment with said therapies only result in partial, but not complete, responses in the majority of patients with relapsed or refractory (R/R) FL. As such, multiply relapsed FL remains a disease with a high, unmet medical need for which improved therapies are needed.
SUMMARY OF THE INVENTION
The present invention relates to methods of treating a subject having a relapsed and/or refractory folliouiar lymphoma (FL) by administration of rnosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a 11/F1 FL that is Rill to at least one prior syste,mic therapy which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g,, rituximab or obinutuzurnab) or other treatment.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen (e.g., R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone), R-CHOP
(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP
(cyclophosphamide, vincristine, and prednisone), or BR (bendamustine and rituximab)) (e.g., at least one chemo-immunotherapy that included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab)).
In some embodiments, the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood.
2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy. In some embodiments, the subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014;
32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3
2 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about
3.5 mg, or about
4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or
5.0 mg to 10.0 mg;
e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg) and the Cl D3 is between 0.2 mg to 50.0 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the C2D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 rug to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about
e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg) and the Cl D3 is between 0.2 mg to 50.0 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the C2D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 rug to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about
6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg);
and (b) the C2D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl D1 and Cl D2 are each less than the Cl D3. In some embodiments, the Cl Dl and Cl D2 are about equal. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250% (e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to about 200%, the Cl D2 is greater than the Cl Dl by about 50% to about 175%, the Cl D2 is greater than the Cl Dl by about 50% to about 150%, the Cl D2 is greater than the Cl Dl by about 50% to about 125%, the Cl D2 is greater than the Cl Dl by about 50% to about 100%, or the Cl D2 is greater than the Cl Dl by about 50%
to about 75%; e.g., the Cl D2 is greater than the Cl Dl by about 50%, the Cl D2 is greater than the Cl Dl by about 100%, the Cl D2 is greater than the Cl Dl by about 150%, the Cl D2 is greater than the Cl Dl by about 200%, or the Cl D2 is greater than the Cl Dl by about 250%).
In some embodiments, (a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, the Cl D3 is 4.2 mg, and the C2D1 is 4.2 mg; (b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, the Cl D3 is 3.0 mg, and the C2D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of the second dosing cycle is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
In some embodiments, the dosing regimen comprises one or more additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, ten dosing cycles, or more). In some embodiments, the dosing regimen comprises one to ten additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, or ten dosing cycles). In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of each of the one or more additional dosing cycles is 28 days ( 1 day). In some embodiments, each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab. In some embodiments, the method comprises administering to the subject each additional dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles. In some embodiments, each additional dose of mosunetuzumab is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg). In some embodiments, the dosing regimen comprises twelve dosing cycles comprising mosunetuzumab and eleven dosing cycles comprising lenalidomide.
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1 .7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the Cl D3 is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the Cl D3, and is between 0.2 mg to 50 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0
and (b) the C2D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl D1 and Cl D2 are each less than the Cl D3. In some embodiments, the Cl Dl and Cl D2 are about equal. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250% (e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to about 200%, the Cl D2 is greater than the Cl Dl by about 50% to about 175%, the Cl D2 is greater than the Cl Dl by about 50% to about 150%, the Cl D2 is greater than the Cl Dl by about 50% to about 125%, the Cl D2 is greater than the Cl Dl by about 50% to about 100%, or the Cl D2 is greater than the Cl Dl by about 50%
to about 75%; e.g., the Cl D2 is greater than the Cl Dl by about 50%, the Cl D2 is greater than the Cl Dl by about 100%, the Cl D2 is greater than the Cl Dl by about 150%, the Cl D2 is greater than the Cl Dl by about 200%, or the Cl D2 is greater than the Cl Dl by about 250%).
In some embodiments, (a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, the Cl D3 is 4.2 mg, and the C2D1 is 4.2 mg; (b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, the Cl D3 is 3.0 mg, and the C2D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of the second dosing cycle is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
In some embodiments, the dosing regimen comprises one or more additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, ten dosing cycles, or more). In some embodiments, the dosing regimen comprises one to ten additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, or ten dosing cycles). In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of each of the one or more additional dosing cycles is 28 days ( 1 day). In some embodiments, each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab. In some embodiments, the method comprises administering to the subject each additional dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles. In some embodiments, each additional dose of mosunetuzumab is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg). In some embodiments, the dosing regimen comprises twelve dosing cycles comprising mosunetuzumab and eleven dosing cycles comprising lenalidomide.
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1 .7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the Cl D3 is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the Cl D3, and is between 0.2 mg to 50 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0
7
8 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl Dl and Cl D2 are each less than the Cl D3. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250%
(e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl Dl and Cl D2 are each less than the Cl D3. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250%
(e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to
9 about 200%, the C1D2 is greater than the Cl Dl by about 50% to about 175%, the C1D2 is greater than the Cl Dl by about 50% to about 150%, the C1D2 is greater than the Cl Dl by about 50% to about 125%, the C1D2 is greater than the Cl Dl by about 50% to about 100%, or the C1D2 is greater than the Cl Dl by about 50% to about 75%; e.g., the C1D2 is greater than the Cl Dl by about 50%, the C1D2 is greater than the Cl Dl by about 100%, the C1D2 is greater than the Cl Dl by about 150%, the C1D2 is greater than the Cl Dl by about 200%, or the C1D2 is greater than the Cl Dl by about 250%).
In some embodiments, (a) the Cl Dl is 0.8 mg, the C1D2 is 2.0 mg, the Cl D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg; (b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the C1D2 is 2.0 mg, the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the C1D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, mosunetuzumab is administered intravenously.
In some embodiments, lenalidomide is administered during the second and subsequent cycles. In some embodiments, lenalidomide is not administered during the first cycle. In some embodiments, lenalidomide is administered daily. In some embodiments, lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is administered at a dose of 20 mg. In some embodiments, lenalidomide is administered orally.
In some embodiments, the subject was previously treated with at least one anti-monoclonal antibody. In some embodiments, the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day) , and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the C1D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises administering 20 mg lenalidomide daily orally on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day (- 1 day) dosing cycle and eleven subsequent 28-day (- 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In some embodiments, the subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI;
Solal-Caligny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior obinutuzumab treatment, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy. In some embodiments, the subject has not been treated with obinutuzumab or rituximab for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Onco/ 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, the FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (02D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, each subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects.
In some embodiments, the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects.
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45% (e.g., less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0%
to about 50%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 45%, between about 30% to about 40%, between about 20% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 45%, or between about 25% to about 45%; e.g., about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 1%, or about 0%).
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 35%. In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%.
In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%; e.g., between 0% and 10%, between 0% and 9%, between 0% and 8%, between 0% and 7%, between 0% and 6%, between 0% and 5%, between 0% and 4%, between 0%
and 3%, between 0% and 2%, between 0% and 1%, between 1% and 3%, between 1%
and 5%, between 1% and 10%, between 3% and 5%, between 5% and 8%, between 5% and 10%, between 8% and 10%, . In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 5%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%.
In some embodiments, the incidence rate of neutropenia is less than 40% (e.g., less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than
In some embodiments, (a) the Cl Dl is 0.8 mg, the C1D2 is 2.0 mg, the Cl D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg; (b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the C1D2 is 2.0 mg, the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the C1D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, mosunetuzumab is administered intravenously.
In some embodiments, lenalidomide is administered during the second and subsequent cycles. In some embodiments, lenalidomide is not administered during the first cycle. In some embodiments, lenalidomide is administered daily. In some embodiments, lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is administered at a dose of 20 mg. In some embodiments, lenalidomide is administered orally.
In some embodiments, the subject was previously treated with at least one anti-monoclonal antibody. In some embodiments, the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day) , and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the C1D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises administering 20 mg lenalidomide daily orally on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day (- 1 day) dosing cycle and eleven subsequent 28-day (- 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In some embodiments, the subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI;
Solal-Caligny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior obinutuzumab treatment, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy. In some embodiments, the subject has not been treated with obinutuzumab or rituximab for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Onco/ 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, the FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (02D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, each subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects.
In some embodiments, the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects.
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45% (e.g., less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0%
to about 50%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 45%, between about 30% to about 40%, between about 20% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 45%, or between about 25% to about 45%; e.g., about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 1%, or about 0%).
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 35%. In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%.
In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%; e.g., between 0% and 10%, between 0% and 9%, between 0% and 8%, between 0% and 7%, between 0% and 6%, between 0% and 5%, between 0% and 4%, between 0%
and 3%, between 0% and 2%, between 0% and 1%, between 1% and 3%, between 1%
and 5%, between 1% and 10%, between 3% and 5%, between 5% and 8%, between 5% and 10%, between 8% and 10%, . In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 5%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%.
In some embodiments, the incidence rate of neutropenia is less than 40% (e.g., less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than
10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0% to about 40%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 40%, between about 30% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 40%, or between about 25% to about 40%; e.g., about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 3%, about 1%, or about 0%). In some embodiments, the incidence rate of neutropenia is less than 30%.
In some embodiments, the incidence rate of neutropenia is less than 20%.
In some embodiments, the overall response rate is at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 80%-100%, between 85-100%, between 87-100%, between 90-100%, between 95-100%, between 80%-90%, between 80-85%, between 85-97%, between 85-95%, between 85-90%, between 85-87%, between 90-95%, or between 93-97%; e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more). In some embodiments, the overall response rate is at least 90%. In some embodiments, the overall response rate is at least 95%. In some embodiments, the overall response rate is at least 99%.
In some embodiments, the complete response rate is at least 65% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more; e.g., between 65-100%, between 75-100%, between 85-100%, between 95-100%, between 65-90%, between 65-80%, between 65-70%, between 65-75%, or between 75-85%; e.g., about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 80%, about 85%, about 90%, or more). In some embodiments, the complete response rate is at least 75%. In some embodiments, the complete response rate is at least 85%.
In some embodiments, each subject was previously treated with at least one anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In some embodiments, the subject is human. In some embodiments, each subject in the population is human.
In some embodiments, the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT). In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40%
(e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, at least 45% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more;
e.g., between 45-100%, between 45-80%, between 45-60%, between 50-70%, between 55-65%, between 70-90%, between 70-80%, between 60-100%, between 80-100%; e.g., about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT).
In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours,
In some embodiments, the incidence rate of neutropenia is less than 20%.
In some embodiments, the overall response rate is at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 80%-100%, between 85-100%, between 87-100%, between 90-100%, between 95-100%, between 80%-90%, between 80-85%, between 85-97%, between 85-95%, between 85-90%, between 85-87%, between 90-95%, or between 93-97%; e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more). In some embodiments, the overall response rate is at least 90%. In some embodiments, the overall response rate is at least 95%. In some embodiments, the overall response rate is at least 99%.
In some embodiments, the complete response rate is at least 65% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more; e.g., between 65-100%, between 75-100%, between 85-100%, between 95-100%, between 65-90%, between 65-80%, between 65-70%, between 65-75%, or between 75-85%; e.g., about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 80%, about 85%, about 90%, or more). In some embodiments, the complete response rate is at least 75%. In some embodiments, the complete response rate is at least 85%.
In some embodiments, each subject was previously treated with at least one anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In some embodiments, the subject is human. In some embodiments, each subject in the population is human.
In some embodiments, the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT). In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40%
(e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, at least 45% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more;
e.g., between 45-100%, between 45-80%, between 45-60%, between 50-70%, between 55-65%, between 70-90%, between 70-80%, between 60-100%, between 80-100%; e.g., about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT).
In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours,
11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or
12 hours before administration of each additional dose of mosunetuzumab.
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A is a schematic of the study design described in Example 1 for the dosing regimen of the combination therapy of mosunetuzumab and lenalidomide. C=cycle; D=day;
FL=follicular lymphoma;
IMC=Internal Monitoring Committee; IV=intravenous; Len=lenalidomide;
Mosun=mosunetuzumab;
RP2D=recommended Phase ll dose; R/R=relapsed or refractory. Note: Cycle 1 is 21 days; Cycle 2 and onward is 28 days.
FIG. 1B is a schematic of the dosing regimen described in Example 1.
Lenalidomide begins at cycle 2 to minimize risk with mosunetuzumab initiation during Cycle 1, when CRS risk is highest.
FIG. 2 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun) or lenalidomide. Clinical cut-off date (CCOD) of April 5, 2021.
FIG. 3 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun). CCOD of April 5, 2021.
FIG. 4 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with lenalidomide. CCOD of April 5, 2021.
FIG. 5 is a swimlane plot showing onset of cytokine release syndrome (CRS) events in 5 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab described in Example 1.
Onset of Grade 1 or Grade 2 CRS is indicated by the light or dark diamond, respectively. CCOD of April 5, 2021.
FIG. 6 is a plot showing observed concentration-time data of mosunetuzumab (in combination with lenalidomide) from Study C041942 overlaid with popPK model simulations based on mosunetuzumab monotherapy data from Study G029781; Simulations were performed at 1/2/30 mg 04W. Filled red circles and lines represent the individual and mean observed mosunetuzumab concentration measurements from Study C041942 at 1/2/30 mg IV dose in combination with lenalidomide. Shaded area represents simulated concentration-time profile for mosunetuzumab th_ monotherapy based on the preliminary population PK model simulations k /5 95th prediction interval) which was developed based on clinical data from Study G029781.
FIG. 7 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 3 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun) or lenalidomide. CCOD of September 13, 2021.
FIG. 8 is a bar graph showing cytokine release syndrome (CRS) events by dosing cycle (C) and day (D) and by CRS Grade (Gr). Values below the graph show the dose of mosunetuzumab associated with each dosing cycle (C) and day (D). The Cl Dl dose is administered on Cycle 1 Day 1, the Cl D2 dose is administered on Cycle 1 Day 8, and the Cl D3 dose is administered on Cycle 1 Day 15. Subsequent doses are administered on Day 1 of each respective dosing cycle (C2, C3+).
FIG. 9 is a bar graph showing neutropenia and febrile neutropenia events by dosing cycle (C) and by neutropenia Grade (Gr). The number of patients who received granulocyte colony-stimulating factor (G-CSF) per dosing cycle (C) is shown below the graph.
FIG. 10 is a bar graph showing anti-tumor activity in patients with 1 diagnostic computed tomography (CT) scan at response assessment. The number above each bar shows %
change from baseline. Changes in tumor burden are quantified by comparing the sum of the product of the diameters (SPD) of target lesions to baseline measurements.
FIG. 11 is a bar graph showing the overall response rate (ORR), complete response rate (CR), and partial response rate (PR) in the 29 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab and 20 mg oral lenalidomide described in Example 3. Response rates are shown for 29 patients as of data cut-off date of September 13, 2021. 95% confidence interval (CI) for each response rate value is shown in parentheses below. Response rates are determined by positron emission tomography-computed tomography (PET-CT).
FIG. 12 is a swimlane plot showing duration of response in all 29 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab and 20 mg oral lenalidomide described in Example 3.
Duration of response are shown for 29 patients as of data cut-off date of September 13, 2021.
DETAILED DESCRIPTION
The present invention relates to methods of treating a subject having a relapsed and/or refractory (RJR) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a R/R FL that is RIR to at least one prior systemic therapy (e.g., one prior treatment with a ohemo-immunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-0D20 monoclonal antibody, e.g., rituxirnab or obinutuzumab) or other treatment. The method comprises administering the effective amount of mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg and the Cl D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
The invention is based, in part, on the discovery that combination therapy involving intravenous administration of mosunetuzumab and oral administration of lenalidomide over multiple dosing cycles (e.g., wherein the first dosing cycle is a step-up, fractionated dosing cycle) exhibits synergistic effects between mosunetuzumab and lenalidomide and can effectively treat subjects having relapsed/refractory (R/R) follicular lymphoma (FL), in particular those who are R/R to prior systemic therapy including an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab; e.g., R-CHOP) while maintaining an acceptable safety profile (e.g., with respect to frequency and severity of adverse events).
I. GENERAL TECHNIQUES
The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (F.M. Ausubel, et al. eds., (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson, B.D.
Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freshney, ed. (1987)); Oligonucleotide Synthesis (M.J. Gait, ed., 1984);
Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press;
Animal Cell Cufture (R.I. Freshney), ed., 1987); Introduction to Cell and Tissue Culture (J.P. Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B.
Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D.M.
Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Cabs, eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994);
Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); lmmunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P.
Finch, 1997); Antibodies: A
Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanotti and J.
D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT. DeVita et al., eds., J.B. Lippincott Company, 1993).
II. DEFINITIONS
It is to be understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.
As used herein, the singular form "a," "an," and "the" includes plural references unless indicated otherwise.
The term "about" as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, hematologic cancers, such as mature B cell cancers, excluding Hodgkin's lymphoma, but including non-Hodgkin's lymphoma (NHL), such as diffuse large B cell lymphoma (DLBCL), which may be relapsed or refractory DLBCL or a Richter's transformation. Other specific examples of cancer also include germinal-center B cell-like (GCB) diffuse large B cell lymphoma (DLBCL), activated B cell-like (ABC) DLBCL, follicular lymphoma (FL), transformed FL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), transformed MZL, high grade B-cell lymphoma, primary mediastinal (thymic) large B cell lymphoma (PMLBCL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), transformed LL, Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B cell lymphoma, hairy cell leukemia variant, heavy chain diseases, a heavy chain disease, y heavy chain disease, p heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma, pediatric nodal marginal zone lymphoma, pediatric follicular lymphoma, primary cutaneous follicle center lymphoma, T
cell/histiocyte rich large B cell lymphoma, primary DLBCL of the CNS, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, lymphomatoid granulomatosis, intravascular large B cell lymphoma, ALK-positive large B cell lymphoma, plasmablastic lymphoma, large B cell lymphoma arising in HHV8-associated multicentric Castleman disease, primary effusion lymphoma: B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma, and B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin's lymphoma. Further examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies, including B cell lymphomas.
More particular examples of such cancers include, but are not limited to, multiple myeloma (MM); low-grade/follicular NHL; small lymphocytic (SL) NHL; intermediate-grade/follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cleaved cell NHL; bulky disease NHL; AIDS-related lymphoma; and acute lymphoblastic leukemia (ALL);
chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD).
"Tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as referred to herein.
A "disorder" is any condition that would benefit from treatment including, but not limited to, chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
The terms ''cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer. In another embodiment, the cell proliferative disorder is a tumor.
The terms "B cell proliferative disorder" or "B cell malignancy" refer to disorders that are associated with some degree of abnormal B cell proliferation and include, for example, lymphomas, leukemias, myelomas, and myelodysplastic syndromes. In some instances, the B
cell proliferative disorder is a lymphoma, such as non-Hodgkin's lymphoma (NHL), including, for example, follicular lymphoma (FL) (e.g., a relapsed and/or refractory FL or transformed FL), diffuse large B cell lymphoma (DLBCL) (e.g., a relapsed or refractory DLBCL or a Richter's transformation), MCL, high grade B-cell lymphoma, or PMLBCL). In another embodiment, the B cell proliferative disorder is a leukemia, such as chronic lymphocytic leukemia (CLL). In one embodiment, the B-cell proliferative disorder is a relapsed and/or refractory FL.
By "Follicular Lymphoma International Prognostic Index" or "FLIFI" is meant a scoring system or index for determining prognostic risk of patients (e.g., with cancer; e.g., an NHL; e.g., a follicular lymphoma (FL)). FLIP! score ranges from 0-5, depending on how many of the five conditions or risk factors a patient may have among the following: (i) age 60 years; (ii) Ann Arbor stage III-IV; hemoglobin level 120 g/L; serum lactate dehydrogenase (LDH) level> upper limit of normal (ULN) (e.g., > 280 units/L); and (v) number of nodal sites > 4. See e.g., Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265. at Table 4.
As used herein, the terms "Ann Arbor staging" or "Ann Arbor stages" refers to a system for classification of stages of lymphoma (e.g., non-Hodgkin's lymphoma (NHL);
e.g., a DLBCL, an FL, an MCL, a high-grade B cell lymphoma, a PMLBCL, or a CLL). Lymphomas (e.g., NHLs) can be classified as one of four Ann Arbor stages. Stage I refers to lymphomas exhibiting involvement of a single lymph node region or of a single extralymphatic organ or site. Stage II refers to lymphomas exhibiting involvement of 2 or more lymph node regions on the same side of the diaphragm.
Stage III refers to lymphomas exhibiting involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of extralymphatic organ or site or by involvement of the spleen, or both. Stage IV refers to lymphomas exhibiting diffuse or disseminated involvement of 1 or more extralymphatic organs or tissues with or without associated lymph node enlargement. Liver involvement is always considered to be diffuse, and, thus, always considered Ann Arbor stage IV.
Lymphatic structures include the lymph nodes, thymus, spleen, appendix, Waldeyer's ring, and Peyer's patches. See Carbone, P.P. et al., Cancer Res. 1971, 31(11):1860-1861.
"Refractory disease" is defined as no complete remission to at least a first-line therapy. In one embodiment, refractory disease defined as no response to or relapse within 6 months of prior therapy. In one embodiment, refractory disease is characterized by one or more of the following: progressive disease (PD) as best response to first-line therapy, stable disease (SD) as best response after at least one first line therapy (e.g., at least one containing an anti CD20-directed therapy, e.g., including an anti-CD20 antibody, e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab), or partial response (PR) as best response, and biopsy-proven residual disease or disease progression after the partial response. "Relapsed disease" is defined as complete remission to first-line therapy. In one embodiment, disease relapse is proven by biopsy. In one embodiment, patients have relapsed after or failed to respond to at least one prior systemic treatment regimen (e.g., at least one containing an anti CD20-directed therapy, e.g., including an anti-CD20 antibody, e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab).
As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
As used herein, "delaying progression" of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a relapsed and/or refractory FL). This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late-stage cancer, such as development of metastasis, may be delayed.
By "reduce" or "inhibit" is meant the ability to cause an overall decrease, for example, of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater. For clarity the term includes also reduction to zero (or below the detection limit of the analytical method), i.e., complete abolishment or elimination. In certain embodiments, reduce or inhibit can refer to the reduction or inhibition of undesirable events, such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or central nervous system (CNS) toxicities, following treatment with mosunetuzumab using the step-up dosing regimen of the invention relative to unchanging, preset dosing with the target dose of mosunetuzumab. In other embodiments, reduce or inhibit can refer to effector function of an antibody that is mediated by the antibody Fc region, such effector functions specifically including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). In other embodiments reduce or inhibit can refer to the symptoms of the R/R FL being treated, the presence or size of metastases, or the size of the primary tumor. In yet other embodiments, reducing or inhibiting cancer relapse means to reduce or inhibit tumor or cancer relapse, or tumor or cancer progression.
As used herein, "administering" is meant a method of giving a dosage of a compound (e.g., a bispecific antibody, e.g., an anti-CD20/anti-CD3 bispecific antibody, e.g., mosunetuzumab) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition including a bispecific antibody (e.g., mosunetuzumab)) to a subject. The compounds and/or compositions utilized in the methods described herein can be administered intravenously (e.g., by intravenous infusion).
A "fixed" or "flat" dose of a therapeutic agent (e.g., a bispecific antibody) herein refers to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient. The fixed or flat dose is therefore not provided as a mg/kg dose or a mg/m2 dose, but rather as an absolute amount of the therapeutic agent (e.g., mg).
A "subject" or an "individual" is a mammal. Mammals include, but are not limited to, primates (e.g., humans and non-human primates such as monkeys), domesticated animals (e.g., cows, sheep, cats, dogs, and horses), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the subject or individual is a human.
"Individual response" or "response" can be assessed using any endpoint indicating a benefit to the subject, including, without limitation, (1) inhibition, to some extent, of disease progression (e.g., progression of a R/R FL, including slowing down and complete arrest; (2) a reduction in tumor size; (3) inhibition (i.e., reduction, slowing down or complete stopping) of cancer cell infiltration into adjacent peripheral organs and/or tissues; (4) inhibition (i.e., reduction, slowing down or complete stopping) of metastasis; (5) relief, to some extent, of one or more symptoms associated with the R/R FL; (6) increase or extend in the length of survival, including overall survival and progression-free survival; and/or (9) decreased mortality at a given point of time following treatment.
As used herein, "complete response" or "CR" refers to disappearance of all target lesions (i.e., all evidence of disease).
As used herein, "partial response" or "PR" refers to at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, or at least a 50%
decrease in the sum of the product of the diameters (SPD) of target lesions, taking as reference the baseline SPD.
As used herein, "objective response rate" (ORR) refers to the sum of complete response (CR) rate and partial response (PR) rate.
As used herein, "duration of objective response" (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression, or death from any cause within 30 days of the last dose of a treatment, whichever occurs first.
As used herein, "tumor burden" refers to the total amount of tumor (e.g., tumor cells or tumor mass) in a subject (e.g., a human subject) having a cancer, e.g., an NHL, e.g., an FL. In some embodiments, tumor burden is defined as the sum of diameters of target lesions or the sum of the product of target lesions. In a particular embodiment, tumor burden is defined as the sum of the product of the diameters of (SPD) target lesions. In some embodiments, the diameters of target lesions is quantified by computed tomography (CT).
"Sustained response" refers to the sustained effect on reducing tumor growth after cessation of a treatment. For example, the tumor size may remain to be the same or smaller as compared to the size at the beginning of the administration phase. In some embodiments, the sustained response has a duration at least the same as the treatment duration, at least 1.5x, 2.0x, 2.5x, or 3.0x length of the treatment duration.
An "effective response" of a subject or a subject's "responsiveness" to treatment with a medicament and similar wording refers to the clinical or therapeutic benefit imparted to a subject as risk for, or suffering from, a disease or disorder, such as cancer. In one embodiment, such benefit includes any one or more of: extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
A subject who "does not have an effective response" to treatment refers to a subject who does not have any one of extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
As used herein, "survival" refers to the patient remaining alive, and includes overall survival as well as progression-free survival.
As used herein, "overall survival" (OS) refers to the percentage of subjects in a group who are alive after a particular duration of time, e.g., 1 year or 5 years from the time of diagnosis or treatment.
As used herein, "progression-free survival" (PFS) refers to the length of time during and after treatment during which the disease being treated (e.g., a R/R FL) does not get worse. Progression-free survival may include the amount of time patients have experienced a complete response or a partial response, as well as the amount of time patients have experienced stable disease.
As used herein, "stable disease" or "SD" refers to neither sufficient shrinkage of target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started.
As used herein, "progressive disease" or "PD" refers to at least a 20%
increase in the SLD of target lesions, taking as reference the smallest SLD, or at least a 50%
increase in the SPD of target legions, taking as reference the smallest SPD, recorded since the treatment started or the presence of one or more new lesions.
As used herein, "delaying progression" of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a relapsed and/or refractory (R/R) follicular lymphoma (FL)). This delay can be of varying lengths of time, depending on the history of the disease and/or subject being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the subject does not develop the disease.
For example, in a late-stage cancer, development of central nervous system (CNS) metastasis, may be delayed.
By "extending survival" is meant increasing overall or progression free survival in a treated patient relative to an untreated patient (e.g., relative to a patient not treated with the medicament), or relative to a patient who does not express a biomarker at the designated level, and/or relative to a patient treated with an approved anti-tumor agent. An objective response refers to a measurable response, including complete response (CR) or partial response (PR).
The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(a02;
diabodies; linear antibodies;
single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
The terms ''full-length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
By "binding domain" is meant a part of a compound or a molecule that specifically binds to a target epitope, antigen, ligand, or receptor. Binding domains include but are not limited to antibodies (e.g., monoclonal, polyclonal, recombinant, humanized, and chimeric antibodies), antibody fragments or portions thereof (e.g., Fab fragments, Fab'2, scFv antibodies, SMIP, domain antibodies, diabodies, minibodies, scFv-Fc, affibodies, nanobodies, and VH and/or VL domains of antibodies), receptors, ligands, aptamers, and other molecules having an identified binding partner.
The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU
numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGi, IgG2, IgG3, IgG4, IgAl, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 6, E, y, and p, respectively.
The term IgG "isotype" or "subclass" as used herein is meant any of the subclasses of immunoglobulins defined by the chemical and antigenic characteristics of their constant regions.
"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains:
FR1, FR2, FR3, and FR4.
Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3.
In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.
An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A
humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A
"humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. MoL Biol., 227:381 (1991); Marks etal., J. MoL Biol., 222:581 (1991). Also available for the preparation of human monoclonal antibodies are methods described in Cole etal., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner etal., J.
Immunol., 147(1):86-95 (1991). See also van Dijk and van de Winkel, Curr.
Opin. Pharmacol., 5:368-74 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos.
6,075,181 and 6,150,584 regarding XENOMOUSETm technology). See also, for example, Li etal., Proc.
Natl. Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody (i.e., mosunetuzumab) to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 61h ed., W.H.
Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL
domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
The term "hypervariable region" or "HVR" as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence ("complementarity determining regions" or "CDRs") and/or form structurally defined loops ("hypervariable loops") and/or contain the antigen-contacting residues ("antigen contacts"). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:
(a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. MoL Biol. 196:901-917(1987));
(b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991));
(c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. MoL Biol. 262: 732-745 (1996)); and (d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR
residues) are numbered herein according to Kabat et al., supra.
An "immunoconjugate" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
The term an "isolated antibody" when used to describe the various antibodies disclosed herein, means an antibody that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007). In preferred embodiments, the antibody (i.e., mosunetuzumab) will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
Isolated antibody includes antibodies in situ within recombinant cells, because at least one component of the polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody (i.e., mosunetuzumab) as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies (i.e., mosunetuzumab) to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA
methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human innmunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
"Affinity" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
The affinity of a molecule X
for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
The terms "anti-CD3 antibody" and "an antibody that binds to CD3" refer to an antibody that is capable of binding CD3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD3. In one embodiment, the extent of binding of an anti-CD3 antibody to an unrelated, non-CD3 protein is less than about 10% of the binding of the antibody to CD3 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD3 has a dissociation constant (KD) of 1 pM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM
(e.g., 10-8 M or less, e.g., from 10-8 M to 10-13 M, e.g., from 10-9 M to 10-
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A is a schematic of the study design described in Example 1 for the dosing regimen of the combination therapy of mosunetuzumab and lenalidomide. C=cycle; D=day;
FL=follicular lymphoma;
IMC=Internal Monitoring Committee; IV=intravenous; Len=lenalidomide;
Mosun=mosunetuzumab;
RP2D=recommended Phase ll dose; R/R=relapsed or refractory. Note: Cycle 1 is 21 days; Cycle 2 and onward is 28 days.
FIG. 1B is a schematic of the dosing regimen described in Example 1.
Lenalidomide begins at cycle 2 to minimize risk with mosunetuzumab initiation during Cycle 1, when CRS risk is highest.
FIG. 2 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun) or lenalidomide. Clinical cut-off date (CCOD) of April 5, 2021.
FIG. 3 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun). CCOD of April 5, 2021.
FIG. 4 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 1 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with lenalidomide. CCOD of April 5, 2021.
FIG. 5 is a swimlane plot showing onset of cytokine release syndrome (CRS) events in 5 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab described in Example 1.
Onset of Grade 1 or Grade 2 CRS is indicated by the light or dark diamond, respectively. CCOD of April 5, 2021.
FIG. 6 is a plot showing observed concentration-time data of mosunetuzumab (in combination with lenalidomide) from Study C041942 overlaid with popPK model simulations based on mosunetuzumab monotherapy data from Study G029781; Simulations were performed at 1/2/30 mg 04W. Filled red circles and lines represent the individual and mean observed mosunetuzumab concentration measurements from Study C041942 at 1/2/30 mg IV dose in combination with lenalidomide. Shaded area represents simulated concentration-time profile for mosunetuzumab th_ monotherapy based on the preliminary population PK model simulations k /5 95th prediction interval) which was developed based on clinical data from Study G029781.
FIG. 7 is a butterfly plot showing adverse events that occurred in 10% of safety-evaluable patients described in Example 3 classified by MedDRA System Organ Class and MedDRA Preferred Term. Based on MedDRA version 23.1. Grade of adverse events is shown in legend. Left side shows all adverse events. Right side shows adverse events attributable to treatment with mosunetuzumab (Mosun) or lenalidomide. CCOD of September 13, 2021.
FIG. 8 is a bar graph showing cytokine release syndrome (CRS) events by dosing cycle (C) and day (D) and by CRS Grade (Gr). Values below the graph show the dose of mosunetuzumab associated with each dosing cycle (C) and day (D). The Cl Dl dose is administered on Cycle 1 Day 1, the Cl D2 dose is administered on Cycle 1 Day 8, and the Cl D3 dose is administered on Cycle 1 Day 15. Subsequent doses are administered on Day 1 of each respective dosing cycle (C2, C3+).
FIG. 9 is a bar graph showing neutropenia and febrile neutropenia events by dosing cycle (C) and by neutropenia Grade (Gr). The number of patients who received granulocyte colony-stimulating factor (G-CSF) per dosing cycle (C) is shown below the graph.
FIG. 10 is a bar graph showing anti-tumor activity in patients with 1 diagnostic computed tomography (CT) scan at response assessment. The number above each bar shows %
change from baseline. Changes in tumor burden are quantified by comparing the sum of the product of the diameters (SPD) of target lesions to baseline measurements.
FIG. 11 is a bar graph showing the overall response rate (ORR), complete response rate (CR), and partial response rate (PR) in the 29 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab and 20 mg oral lenalidomide described in Example 3. Response rates are shown for 29 patients as of data cut-off date of September 13, 2021. 95% confidence interval (CI) for each response rate value is shown in parentheses below. Response rates are determined by positron emission tomography-computed tomography (PET-CT).
FIG. 12 is a swimlane plot showing duration of response in all 29 patients treated with the 1/2/30 mg dosing regimen of mosunetuzumab and 20 mg oral lenalidomide described in Example 3.
Duration of response are shown for 29 patients as of data cut-off date of September 13, 2021.
DETAILED DESCRIPTION
The present invention relates to methods of treating a subject having a relapsed and/or refractory (RJR) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a R/R FL that is RIR to at least one prior systemic therapy (e.g., one prior treatment with a ohemo-immunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-0D20 monoclonal antibody, e.g., rituxirnab or obinutuzumab) or other treatment. The method comprises administering the effective amount of mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg and the Cl D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
The invention is based, in part, on the discovery that combination therapy involving intravenous administration of mosunetuzumab and oral administration of lenalidomide over multiple dosing cycles (e.g., wherein the first dosing cycle is a step-up, fractionated dosing cycle) exhibits synergistic effects between mosunetuzumab and lenalidomide and can effectively treat subjects having relapsed/refractory (R/R) follicular lymphoma (FL), in particular those who are R/R to prior systemic therapy including an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab; e.g., R-CHOP) while maintaining an acceptable safety profile (e.g., with respect to frequency and severity of adverse events).
I. GENERAL TECHNIQUES
The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (F.M. Ausubel, et al. eds., (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson, B.D.
Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freshney, ed. (1987)); Oligonucleotide Synthesis (M.J. Gait, ed., 1984);
Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press;
Animal Cell Cufture (R.I. Freshney), ed., 1987); Introduction to Cell and Tissue Culture (J.P. Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B.
Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D.M.
Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Cabs, eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994);
Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); lmmunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P.
Finch, 1997); Antibodies: A
Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanotti and J.
D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT. DeVita et al., eds., J.B. Lippincott Company, 1993).
II. DEFINITIONS
It is to be understood that aspects and embodiments of the invention described herein include "comprising," "consisting," and "consisting essentially of" aspects and embodiments.
As used herein, the singular form "a," "an," and "the" includes plural references unless indicated otherwise.
The term "about" as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, hematologic cancers, such as mature B cell cancers, excluding Hodgkin's lymphoma, but including non-Hodgkin's lymphoma (NHL), such as diffuse large B cell lymphoma (DLBCL), which may be relapsed or refractory DLBCL or a Richter's transformation. Other specific examples of cancer also include germinal-center B cell-like (GCB) diffuse large B cell lymphoma (DLBCL), activated B cell-like (ABC) DLBCL, follicular lymphoma (FL), transformed FL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), transformed MZL, high grade B-cell lymphoma, primary mediastinal (thymic) large B cell lymphoma (PMLBCL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), transformed LL, Waldenstrom macroglobulinemia (WM), central nervous system lymphoma (CNSL), Burkitt's lymphoma (BL), B cell prolymphocytic leukemia, splenic marginal zone lymphoma, hairy cell leukemia, splenic lymphoma/leukemia, unclassifiable, splenic diffuse red pulp small B cell lymphoma, hairy cell leukemia variant, heavy chain diseases, a heavy chain disease, y heavy chain disease, p heavy chain disease, plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmacytoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma, pediatric nodal marginal zone lymphoma, pediatric follicular lymphoma, primary cutaneous follicle center lymphoma, T
cell/histiocyte rich large B cell lymphoma, primary DLBCL of the CNS, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, lymphomatoid granulomatosis, intravascular large B cell lymphoma, ALK-positive large B cell lymphoma, plasmablastic lymphoma, large B cell lymphoma arising in HHV8-associated multicentric Castleman disease, primary effusion lymphoma: B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma, and B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin's lymphoma. Further examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies, including B cell lymphomas.
More particular examples of such cancers include, but are not limited to, multiple myeloma (MM); low-grade/follicular NHL; small lymphocytic (SL) NHL; intermediate-grade/follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cleaved cell NHL; bulky disease NHL; AIDS-related lymphoma; and acute lymphoblastic leukemia (ALL);
chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD).
"Tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as referred to herein.
A "disorder" is any condition that would benefit from treatment including, but not limited to, chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
The terms ''cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer. In another embodiment, the cell proliferative disorder is a tumor.
The terms "B cell proliferative disorder" or "B cell malignancy" refer to disorders that are associated with some degree of abnormal B cell proliferation and include, for example, lymphomas, leukemias, myelomas, and myelodysplastic syndromes. In some instances, the B
cell proliferative disorder is a lymphoma, such as non-Hodgkin's lymphoma (NHL), including, for example, follicular lymphoma (FL) (e.g., a relapsed and/or refractory FL or transformed FL), diffuse large B cell lymphoma (DLBCL) (e.g., a relapsed or refractory DLBCL or a Richter's transformation), MCL, high grade B-cell lymphoma, or PMLBCL). In another embodiment, the B cell proliferative disorder is a leukemia, such as chronic lymphocytic leukemia (CLL). In one embodiment, the B-cell proliferative disorder is a relapsed and/or refractory FL.
By "Follicular Lymphoma International Prognostic Index" or "FLIFI" is meant a scoring system or index for determining prognostic risk of patients (e.g., with cancer; e.g., an NHL; e.g., a follicular lymphoma (FL)). FLIP! score ranges from 0-5, depending on how many of the five conditions or risk factors a patient may have among the following: (i) age 60 years; (ii) Ann Arbor stage III-IV; hemoglobin level 120 g/L; serum lactate dehydrogenase (LDH) level> upper limit of normal (ULN) (e.g., > 280 units/L); and (v) number of nodal sites > 4. See e.g., Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265. at Table 4.
As used herein, the terms "Ann Arbor staging" or "Ann Arbor stages" refers to a system for classification of stages of lymphoma (e.g., non-Hodgkin's lymphoma (NHL);
e.g., a DLBCL, an FL, an MCL, a high-grade B cell lymphoma, a PMLBCL, or a CLL). Lymphomas (e.g., NHLs) can be classified as one of four Ann Arbor stages. Stage I refers to lymphomas exhibiting involvement of a single lymph node region or of a single extralymphatic organ or site. Stage II refers to lymphomas exhibiting involvement of 2 or more lymph node regions on the same side of the diaphragm.
Stage III refers to lymphomas exhibiting involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by localized involvement of extralymphatic organ or site or by involvement of the spleen, or both. Stage IV refers to lymphomas exhibiting diffuse or disseminated involvement of 1 or more extralymphatic organs or tissues with or without associated lymph node enlargement. Liver involvement is always considered to be diffuse, and, thus, always considered Ann Arbor stage IV.
Lymphatic structures include the lymph nodes, thymus, spleen, appendix, Waldeyer's ring, and Peyer's patches. See Carbone, P.P. et al., Cancer Res. 1971, 31(11):1860-1861.
"Refractory disease" is defined as no complete remission to at least a first-line therapy. In one embodiment, refractory disease defined as no response to or relapse within 6 months of prior therapy. In one embodiment, refractory disease is characterized by one or more of the following: progressive disease (PD) as best response to first-line therapy, stable disease (SD) as best response after at least one first line therapy (e.g., at least one containing an anti CD20-directed therapy, e.g., including an anti-CD20 antibody, e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab), or partial response (PR) as best response, and biopsy-proven residual disease or disease progression after the partial response. "Relapsed disease" is defined as complete remission to first-line therapy. In one embodiment, disease relapse is proven by biopsy. In one embodiment, patients have relapsed after or failed to respond to at least one prior systemic treatment regimen (e.g., at least one containing an anti CD20-directed therapy, e.g., including an anti-CD20 antibody, e.g., an anti-CD20 monoclonal antibody, e.g., rituximab or obinutuzumab).
As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
As used herein, "delaying progression" of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a relapsed and/or refractory FL). This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late-stage cancer, such as development of metastasis, may be delayed.
By "reduce" or "inhibit" is meant the ability to cause an overall decrease, for example, of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or greater. For clarity the term includes also reduction to zero (or below the detection limit of the analytical method), i.e., complete abolishment or elimination. In certain embodiments, reduce or inhibit can refer to the reduction or inhibition of undesirable events, such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or central nervous system (CNS) toxicities, following treatment with mosunetuzumab using the step-up dosing regimen of the invention relative to unchanging, preset dosing with the target dose of mosunetuzumab. In other embodiments, reduce or inhibit can refer to effector function of an antibody that is mediated by the antibody Fc region, such effector functions specifically including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). In other embodiments reduce or inhibit can refer to the symptoms of the R/R FL being treated, the presence or size of metastases, or the size of the primary tumor. In yet other embodiments, reducing or inhibiting cancer relapse means to reduce or inhibit tumor or cancer relapse, or tumor or cancer progression.
As used herein, "administering" is meant a method of giving a dosage of a compound (e.g., a bispecific antibody, e.g., an anti-CD20/anti-CD3 bispecific antibody, e.g., mosunetuzumab) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition including a bispecific antibody (e.g., mosunetuzumab)) to a subject. The compounds and/or compositions utilized in the methods described herein can be administered intravenously (e.g., by intravenous infusion).
A "fixed" or "flat" dose of a therapeutic agent (e.g., a bispecific antibody) herein refers to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient. The fixed or flat dose is therefore not provided as a mg/kg dose or a mg/m2 dose, but rather as an absolute amount of the therapeutic agent (e.g., mg).
A "subject" or an "individual" is a mammal. Mammals include, but are not limited to, primates (e.g., humans and non-human primates such as monkeys), domesticated animals (e.g., cows, sheep, cats, dogs, and horses), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the subject or individual is a human.
"Individual response" or "response" can be assessed using any endpoint indicating a benefit to the subject, including, without limitation, (1) inhibition, to some extent, of disease progression (e.g., progression of a R/R FL, including slowing down and complete arrest; (2) a reduction in tumor size; (3) inhibition (i.e., reduction, slowing down or complete stopping) of cancer cell infiltration into adjacent peripheral organs and/or tissues; (4) inhibition (i.e., reduction, slowing down or complete stopping) of metastasis; (5) relief, to some extent, of one or more symptoms associated with the R/R FL; (6) increase or extend in the length of survival, including overall survival and progression-free survival; and/or (9) decreased mortality at a given point of time following treatment.
As used herein, "complete response" or "CR" refers to disappearance of all target lesions (i.e., all evidence of disease).
As used herein, "partial response" or "PR" refers to at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, or at least a 50%
decrease in the sum of the product of the diameters (SPD) of target lesions, taking as reference the baseline SPD.
As used herein, "objective response rate" (ORR) refers to the sum of complete response (CR) rate and partial response (PR) rate.
As used herein, "duration of objective response" (DOR) is defined as the time from the first occurrence of a documented objective response to disease progression, or death from any cause within 30 days of the last dose of a treatment, whichever occurs first.
As used herein, "tumor burden" refers to the total amount of tumor (e.g., tumor cells or tumor mass) in a subject (e.g., a human subject) having a cancer, e.g., an NHL, e.g., an FL. In some embodiments, tumor burden is defined as the sum of diameters of target lesions or the sum of the product of target lesions. In a particular embodiment, tumor burden is defined as the sum of the product of the diameters of (SPD) target lesions. In some embodiments, the diameters of target lesions is quantified by computed tomography (CT).
"Sustained response" refers to the sustained effect on reducing tumor growth after cessation of a treatment. For example, the tumor size may remain to be the same or smaller as compared to the size at the beginning of the administration phase. In some embodiments, the sustained response has a duration at least the same as the treatment duration, at least 1.5x, 2.0x, 2.5x, or 3.0x length of the treatment duration.
An "effective response" of a subject or a subject's "responsiveness" to treatment with a medicament and similar wording refers to the clinical or therapeutic benefit imparted to a subject as risk for, or suffering from, a disease or disorder, such as cancer. In one embodiment, such benefit includes any one or more of: extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
A subject who "does not have an effective response" to treatment refers to a subject who does not have any one of extending survival (including overall survival and progression free survival); resulting in an objective response (including a complete response or a partial response); or improving signs or symptoms of cancer.
As used herein, "survival" refers to the patient remaining alive, and includes overall survival as well as progression-free survival.
As used herein, "overall survival" (OS) refers to the percentage of subjects in a group who are alive after a particular duration of time, e.g., 1 year or 5 years from the time of diagnosis or treatment.
As used herein, "progression-free survival" (PFS) refers to the length of time during and after treatment during which the disease being treated (e.g., a R/R FL) does not get worse. Progression-free survival may include the amount of time patients have experienced a complete response or a partial response, as well as the amount of time patients have experienced stable disease.
As used herein, "stable disease" or "SD" refers to neither sufficient shrinkage of target lesions to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started.
As used herein, "progressive disease" or "PD" refers to at least a 20%
increase in the SLD of target lesions, taking as reference the smallest SLD, or at least a 50%
increase in the SPD of target legions, taking as reference the smallest SPD, recorded since the treatment started or the presence of one or more new lesions.
As used herein, "delaying progression" of a disorder or disease means to defer, hinder, slow, retard, stabilize, and/or postpone development of the disease or disorder (e.g., a relapsed and/or refractory (R/R) follicular lymphoma (FL)). This delay can be of varying lengths of time, depending on the history of the disease and/or subject being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the subject does not develop the disease.
For example, in a late-stage cancer, development of central nervous system (CNS) metastasis, may be delayed.
By "extending survival" is meant increasing overall or progression free survival in a treated patient relative to an untreated patient (e.g., relative to a patient not treated with the medicament), or relative to a patient who does not express a biomarker at the designated level, and/or relative to a patient treated with an approved anti-tumor agent. An objective response refers to a measurable response, including complete response (CR) or partial response (PR).
The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(a02;
diabodies; linear antibodies;
single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
The terms ''full-length antibody," "intact antibody," and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
By "binding domain" is meant a part of a compound or a molecule that specifically binds to a target epitope, antigen, ligand, or receptor. Binding domains include but are not limited to antibodies (e.g., monoclonal, polyclonal, recombinant, humanized, and chimeric antibodies), antibody fragments or portions thereof (e.g., Fab fragments, Fab'2, scFv antibodies, SMIP, domain antibodies, diabodies, minibodies, scFv-Fc, affibodies, nanobodies, and VH and/or VL domains of antibodies), receptors, ligands, aptamers, and other molecules having an identified binding partner.
The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU
numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGi, IgG2, IgG3, IgG4, IgAl, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 6, E, y, and p, respectively.
The term IgG "isotype" or "subclass" as used herein is meant any of the subclasses of immunoglobulins defined by the chemical and antigenic characteristics of their constant regions.
"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains:
FR1, FR2, FR3, and FR4.
Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols. 1-3.
In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.
An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A
humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A
"humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. MoL Biol., 227:381 (1991); Marks etal., J. MoL Biol., 222:581 (1991). Also available for the preparation of human monoclonal antibodies are methods described in Cole etal., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner etal., J.
Immunol., 147(1):86-95 (1991). See also van Dijk and van de Winkel, Curr.
Opin. Pharmacol., 5:368-74 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos.
6,075,181 and 6,150,584 regarding XENOMOUSETm technology). See also, for example, Li etal., Proc.
Natl. Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody (i.e., mosunetuzumab) to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 61h ed., W.H.
Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL
domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
The term "hypervariable region" or "HVR" as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence ("complementarity determining regions" or "CDRs") and/or form structurally defined loops ("hypervariable loops") and/or contain the antigen-contacting residues ("antigen contacts"). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:
(a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. MoL Biol. 196:901-917(1987));
(b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991));
(c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. MoL Biol. 262: 732-745 (1996)); and (d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR
residues) are numbered herein according to Kabat et al., supra.
An "immunoconjugate" is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
The term an "isolated antibody" when used to describe the various antibodies disclosed herein, means an antibody that has been identified and separated and/or recovered from a cell or cell culture from which it was expressed. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007). In preferred embodiments, the antibody (i.e., mosunetuzumab) will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
Isolated antibody includes antibodies in situ within recombinant cells, because at least one component of the polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody (i.e., mosunetuzumab) as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies (i.e., mosunetuzumab) to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA
methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human innmunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
"Affinity" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
The affinity of a molecule X
for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
An "affinity matured" antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
The terms "anti-CD3 antibody" and "an antibody that binds to CD3" refer to an antibody that is capable of binding CD3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD3. In one embodiment, the extent of binding of an anti-CD3 antibody to an unrelated, non-CD3 protein is less than about 10% of the binding of the antibody to CD3 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD3 has a dissociation constant (KD) of 1 pM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM
(e.g., 10-8 M or less, e.g., from 10-8 M to 10-13 M, e.g., from 10-9 M to 10-
13 M). In certain embodiments, an anti-CD3 antibody binds to an epitope of CD3 that is conserved among CD3 from different species.
The term "cluster of differentiation 3" or "CD3," as used herein, refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3E, CD3y, CD3a, and 0D38 chains. The term encompasses "full-length," unprocessed CD3 (e.g., unprocessed or unmodified CD3E or CD3y), as well as any form of CD3 that results from processing in the cell. The term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants.
CD3 includes, for example, human CD3c protein (NCBI RefSeq No. NP 000724), which is 207 amino acids in length, and human CD3y protein (NCB! RefSeq No. NP 000064), which is 182 amino acids in length.
The terms ''anti-CD20 antibody" and "an antibody that binds to CD20" refer to an antibody that is capable of binding CD20 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD20. In one embodiment, the extent of binding of an anti-CD20 antibody to an unrelated, non-CD20 protein is less than about 10% of the binding of the antibody to CD20 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD20 has a dissociation constant (KO of 1 pM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM (e.g., 10-8M or less, e.g., from 10-8 M to 1013 M, e.g., from 10-9 M to 1013 M). In certain embodiments, an anti-CD20 antibody binds to an epitope of CD20 that is conserved among CD20 from different species. In some embodiments, the anti-CD20 antibody is a monoclonal antibody. In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is rituximab. In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is obinutuzumab.
As used herein, the term "rituximab" or "RITUXANO" refers to an anti-CD20 antibody (e.g., anti-CD20 monoclonal antibody) having the Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 77 (WHO Drug Information, Vol. 11, No. 2, 1997, p. 99), or the CAS
Registry Number 174722-31-7.
As used herein, the term "obinutuzumab" or "GAZYVAO" refers to an anti-CD20 antibody (e.g., anti-CD20 monoclonal antibody) having the Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 99 (WHO Drug Information, Vol.
22, No. 2, 2008, p.
396), Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 108 (WHO Drug Information, Vol. 26, No. 4,2012, p.453), or the CAS Registry Number 949142-50-1.
The term "cluster of differentiation 20" or "CD20," as used herein, refers to any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses "full-length," unprocessed CD20, as well as any form of CD20 that results from processing in the cell. The term also encompasses naturally occurring variants of CD20, including, for example, splice variants or allelic variants. CD20 includes, for example, human CD20 protein (see, e.g., NCBI RefSeq Nos. NP 068769.2 and NP 690605.1), which is 297 amino acids in length and may be generated, for example, from variant mRNA transcripts that lack a portion of the 5' UTR (see, e.g., NCB! RefSeq No. NM 021950.3) or longer variant mRNA transcripts (see, e.g., NCB! RefSeq No.
NM 152866.2).
The terms "anti-CD20/anti-CD3 bispecific antibody," "bispecific anti-CD20/anti-CD3 antibody,"
and "antibody that binds to CD20 and CD3," or variants thereof, refer to a multispecific antibody (e.g., a bispecific antibody) that is capable of binding to CD20 and CD3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD20 and/or CD3. In one embodiment, the extent of binding of a bispecific antibody that binds to CD20 and CD3 to an unrelated, non-CD3 protein and/or non-CD20 protein is less than about 10% of the binding of the antibody to CD3 and/or CD20 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, a bispecific antibody that binds to CD20 and CD3 has a dissociation constant (KD) of 1 pM, 5 100 nM, 5 10 nM, 1 nM, 5 0.1 nM, 5 0.01 nM, or 5 0.001 nM (e.g., 10-8 M or less, e.g., from 10-8M
to 10-13M, e.g., from 10-9M
to 10-13 M). In certain embodiments, a bispecific antibody that binds to CD20 and CD3 binds to an epitope of CD3 that is conserved among CD3 from different species and/or an epitope of CD20 that is conserved among 0D20 from different species. In one embodiment, the bispecific antibody binds monovalently to CD20 and binds monovalently to CD3. In some embodiments, a bispecific antibody that binds to CD20 and CD3 is rnosunetuzumab.
As used herein, the term "mosunetuzumab" refers to an anti-CD20/anti-CD3 bispecific antibody having the International Nonproprietary Names for Pharmaceutical Substances (INN) List 117 (WHO Drug Information, Vol. 31, No. 2, 2017, p. 303), or the CAS Registry Number 1905409-39-3.
As used herein, the term "lenalidomide" refers to a compound having the CAS
Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindo1-2-yl)piperidine-2,6-dione.
Lenalidomide is also known by tradenames including REVLIMIDO, linamid, and lenalid. Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula C13H13N303.
As used herein, the term "binds," ''specifically binds to," or is "specific for" refers to measurable and reproducible interactions such as binding between a target and an antibody, which is determinative of the presence of the target in the presence of a heterogeneous population of molecules including biological molecules. For example, an antibody that specifically binds to a target (which can be an epitope) is an antibody that binds this target with greater affinity, avidity, more readily, and/or with greater duration than it binds to other targets. In one embodiment, the extent of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target as measured, for example, by a radioimmunoassay (RIA). In certain embodiments, an antibody that specifically binds to a target has a dissociation constant (KD) of 1 pM, 100 nM, 10 nM, 1 nM, or 0.1 nM. In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved among the protein from different species. In another embodiment, specific binding can include, but does not require exclusive binding. The term as used herein can be exhibited, for example, by a molecule having a KD for the target of 10-4 M or lower, alternatively 10-5 M or lower, alternatively 10-6 M or lower, alternatively 10-7 M or lower, alternatively 10-8 M or lower, alternatively 10-9 M or lower, alternatively 10-10 M or lower, alternatively 10-11 M or lower, alternatively 10-12 M or lower or a Kr) in the range of 10-4 M to 10-6 M or 10-6 M to 10-10 M or 10-7 M to 10-9 M. As will be appreciated by the skilled artisan, affinity and KD values are inversely related. A high affinity for an antigen is measured by a low KD
value. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
"Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNO (DNASTARG) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the (% amino acid sequence identity of A to B
will not equal the %
amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A
pharmaceutically acceptable carrier includes, but is not limited to, a buffcr, cxcipicnt, stabilizer, or preservative.
As used herein, the term "chemotherapeutic agent" refers to a compound useful in the treatment of a cancer, such as a R/R FL. Examples of chemotherapeutic agents include EG
FR inhibitors (including small molecule inhibitors (e.g., erlotinib (TARCEVAO, Genentech/OSI Pharm.);
PD 183805 (Cl 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-743-(4-morpholinyl)propoxy]-6-quinazolinyll-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSAO) 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-y1)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166 ((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yll-phenol); (R)-6-(4-hydroxyphenyI)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine);
CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazoliny1]-2-butynamide); EKB-569 (N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinoliny1]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); A01571 (SU 5271; Pfizer); and dual EGFR/HER2 tyrosine kinase inhibitors such as lapatinib (TYKERB , GSK572016 or N-[3-chloro-4-[(3 fluorophenyl)methoxy]phenyI]-6[5[[[2methylsulfonypethyl]amino]methyl]-2-furanyl]-4-quinazolinamine)); a tyrosine kinase inhibitor (e.g., an EGFR inhibitor; a small molecule HER2 tyrosine kinase inhibitor such as TAK165 (Takeda); CP-724,714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER
inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; PKI-166 (Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Rat-1 inhibitors such as antisense agent ISIS-5132 (ISIS
Pharmaceuticals) which inhibit Rat-1 signaling; non-HER-targeted tyrosine kinase inhibitors such as imatinib mesylate (GLEEVECO, Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors such as sunitinib (SUTENTO, Pfizer); VEGF receptor tyrosine kinase inhibitors such as vatalanib (PTK787/ZK222584, Novartis/Schering AG); MAPK extracellular regulated kinase I inhibitor CI-1040 (Pharmacia);
quinazolines, such as PD 153035,4-(3-chloroanilino) quinazoline;
pyridopyrimidines; pyrimidopyrimidines;
pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706;
pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidines; curcumin (diferuloyl methane, 4,5-bis (4-fluoroanilino)phthalimide); tyrphostines containing nitrothiophene moieties;
PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to HER-encoding nucleic acid); quinoxalines (U.S.
Patent No. 5,804,396); tryphostins (U.S. Patent No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787 (Novartis/Schering AG); pan-HER inhibitors such as CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis/Lilly); PKI
166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth);
Semaxinib (Pfizer);
ZD6474 (AstraZeneca); PTK-787 (Novartis/Schering AG); INC-1C11 (Imolone); and rapamycin (sirolimus, RAPAMUNEO)); proteasome inhibitors such as bortezomib (VELCADEO, Millennium Pharm.); disulfiram;
epigallocatechin gallate; salinosporamide A; carfilzomib; 17-AAG
(geldanamycin); radicicol; lactate dehydrogenase A (LDH-A); fulvestrant (FASLODEXO, AstraZeneca); letrozole (FEMARAO, Novartis), finasunate (VATALANIBO, Novartis); oxaliplatin (ELOXATING, Sanofi); 5-FU (5-fluorouracil); leucovorin;
lonafamib (SCH 66336); sorafenib (NEXAVARO, Bayer Labs); AG1478, alkylating agents such as thiotepa and CYTOXAN cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including topotecan and irinotecan);
bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8); adrenocorticosteroids (including prednisone and prednisolone);
cyproterone acetate; 5a-reductases including finasteride and dutasteride);
vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat dolastatin; aldesleukin, talc duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin y1 and calicheamicin w1); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;
pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane;
folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;
demecolcine; diaziquone;
elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate;
hydroxyurea; lentinan;
lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone;
mitoxantrone:
mopidamnol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKO polysaccharide complex (JHS Natural Products); razoxane; rhizoxin;
sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan;
vindesine; dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa;
chloranmbucil; GEMZARO (gemcitabine); 6-thioguanine; mercaptopurine;
methotrexate; etoposide (VP-16); ifosfamide; mitoxantrone; novantrone; teniposide; edatrexate; daunomycin;
aminopterin; capecitabine (XELODA0); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;
difluoromethylornithine (DMF0);
retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above.
Chemotherapeutic agents also include (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEXO; tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON
(toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE
(megestrol acetate), AROMASINO (exemestane; Pfizer), formestanie, fadrozole, RIVISORO (vorozole), FEMARAO (letrozole;
Novartis), and ARIMIDEXO (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; buserelin, tripterelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all transretionic acid, fenretinide, as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;
(vii) ribozymes such as VEGF
expression inhibitors (e.g., ANGIOZYMEO) and HER2 expression inhibitors;
(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN , LEUVECTIN , and VAXIDO; (ix) growth inhibitory agents including vincas (e.g., vincristine and vinblastine), NAVELBINEO
(vinorelbine), taxanes (e.g., paclitaxel, nab-paclitaxel, and docetaxel), topoisomerase II inhibitors (e.g., doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin), and DNA alkylating agents (e.g., tamoxigen, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C); and (x) pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above.
The term "chemo-immunotherapy" refers to combination therapy that includes both chemotherapy drugs and immunotherapeutic agents. In some embodiments, chemo-immunotherapy is used to treat a cancer, e.g., a CD20-positive cancer, e.g., a NHL, e.g., a FL. In some embodiments, immunotherapeutic agents include an antibody, e.g., an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody). In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is rituximab or obinutuzumab. In some embodiments, chemo-immunotherapy includes R-CHOP.
The term "R-CHOP" as used herein refers to a treatment comprising rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. In some embodiments, R-CHOP is a chemotherapy treatment or regimen used in the treatment of a cancer, optionally a B cell proliferative disorder (e.g., a non-Hodgkin's lymphoma; e.g., a DLBCL or a high grade B-cell lymphoma). In some embodiments, R-CHOP is the standard of care (SOC) or standard therapy to be administered to a subject to treat the cancer, optionally the B cell proliferative disorder (e.g., the non-Hodgkin's lymphoma; e.g., the DLBCL or the high grade B-cell lymphoma). In some embodiments, R-CHOP is the standard front-line or first-line therapy to be administered to a previously untreated subject. In some embodiments, R-CHOP is administered every 3 weeks (in 21-day dosing cycles) for 3 to 6 dosing cycles. In some embodiments, the dosing regimen for R-CHOP therapy comprises 21-day dosing cycles, wherein during each dosing cycle, the subject is administered 375 mg/m2 rituximab IV, and also administered cyclophosphamide, doxorubicin, vincristine, and prednisone.
In some embodiments, the dosing regimen for R-CHOP therapy further comprises 750 mg/m2 cyclophosphamide IV, 50 mg/m2 doxorubicin IV, 1.4 mg/m2 vincristine IV, and 5 days of 100 mg or 40 mg/m2 per day prednisone oral. In some embodiments, a maximum single dose of vincristine is 2 mg.
The term "cytotoxic agent" as used herein refers to any agent that is detrimental to cells (e.g., causes cell death, inhibits proliferation, or otherwise hinders a cellular function). Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., 211,41, 1311, 1251, 90y, 186Re, iaeRe, 153sm, 212Bi, 32p, 212Pb, and radioactive isotopes of Lu); chemotherapeutic agents; enzymes and fragments thereof such as nucleolytic enzymes; and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
Exemplary cytotoxic agents can be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase 1 inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism. In one instance, the cytotoxic agent is a platinum-based chemotherapeutic agent (e.g., carboplatin or cisplatin). In one instance, the cytotoxic agent is an antagonist of EG FR, e.g., N-(3-ethynylphenyI)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (e.g., erlotinib).
In one instance the cytotoxic agent is a RAF inhibitor, e.g., a BRAF and/or CRAF inhibitor. In one instance the RAF inhibitor is vemurafenib. In one instance, the cytotoxic agent is a PI3K inhibitor.
The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
The term "synergistic effect" is used to refer to an effect resulting from the combination use of two or more therapeutic products (e.g., mosunetuzumab and lenalidomide), which is greater than the sum of the effects observed when the two or more therapeutic products are used individually. In some embodiments, synergistic effect is observed in the response rate (e.g., complete response rate or overall response rate) of a population of subjects having relapsed and/or refractory (R/R) non-Hodgkin's Lymphoma (NHL; e.g., R/R follicular lymphoma (FL)) treated with a combination therapy comprising mosunetuzumab and lenalidomide. In some embodiments, a population of subjects having R/R FL exhibits a higher complete response rate when treated with combination therapy comprising mosunetuzumab and lenalidomide compared to a population of subjects treated with monotherapy mosunetuzumab or lenalidomide. In some embodiments, a population of subjects having R/R FL exhibits a higher overall response rate when treated with combination therapy comprising mosunetuzumab and lenalidomide compared to a population of subjects treated with monotherapy mosunetuzumab or lenalidomide.
III. THERAPEUTIC METHODS
Provided herein are methods of treating a subject having a relapsed and/or refractory (R/R) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomkte as a combination therapy, in particular, the present invention relates to methods of treating a subject having a R/R FL that is R/R to at :east one prior systemic therapy (e.g., one prior treatment with a cherne-immunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; rituxirnab or obinutuzumab) or other treatment. In some embodiments, the FL is a Graded FL (e.g., Grade 1, 2, or 3a, but not Grade 3b FL). In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90). In some embodiments, the subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy. In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014;
32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
A. Therapeutic Methods for Dosing of Mosunetuzumab The present invention relates to methods of treating a subject having a relapsed and/or refractory (R/R) follicuiar lymphoma (FL) by administration of mosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a RIR FL that is RIR to at least one prior systemic therapy (e.g., one prior treatment with a onerno-irnmunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituxirnab or obinutuzurnab) or other treatment. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the C1D1 is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg;
e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg) and the Cl D3 is between 0.2 mg to 50.0 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 rug to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the C2D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 rng, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg);
and (b) the C2D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl Dl and Cl D2 are each less than the Cl D3. In some embodiments, the Cl Dl and Cl D2 are about equal. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250% (e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to about 200%, the Cl D2 is greater than the Cl Dl by about 50% to about 175%, the Cl D2 is greater than the Cl Dl by about 50% to about 150%, the Cl D2 is greater than the Cl Dl by about 50% to about 125%, the Cl D2 is greater than the Cl Dl by about 50% to about 100%, or the Cl D2 is greater than the Cl Dl by about 50%
to about 75%; e.g., the Cl D2 is greater than the Cl Dl by about 50%, the Cl D2 is greater than the Cl Dl by about 100%, the Cl D2 is greater than the Cl Dl by about 150%, the Cl D2 is greater than the Cl Dl by about 200%, or the Cl D2 is greater than the Cl Dl by about 250%).
In some embodiments, (a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 4.2 mg, and the 02D1 is 4.2 mg; (b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the Cl D3 is 3.0 mg, and the C2D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of the second dosing cycle is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
In some embodiments, the dosing regimen comprises one or more additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, ten dosing cycles, or more). In some embodiments, the dosing regimen comprises one to ten additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, or ten dosing cycles). In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of each of the one or more additional dosing cycles is 28 days ( 1 day). In some embodiments, each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab. In some embodiments, the method comprises administering to the subject each additional dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles. In some embodiments, each additional dose of mosunetuzumab is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the Cl D3 is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the Cl D3, and is between 0.2 mg to 50 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the C1D1 and C1D2 are each less than the Cl D3. In some embodiments, the C1D2 is greater than the C1D1 by about 50% to about 250%
(e.g., the C1D2 is greater than the C1D1 by about 50% to about 225%, the C1D2 is greater than the C1D1 by about 50% to about 200%, the C1D2 is greater than the C1D1 by about 50% to about 175%, the C1D2 is greater than the C1D1 by about 50% to about 150%, the C1D2 is greater than the C1D1 by about 50% to about 125%, the C1D2 is greater than the C1D1 by about 50% to about 100%, or the C1D2 is greater than the C1D1 by about 50% to about 75%; e.g., the C1D2 is greater than the C1D1 by about 50%, the C1D2 is greater than the C1D1 by about 100%, the C1D2 is greater than the C1D1 by about 150%, the C1D2 is greater than the C1D1 by about 200%, or the C1D2 is greater than the C1D1 by about 250%).
In some embodiments, (a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, the Cl D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg; (b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the C1D1, the C1D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, mosunetuzumab is administered intravenously.
In some embodiments, lenalidomide is administered during the second and subsequent cycles. In some embodiments, lenalidomide is not administered during the first cycle. In some embodiments, lenalidomide is administered daily. In some embodiments, lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is administered at a dose of 20 mg. In some embodiments, lenalidomide is administered orally.
In some embodiments, the subject was previously treated with at least one anti-monoclonal antibody. In some embodiments, the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day) , and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises administering 20 mg lenalidomide daily orally on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of each additional dose of mosunetuzumab.
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 80%-100%, between 85-100%, between 87-100%, between 90-100%, between 95-100%, between 80%-90%, between 80-85%, between 85-97%, between 85-95%, between 85-90%, between 85-87%, between 90-95%, or between 93-97%; e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more). In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 90%. In some embodiments, the overall response rate in a population of subjects having R/R
FL is at least 95%.
In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 99%.
In some embodiments, the complete response rate in a population of subjects having R/R
FL is at least 65% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more; e.g., between 65-100%, between 75-100%, between 85-100%, between 95-100%, between 65-90%, between 65-80%, between 65-70%, between 65-75%, or between 75-85%; e.g., about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 80%, about 85%, about 90%, or more). In some embodiments, the complete response rate in a population of subjects having R/R
FL is at least 75%.
In some embodiments, the complete response rate in a population of subjects having R/R FL is at least 85%.
In some embodiments, combination therapy with mosunetuzumab and lenalidomide exhibits synergistic effects in the efficacy of the therapy compared to therapy with mosunetuzumab or lenalidomide alone for treating subjects with R/R FL. In some embodiments, a population of subjects with R/R FL treated with a combination therapy with mosunetuzumab and lenalidomide exhibits a higher overall response rate compared to a population of subjects treated with monotherapy of mosunetuzumab or lenalidomide alone. In some embodiments, a population of subjects with R/R FL treated with a combination therapy with mosunetuzumab and lenalidomide exhibits a higher complete response rate compared to a population of subjects treated with monotherapy of mosunetuzumab or lenalidomide alone.
In some embodiments, the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT). In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40%
(e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, at least 45% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more;
e.g., between 45-100%, between 45-80%, between 45-60%, between 50-70%, between 55-65%, between 70-90%, between 70-80%, between 60-100%, between 80-100%; e.g., about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT).
In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, the subject is human. In some embodiments, each subject in the population is human.
B. Dosing Strategies for Mitigating Adverse Events The present invention relates to methods of treating a subject having a relapsed and/or refractory (RIR) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a RIR FL that is RiR to at least one prior systemic therapy (e.g., one prior treatment with a chemo-imrnunotherapy regimen) which included an anti-0D20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituximab or obinuturumab) or other treatment. The therapies and dosing regimens described herein provide acceptable safety profiles in subjects with RIR FL treated with the described dosing regimens.
1. CRS Symptoms and Grading Any of the methods described herein may involve monitoring a subject for cytokine release syndrome (CRS), e.g., a CRS event following commencement of any of the methods described above.
Current clinical management focuses on treating the individual signs and symptoms, providing supportive care, and attempting to dampen the inflammatory response using a high dose of corticosteroids.
However, this approach is not always successful, especially in the case of late intervention. The CRS
grading criteria used by the methods described herein are published by the American Society for Transplantation and Cellular Therapy (ASTCT) to define mild, moderate, severe, or life-threatening CRS
and harmonize reporting across clinical trials to allow rapid recognition and treatment of CRS (Lee et al.
Biol Blood Marrow Transplantation. 25(4): 625-638, 2019). The ASTCT criteria is intended to be objective, easy to apply, and more accurately categorize the severity of CRS.
This CRS grading system is shown below in Table 1.
Table 1. CRS Grading System CRS
Parameter Grade 1 Grade 2 Grade 3 Grade 4 Fever Temperature Temperature Temperature Temperature with Hypotension None Not requiring Requiring a Requiring multiple vasopressors vasopressor with or vasopressors without vasopressin (excluding vasopressin) and/or Hypoxia None Requiring low-glow Requiring high-flow Requiring positive nasal cannula or nasal cannula, pressure blow-by facemask, (e.g., CRAP, BiPAP, nonrebreather mask intubation and or Venturi mask mechanical ventilation) ASTCT = American Society for Transplantation and Cellular Therapy; BiPAP =
bilevel positive airway pressure; CRAP = continuous positive airway pressure; CRS = cytokine release syndrome; CTCAE =
Common Terminology Criteria for Adverse Events.
Fever is defined as a temperature 38 00 not attributable to any other cause.
In subjects who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is determined by hypotension and/or hypoxia.
CRS grade is determined by the more severe event, hypotension or hypoxia not attributable to any other cause. For example, a subject with temperature of 39.5 C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as Grade 3 CRS.
Low-flow nasal cannula is defined as oxygen delivered at 6 L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at >6 L/minute.
CRS is associated with elevations in a wide array of cytokines, including marked elevations in IFN-y, IL-6, and TNF-oc levels. Emerging evidence implicates IL-6, in particular, as a central mediator in CRS. IL-6 is a proinflammatory, multi-functional cytokine produced by a variety of cell types, which has been shown to be involved in a diverse array of physiological processes, including T cell activation.
Regardless of the inciting agent, CRS is associated with high IL-6 levels (Nagorsen et al. Cytokine. 25(1):
31-5, 2004; Lee et al. Blood. 124(2): 188-95, 2014); Doesegger et al. Clin.
Transl. Immunology. 4(7): e39, 2015), and IL-6 correlates with the severity of CRS, with subjects who experience a Grade 4 or 5 CRS
event having much higher IL-6 levels compared to subjects who do not experience CRS or experience milder CRS (Grades 0-3) (Chen et al. J. lmmunol. Methods. 434:1-8, 2016).
Therefore, blocking the inflammatory action of IL-6 using an agent that inhibits IL-6-mediated signaling to manage CRS observed in subjects during the double-step fractionated, dose-escalation dosing regimen is an alternative to steroid treatment that would not be expected to negatively impact T
cell function or diminish the efficacy or clinical benefit of mosunetuzumab therapy in the treatment of CD20-positive cell proliferative disorders (e.g., a B cell proliferative disorders).
If the subject has a CRS event that does not resolve or worsens within 24 hours of administering the IL-6R antagonist to treat the symptoms of the CRS event, and the method may further comprise administering to the subject one or more additional doses of the IL-6R
antagonist to manage the CRS
event. The subject may be administered a corticosteroid, such as methylprednisolone or dexamethasone if CRS event is not managed through administration of the IL-6R antagonist.
2. Other Adverse Events and Grading Any of the methods described herein may involve monitoring a subject for additional non-CRS
adverse events. Incidence, nature, and severity of physical findings and adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5.0). Other than CRS, one of the most common adverse events reported in patients undergoing treatment with mosunetuzumab and/or lenalidomide is neutropenia (e.g., febrile neutropenia).
Neutropenia is characterized by an abnormally low blood count of neutrophils, which are a type of white blood cells. Neutropenia may lead to an increased risk of infection. The generally accepted reference range for absolute neutrophil count (ANC) in adult humans is 1,500 to 8,000 cells/p1 of blood.
Mild neutropenia is characterized by ANC between 1,000-1,500 cells/p.L (Grade 1-2); moderate neutropenia is characterized by ANC between 500 and 1,000 cells/pt (Grade 3), and severe neutropenia is characterized by ANC below 500 cells/4 (Grade 4). Febrile neutropenia (Grade 3+ neutropenia) is characterized by ANC below 1,000 cells/.LL in addition to either a single temperature measurement greater than 38.3 C or sustained temperature measurements greater than 38 C
for more than one hour.
3. Dosing Regimens with Acceptable Safety Profiles In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, each subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Onco/ 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In one aspect, the methods of the invention features premedication with corticosteroids to reduce adverse effects of mosunetuzumab administration. In some embodiments, premedication with corticosteroids reduces the rate of cytokine release syndrome (CRS) in subjects treated with mosunetuzumab (e.g., subjects administered a combination of mosunetuzumab and lenalidomide).
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, the corticosteroid used is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg). In some embodiments, dexamethasone is administered intravenously.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the Cl Dl-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose Cl Dl-Cl D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of each additional dose of mosunetuzumab.
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
In some embodiments, the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects having R/R
FL. In some embodiments, the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects. In some embodiments, the incidence rate of an adverse event is not significantly higher in a population of subjects having R/R FL
when treated with a combination therapy of mosunetuzumab and lenalidomide in comparison to a population of subjects having R/R FL treated with a monotherapy of mosunetuzumab or lenalidomide alone.
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45% (e.g., less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0%
to about 50%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 45%, between about 30% to about 40%, between about 20% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 45%, or between about 25% to about 45%; e.g., about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 1%, or about 0%).
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 35%. In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%. In some embodiments, the incidence rate of CRS is about 30%.
In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%; e.g., between 0% and 10%, between 0% and 9%, between 0% and 8%, between 0% and 7%, between 0% and 6%, between 0% and 5%, between 0% and 4%, between 0%
and 3%, between 0% and 2%, between 0% and 1%, between 1% and 3%, between 1%
and 5%, between 1% and 10%, between 3% and 5%, between 5% and 8%, between 5% and 10%, or between 8% and 10%). In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 5%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%. In some embodiments, the incidence rate of CRS having a grade of 3 or higher is about 0%.
In some embodiments, the incidence rate of neutropenia in a population of patients having R/R FL and treated with combination therapy of mosunetuzumab and lenalidomide is less than 40%
(e.g., less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0% to about 40%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 40%, between about 30% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 40%, or between about 25% to about 40%;
e.g., about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 3%, about 1%, or about 0%). In some embodiments, the incidence rate of neutropenia is less than 30%. In some embodiments, the incidence rate of neutropenia is less than 20%. In some embodiments, the incidence rate of neutropenia having Grade of 3 or 4 is about 19%. In some embodiments, the incidence rate of febrile neutropenia is about 0%.
The methods described herein may result in an acceptable safety profile for subjects having R/R
mosunetuzumab being treated with combination therapy of mosunetuzumab and lenalidomide. In some instances, treatment using the methods described herein that result in intravenously administering mosunetuzumab in the context of a fractionated, dose-escalation dosing regimen and oral administration of lenalidomide results in a reduction (e.g., by 20% or greater, 25% or greater, 30% or greater, 35% or greater, 40% or greater, 45% or greater, 50% or greater, 55% or greater, 60%
or greater, 65% or greater, 70% or greater, 75% or greater, BO% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, or 99% or greater; e.g., between 20%
and 100%, between 20%
and 90%, between 20% and 80%, between 20% and 70%, between 20% and 60%, between 20% and 50%, between 20% and 40%, between 20% and 30%, between 40% and 100%, between 60% and 100%, between 80% and 100%, between 30% and 70%, between 40% and 60%, between 30%
and 50%, between 50% and 80%, or between 90% and 100%; e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 99%, or about 100%) or complete inhibition (100% reduction) of undesirable adverse events, such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or hepatotoxicities, following treatment with mosunetuzurnab using the fractionated, dose-escalation dosing regimen of the invention relative to treatment with mosunetuzurnab using a non-fractioned dosing regimen.
IV. THERAPEUTIC AGENTS
A. Mosunetuzumab The invention provides mosunotuzumab, a bispecific antibody that binds to CD20 and CD3, useful for treating relapsed and/or refractory (R/R) follicular lymphoma (FL).
The FL may be of Grades 1, 2, or 3a, but not Grade 3b.
In some instances, the invention provides mosunetuzumab that includes an anti-CD20 arm having a first binding domain comprising at least one, two, three, four, five, or six hypervariable regions (HVRs) selected from (a) an HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID
NO: 1); (b) an HVR-H2 comprising the amino acid sequence of AlYPGNGDTSYNQKFKG
(SEQ ID NO:
2); (c) an HVR-H3 comprising the amino acid sequence of VVYYSNSYWYFDV (SEQ ID
NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) an comprising the amino acid sequence of APSNLAS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6). In some instances, rnosunetuzumab comprises at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 17-20, respectively, and/or at least one (e.g., 1, 2,3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID
NOs: 21-24, respectively. In some instances, mesunetuzumab comprises an anti-CD20 arm comprising a first binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 7; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 8;
or (c) a VH domain as in (a) and a VL domain as in (b). Accordingly, in some instances, the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO: 7 and a VL domain comprising an amino acid sequence of SEQ ID NO: 8.
In some instances, the invention provides mosunetuzurnab that includes an anti-CD3 arm having a second binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) an HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) an HVR-H3 comprising the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11); (d) an HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) an HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and (f) an HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14). In some instances, mosunetuzumab comprises at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 25-28, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs:
29-32, respectively.
In some instances, mesunetuzurnab comprises an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 15; (b) a VL domain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 16; or (c) a VH domain as in (a) and a VL
domain as in (b).
Accordingly, in some instances, the second binding domain comprises a VH
domain comprising an amino acid sequence of SEQ ID NO: 15 and a VL domain comprising an amino acid sequence of SEQ ID NO:
16.
In some instances, the invention provides mosunetuzumab that includes (1) an anti-CD20 arm having a first binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1); (b) an HVR-H2 comprising the amino acid sequence of AlYPGNGDTSYNQKFKG (SEQ ID NO: 2); (c) an comprising the amino acid sequence of VVYYSNSYWYFDV (SEQ ID NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) an HVR-L2 comprising the amino acid sequence of APSNLAS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6); and (2) an anti-CD3 arm having a second binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) an HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) an HVR-H3 comprising the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11); (d) an HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) an HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and (f) an HVR-L3 comprising the amino acid sequence of TQSFILRT
(SEQ ID NO: 14). In some instances, mosunetuzumab comprises (1) at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID
NOs: 17-20, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-Li, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs: 21-24, respectively, and (2) at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 25-28, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID
NOs: 29-32, respectively. In some instances, mosunetuzumab comprises (1) an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
sequence identity) to, or the sequence of, SEQ ID NO: 7; (b) a VL domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 8; or (c) a VH domain as in (a) and a VL domain as in (b), and (2) an anti-CD3 arm comprising a second binding domain comprising (a) a VH
domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO:
15; (b) a VL domain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 16; or (c) a VH domain as in (a) and a VL domain as in (b). In some instances, mosuretuzumab comprises (1) a first binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 7 and a VL domain comprising an amino acid sequence of SEQ ID NO: 8 and (2) a second binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID
NO: 15 and a VL domain comprising an amino acid sequence of SEQ ID NO: 16.
In some instances, rnosunetuzurnab has the International Nonproprietary Names for Pharmaceutical Substances (INN) List 117 (WHO Drug Information, Vol. 31, No.
2, 2017, p. 303), or CAS
Registry No. 1905409-39-3, and having (1) an anti-CD20 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 33 and 34 , respectively; and (2) an anti-CD3 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 35 and 36, respectively. In some instances, mosunetuzumab comprises (1) an anti-CD20 arm comprising a first binding domain comprising (a) a heavy chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ
ID NO: 33; (b) a light chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO:
34; or (c) a heavy chain as in (a) and a light chain as in (b), and (2) an anti-CD3 arm comprising a second binding domain comprising (a) a heavy chain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 35; (b) a light chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
sequence identity) to, or the sequence of, SEQ ID NO: 36; or (c) a heavy chain as in (a) and a light chain as in (b). In some instances, rflosunetuzurnab comprises (1) an anti-CD20 arm comprising a first binding domain comprising a heavy chain comprising an amino acid sequence of SEQ ID
NO: 33 and a light chain comprising an amino acid sequence of SEQ ID NO: 34 and (2) an anti-CD3 arm comprising a second binding domain comprising a heavy chain comprising an amino acid sequence of SEQ ID NO: 35 and a light chain comprising an amino acid sequence of SEQ ID NO: 36.
Amino acid sequences of mosunetuzumab are summarized in Table 2 below.
Table 2. Sequence 113s for Mosunetuzumab CD3 Arm CD20 Arm SEQ ID NO: Description SEQ ID NO: Description
The term "cluster of differentiation 3" or "CD3," as used herein, refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3E, CD3y, CD3a, and 0D38 chains. The term encompasses "full-length," unprocessed CD3 (e.g., unprocessed or unmodified CD3E or CD3y), as well as any form of CD3 that results from processing in the cell. The term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants.
CD3 includes, for example, human CD3c protein (NCBI RefSeq No. NP 000724), which is 207 amino acids in length, and human CD3y protein (NCB! RefSeq No. NP 000064), which is 182 amino acids in length.
The terms ''anti-CD20 antibody" and "an antibody that binds to CD20" refer to an antibody that is capable of binding CD20 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD20. In one embodiment, the extent of binding of an anti-CD20 antibody to an unrelated, non-CD20 protein is less than about 10% of the binding of the antibody to CD20 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to CD20 has a dissociation constant (KO of 1 pM, 100 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or 0.001 nM (e.g., 10-8M or less, e.g., from 10-8 M to 1013 M, e.g., from 10-9 M to 1013 M). In certain embodiments, an anti-CD20 antibody binds to an epitope of CD20 that is conserved among CD20 from different species. In some embodiments, the anti-CD20 antibody is a monoclonal antibody. In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is rituximab. In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is obinutuzumab.
As used herein, the term "rituximab" or "RITUXANO" refers to an anti-CD20 antibody (e.g., anti-CD20 monoclonal antibody) having the Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 77 (WHO Drug Information, Vol. 11, No. 2, 1997, p. 99), or the CAS
Registry Number 174722-31-7.
As used herein, the term "obinutuzumab" or "GAZYVAO" refers to an anti-CD20 antibody (e.g., anti-CD20 monoclonal antibody) having the Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 99 (WHO Drug Information, Vol.
22, No. 2, 2008, p.
396), Proposed International Nonproprietary Names for Pharmaceutical Substances (Proposed INN) List 108 (WHO Drug Information, Vol. 26, No. 4,2012, p.453), or the CAS Registry Number 949142-50-1.
The term "cluster of differentiation 20" or "CD20," as used herein, refers to any native CD20 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses "full-length," unprocessed CD20, as well as any form of CD20 that results from processing in the cell. The term also encompasses naturally occurring variants of CD20, including, for example, splice variants or allelic variants. CD20 includes, for example, human CD20 protein (see, e.g., NCBI RefSeq Nos. NP 068769.2 and NP 690605.1), which is 297 amino acids in length and may be generated, for example, from variant mRNA transcripts that lack a portion of the 5' UTR (see, e.g., NCB! RefSeq No. NM 021950.3) or longer variant mRNA transcripts (see, e.g., NCB! RefSeq No.
NM 152866.2).
The terms "anti-CD20/anti-CD3 bispecific antibody," "bispecific anti-CD20/anti-CD3 antibody,"
and "antibody that binds to CD20 and CD3," or variants thereof, refer to a multispecific antibody (e.g., a bispecific antibody) that is capable of binding to CD20 and CD3 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting CD20 and/or CD3. In one embodiment, the extent of binding of a bispecific antibody that binds to CD20 and CD3 to an unrelated, non-CD3 protein and/or non-CD20 protein is less than about 10% of the binding of the antibody to CD3 and/or CD20 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, a bispecific antibody that binds to CD20 and CD3 has a dissociation constant (KD) of 1 pM, 5 100 nM, 5 10 nM, 1 nM, 5 0.1 nM, 5 0.01 nM, or 5 0.001 nM (e.g., 10-8 M or less, e.g., from 10-8M
to 10-13M, e.g., from 10-9M
to 10-13 M). In certain embodiments, a bispecific antibody that binds to CD20 and CD3 binds to an epitope of CD3 that is conserved among CD3 from different species and/or an epitope of CD20 that is conserved among 0D20 from different species. In one embodiment, the bispecific antibody binds monovalently to CD20 and binds monovalently to CD3. In some embodiments, a bispecific antibody that binds to CD20 and CD3 is rnosunetuzumab.
As used herein, the term "mosunetuzumab" refers to an anti-CD20/anti-CD3 bispecific antibody having the International Nonproprietary Names for Pharmaceutical Substances (INN) List 117 (WHO Drug Information, Vol. 31, No. 2, 2017, p. 303), or the CAS Registry Number 1905409-39-3.
As used herein, the term "lenalidomide" refers to a compound having the CAS
Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindo1-2-yl)piperidine-2,6-dione.
Lenalidomide is also known by tradenames including REVLIMIDO, linamid, and lenalid. Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula C13H13N303.
As used herein, the term "binds," ''specifically binds to," or is "specific for" refers to measurable and reproducible interactions such as binding between a target and an antibody, which is determinative of the presence of the target in the presence of a heterogeneous population of molecules including biological molecules. For example, an antibody that specifically binds to a target (which can be an epitope) is an antibody that binds this target with greater affinity, avidity, more readily, and/or with greater duration than it binds to other targets. In one embodiment, the extent of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target as measured, for example, by a radioimmunoassay (RIA). In certain embodiments, an antibody that specifically binds to a target has a dissociation constant (KD) of 1 pM, 100 nM, 10 nM, 1 nM, or 0.1 nM. In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved among the protein from different species. In another embodiment, specific binding can include, but does not require exclusive binding. The term as used herein can be exhibited, for example, by a molecule having a KD for the target of 10-4 M or lower, alternatively 10-5 M or lower, alternatively 10-6 M or lower, alternatively 10-7 M or lower, alternatively 10-8 M or lower, alternatively 10-9 M or lower, alternatively 10-10 M or lower, alternatively 10-11 M or lower, alternatively 10-12 M or lower or a Kr) in the range of 10-4 M to 10-6 M or 10-6 M to 10-10 M or 10-7 M to 10-9 M. As will be appreciated by the skilled artisan, affinity and KD values are inversely related. A high affinity for an antigen is measured by a low KD
value. In one embodiment, the term "specific binding" refers to binding where a molecule binds to a particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.
"Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNO (DNASTARG) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the (% amino acid sequence identity of A to B
will not equal the %
amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A
pharmaceutically acceptable carrier includes, but is not limited to, a buffcr, cxcipicnt, stabilizer, or preservative.
As used herein, the term "chemotherapeutic agent" refers to a compound useful in the treatment of a cancer, such as a R/R FL. Examples of chemotherapeutic agents include EG
FR inhibitors (including small molecule inhibitors (e.g., erlotinib (TARCEVAO, Genentech/OSI Pharm.);
PD 183805 (Cl 1033, 2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-743-(4-morpholinyl)propoxy]-6-quinazolinyll-, dihydrochloride, Pfizer Inc.); ZD1839, gefitinib (IRESSAO) 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-methylphenyl-amino)-quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-phenyl)-N2-(1-methyl-piperidin-4-y1)-pyrimido[5,4-d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166 ((R)-4-[4-[(1-phenylethyl)amino]-1H-pyrrolo[2,3-d]pyrimidin-6-yll-phenol); (R)-6-(4-hydroxyphenyI)-4-[(1-phenylethyl)amino]-7H-pyrrolo[2,3-d]pyrimidine);
CL-387785 (N-[4-[(3-bromophenyl)amino]-6-quinazoliny1]-2-butynamide); EKB-569 (N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinoliny1]-4-(dimethylamino)-2-butenamide) (Wyeth); AG1478 (Pfizer); A01571 (SU 5271; Pfizer); and dual EGFR/HER2 tyrosine kinase inhibitors such as lapatinib (TYKERB , GSK572016 or N-[3-chloro-4-[(3 fluorophenyl)methoxy]phenyI]-6[5[[[2methylsulfonypethyl]amino]methyl]-2-furanyl]-4-quinazolinamine)); a tyrosine kinase inhibitor (e.g., an EGFR inhibitor; a small molecule HER2 tyrosine kinase inhibitor such as TAK165 (Takeda); CP-724,714, an oral selective inhibitor of the ErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER
inhibitors such as EKB-569 (available from Wyeth) which preferentially binds EGFR but inhibits both HER2 and EGFR-overexpressing cells; PKI-166 (Novartis); pan-HER inhibitors such as canertinib (CI-1033; Pharmacia); Rat-1 inhibitors such as antisense agent ISIS-5132 (ISIS
Pharmaceuticals) which inhibit Rat-1 signaling; non-HER-targeted tyrosine kinase inhibitors such as imatinib mesylate (GLEEVECO, Glaxo SmithKline); multi-targeted tyrosine kinase inhibitors such as sunitinib (SUTENTO, Pfizer); VEGF receptor tyrosine kinase inhibitors such as vatalanib (PTK787/ZK222584, Novartis/Schering AG); MAPK extracellular regulated kinase I inhibitor CI-1040 (Pharmacia);
quinazolines, such as PD 153035,4-(3-chloroanilino) quinazoline;
pyridopyrimidines; pyrimidopyrimidines;
pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706;
pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d] pyrimidines; curcumin (diferuloyl methane, 4,5-bis (4-fluoroanilino)phthalimide); tyrphostines containing nitrothiophene moieties;
PD-0183805 (Warner-Lamber); antisense molecules (e.g., those that bind to HER-encoding nucleic acid); quinoxalines (U.S.
Patent No. 5,804,396); tryphostins (U.S. Patent No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787 (Novartis/Schering AG); pan-HER inhibitors such as CI-1033 (Pfizer); Affinitac (ISIS 3521; Isis/Lilly); PKI
166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth);
Semaxinib (Pfizer);
ZD6474 (AstraZeneca); PTK-787 (Novartis/Schering AG); INC-1C11 (Imolone); and rapamycin (sirolimus, RAPAMUNEO)); proteasome inhibitors such as bortezomib (VELCADEO, Millennium Pharm.); disulfiram;
epigallocatechin gallate; salinosporamide A; carfilzomib; 17-AAG
(geldanamycin); radicicol; lactate dehydrogenase A (LDH-A); fulvestrant (FASLODEXO, AstraZeneca); letrozole (FEMARAO, Novartis), finasunate (VATALANIBO, Novartis); oxaliplatin (ELOXATING, Sanofi); 5-FU (5-fluorouracil); leucovorin;
lonafamib (SCH 66336); sorafenib (NEXAVARO, Bayer Labs); AG1478, alkylating agents such as thiotepa and CYTOXAN cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including topotecan and irinotecan);
bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8); adrenocorticosteroids (including prednisone and prednisolone);
cyproterone acetate; 5a-reductases including finasteride and dutasteride);
vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat dolastatin; aldesleukin, talc duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin y1 and calicheamicin w1); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;
pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane;
folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine;
demecolcine; diaziquone;
elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate;
hydroxyurea; lentinan;
lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone;
mitoxantrone:
mopidamnol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic acid; 2-ethylhydrazide; procarbazine; PSKO polysaccharide complex (JHS Natural Products); razoxane; rhizoxin;
sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan;
vindesine; dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa;
chloranmbucil; GEMZARO (gemcitabine); 6-thioguanine; mercaptopurine;
methotrexate; etoposide (VP-16); ifosfamide; mitoxantrone; novantrone; teniposide; edatrexate; daunomycin;
aminopterin; capecitabine (XELODA0); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;
difluoromethylornithine (DMF0);
retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above.
Chemotherapeutic agents also include (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEXO; tamoxifen citrate), raloxifene, droloxifene, iodoxyfene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON
(toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE
(megestrol acetate), AROMASINO (exemestane; Pfizer), formestanie, fadrozole, RIVISORO (vorozole), FEMARAO (letrozole;
Novartis), and ARIMIDEXO (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; buserelin, tripterelin, medroxyprogesterone acetate, diethylstilbestrol, premarin, fluoxymesterone, all transretionic acid, fenretinide, as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, such as, for example, PKC-alpha, Ralf and H-Ras;
(vii) ribozymes such as VEGF
expression inhibitors (e.g., ANGIOZYMEO) and HER2 expression inhibitors;
(viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN , LEUVECTIN , and VAXIDO; (ix) growth inhibitory agents including vincas (e.g., vincristine and vinblastine), NAVELBINEO
(vinorelbine), taxanes (e.g., paclitaxel, nab-paclitaxel, and docetaxel), topoisomerase II inhibitors (e.g., doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin), and DNA alkylating agents (e.g., tamoxigen, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C); and (x) pharmaceutically acceptable salts, acids, prodrugs, and derivatives of any of the above.
The term "chemo-immunotherapy" refers to combination therapy that includes both chemotherapy drugs and immunotherapeutic agents. In some embodiments, chemo-immunotherapy is used to treat a cancer, e.g., a CD20-positive cancer, e.g., a NHL, e.g., a FL. In some embodiments, immunotherapeutic agents include an antibody, e.g., an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody). In some embodiments, the anti-CD20 antibody or anti-CD20 monoclonal antibody is rituximab or obinutuzumab. In some embodiments, chemo-immunotherapy includes R-CHOP.
The term "R-CHOP" as used herein refers to a treatment comprising rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. In some embodiments, R-CHOP is a chemotherapy treatment or regimen used in the treatment of a cancer, optionally a B cell proliferative disorder (e.g., a non-Hodgkin's lymphoma; e.g., a DLBCL or a high grade B-cell lymphoma). In some embodiments, R-CHOP is the standard of care (SOC) or standard therapy to be administered to a subject to treat the cancer, optionally the B cell proliferative disorder (e.g., the non-Hodgkin's lymphoma; e.g., the DLBCL or the high grade B-cell lymphoma). In some embodiments, R-CHOP is the standard front-line or first-line therapy to be administered to a previously untreated subject. In some embodiments, R-CHOP is administered every 3 weeks (in 21-day dosing cycles) for 3 to 6 dosing cycles. In some embodiments, the dosing regimen for R-CHOP therapy comprises 21-day dosing cycles, wherein during each dosing cycle, the subject is administered 375 mg/m2 rituximab IV, and also administered cyclophosphamide, doxorubicin, vincristine, and prednisone.
In some embodiments, the dosing regimen for R-CHOP therapy further comprises 750 mg/m2 cyclophosphamide IV, 50 mg/m2 doxorubicin IV, 1.4 mg/m2 vincristine IV, and 5 days of 100 mg or 40 mg/m2 per day prednisone oral. In some embodiments, a maximum single dose of vincristine is 2 mg.
The term "cytotoxic agent" as used herein refers to any agent that is detrimental to cells (e.g., causes cell death, inhibits proliferation, or otherwise hinders a cellular function). Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., 211,41, 1311, 1251, 90y, 186Re, iaeRe, 153sm, 212Bi, 32p, 212Pb, and radioactive isotopes of Lu); chemotherapeutic agents; enzymes and fragments thereof such as nucleolytic enzymes; and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.
Exemplary cytotoxic agents can be selected from anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase 1 inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, inhibitors of LDH-A, inhibitors of fatty acid biosynthesis, cell cycle signaling inhibitors, HDAC inhibitors, proteasome inhibitors, and inhibitors of cancer metabolism. In one instance, the cytotoxic agent is a platinum-based chemotherapeutic agent (e.g., carboplatin or cisplatin). In one instance, the cytotoxic agent is an antagonist of EG FR, e.g., N-(3-ethynylphenyI)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (e.g., erlotinib).
In one instance the cytotoxic agent is a RAF inhibitor, e.g., a BRAF and/or CRAF inhibitor. In one instance the RAF inhibitor is vemurafenib. In one instance, the cytotoxic agent is a PI3K inhibitor.
The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
The term "synergistic effect" is used to refer to an effect resulting from the combination use of two or more therapeutic products (e.g., mosunetuzumab and lenalidomide), which is greater than the sum of the effects observed when the two or more therapeutic products are used individually. In some embodiments, synergistic effect is observed in the response rate (e.g., complete response rate or overall response rate) of a population of subjects having relapsed and/or refractory (R/R) non-Hodgkin's Lymphoma (NHL; e.g., R/R follicular lymphoma (FL)) treated with a combination therapy comprising mosunetuzumab and lenalidomide. In some embodiments, a population of subjects having R/R FL exhibits a higher complete response rate when treated with combination therapy comprising mosunetuzumab and lenalidomide compared to a population of subjects treated with monotherapy mosunetuzumab or lenalidomide. In some embodiments, a population of subjects having R/R FL exhibits a higher overall response rate when treated with combination therapy comprising mosunetuzumab and lenalidomide compared to a population of subjects treated with monotherapy mosunetuzumab or lenalidomide.
III. THERAPEUTIC METHODS
Provided herein are methods of treating a subject having a relapsed and/or refractory (R/R) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidomkte as a combination therapy, in particular, the present invention relates to methods of treating a subject having a R/R FL that is R/R to at :east one prior systemic therapy (e.g., one prior treatment with a cherne-immunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; rituxirnab or obinutuzumab) or other treatment. In some embodiments, the FL is a Graded FL (e.g., Grade 1, 2, or 3a, but not Grade 3b FL). In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90). In some embodiments, the subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy. In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014;
32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
A. Therapeutic Methods for Dosing of Mosunetuzumab The present invention relates to methods of treating a subject having a relapsed and/or refractory (R/R) follicuiar lymphoma (FL) by administration of mosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a RIR FL that is RIR to at least one prior systemic therapy (e.g., one prior treatment with a onerno-irnmunotherapy regimen) which included an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituxirnab or obinutuzurnab) or other treatment. In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9). In some embodiments the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the C1D1 is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg;
e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg) and the Cl D3 is between 0.2 mg to 50.0 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg (e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 rug to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the C2D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 rng, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg);
and (b) the C2D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the Cl Dl and Cl D2 are each less than the Cl D3. In some embodiments, the Cl Dl and Cl D2 are about equal. In some embodiments, the Cl D2 is greater than the Cl Dl by about 50% to about 250% (e.g., the Cl D2 is greater than the Cl Dl by about 50% to about 225%, the Cl D2 is greater than the Cl Dl by about 50% to about 200%, the Cl D2 is greater than the Cl Dl by about 50% to about 175%, the Cl D2 is greater than the Cl Dl by about 50% to about 150%, the Cl D2 is greater than the Cl Dl by about 50% to about 125%, the Cl D2 is greater than the Cl Dl by about 50% to about 100%, or the Cl D2 is greater than the Cl Dl by about 50%
to about 75%; e.g., the Cl D2 is greater than the Cl Dl by about 50%, the Cl D2 is greater than the Cl Dl by about 100%, the Cl D2 is greater than the Cl Dl by about 150%, the Cl D2 is greater than the Cl Dl by about 200%, or the Cl D2 is greater than the Cl Dl by about 250%).
In some embodiments, (a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 4.2 mg, and the 02D1 is 4.2 mg; (b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the Cl D3 is 3.0 mg, and the C2D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of the second dosing cycle is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
In some embodiments, the dosing regimen comprises one or more additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, ten dosing cycles, or more). In some embodiments, the dosing regimen comprises one to ten additional dosing cycles (e.g., one dosing cycle, two dosing cycles, three dosing cycles, four dosing cycles, five dosing cycles, six dosing cycles, seven dosing cycles, eight dosing cycles, nine dosing cycles, or ten dosing cycles). In some embodiments, the dosing regimen comprises ten additional dosing cycles. In some embodiments, the length of each of the one or more additional dosing cycles is 28 days ( 1 day). In some embodiments, each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab. In some embodiments, the method comprises administering to the subject each additional dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles. In some embodiments, each additional dose of mosunetuzumab is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg (e.g., 0.05 mg to 4.0 mg, 0.1 mg to 4.0 mg, 0.2 mg to 4.0 mg, 0.3 mg to 4.0 mg, 0.4 mg to 4.0 mg, 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.1 mg to 3.5 mg, 0.1 mg to 3.0 mg, 0.1 mg to 2.5 mg, 0.1 mg to 2.0 mg, 0.1 mg to 1.5 mg, 0.1 mg to 1 mg, 0.1 mg to 0.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.05 mg, about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 0.05 mg to 20.0 mg (e.g., 0.1 mg to 20.0 mg, 0.2 mg to 20.0 mg, 0.3 mg to 20.0 mg, 0.4 mg to 20.0 mg, 0.5 mg to 20.0 mg, 1.0 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 0.5 mg to 15.0 mg, 0.5 mg to 10.0 mg, 0.5 mg to 9.0 mg, 0.5 mg to 8.0 mg, 0.5 mg to 7.0 mg, 0.5 mg to 6.0 mg, 0.5 mg to 5.0 mg, 0.5 mg to 4.0 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 0.1 mg, about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the Cl D3 is between 0.2 mg to 50.0 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the Cl D3, and is between 0.2 mg to 50 mg(e.g., 0.3 mg to 50.0 mg, 0.4 mg to 50.0 mg, 0.5 mg to 50.0 mg, 1.0 mg to 50.0 mg, 2.0 mg to 50.0 mg, 3.0 mg to 50.0 mg, 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 1.0 mg to 45.0 mg, 1.0 mg to 40.0 mg, 1.0 mg to 35.0 mg, 1.0 mg to 30.0 mg, 1.0 mg to 25.0 mg, 1.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 4.0 mg to 4.5 mg, 3.0 mg to 10.0 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 0.2 mg, about 0.5 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.4 mg to 4.0 mg (e.g., 0.5 mg to 4.0 mg, 0.75 mg to 4.0 mg, 1.0 mg to 4.0 mg, 1.25 mg to 4.0 mg, 1.5 mg to 4.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 4.0 mg, 3.0 mg to 4.0 mg, 3.5 mg to 4.0 mg, 0.5 mg to 3.5 mg, 0.5 mg to 3.0 mg, 0.5 mg to 2.0 mg, 0.5 mg to 1.0 mg, 0.75 mg to 1.25 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, 0.7 mg to 0.9 mg, or 0.9 mg to 1.1 mg; e.g., about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, about 3.0 mg, about 3.5 mg, or about 4.0 mg), the Cl D2 is between 1.0 mg to 20.0 mg (e.g., 1.1 mg to 20.0 mg, 1.2 mg to 20.0 mg, 1.3 mg to 20.0 mg, 1.4 mg to 20.0 mg, 1.5 mg to 20.0 mg, 2.0 mg to 20.0 mg, 3.0 mg to 20.0 mg, 4.0 mg to 20.0 mg, 5.0 mg to 20.0 mg, 6.0 mg to 20.0 mg, 7.0 mg to 20.0 mg, 8.0 mg to 20.0 mg, 9.0 mg to 20.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 1.0 mg to 15.0 mg, 1.0 mg to 10.0 mg, 1.0 mg to 9.0 mg, 1.0 mg to 8.0 mg, 1.0 mg to 7.0 mg, 1.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.0 mg, 10.0 mg to 20.0 mg, 15.0 mg to 20.0 mg, 5.0 mg to 15.0 mg, or 5.0 mg to 10.0 mg; e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 15.0 mg, or about 20.0 mg), and the C1D3 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg (e.g., 4.0 mg to 50.0 mg, 5.0 mg to 50.0 mg, 10.0 mg to 50.0 mg, 15.0 mg to 50.0 mg, 20.0 mg to 50.0 mg, 25.0 mg to 50.0 mg, 30.0 mg to 50.0 mg, 35.0 mg to 50.0 mg, 40.0 mg to 50.0 mg, 45.0 mg to 50.0 mg, 3.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 25.0 mg to 50.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, about 45.0 mg, or about 50.0 mg).
In some embodiments, (a) the Cl Dl is between 0.8 mg to 3.0 mg (e.g., 0.9 mg to 3.0 mg, 1.0 mg to 3.0 mg, 1.25 mg to 3.0 mg, 1.5 mg to 3.0 mg, 2.0 mg to 3.0 mg, 2.5 mg to 3.0 mg, 0.8 mg to 3.0 mg, 0.8 mg to 2.5 mg, 0.8 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.8 mg to 1.0 mg, 1.0 mg to 3.0 mg, 1.5 mg to 2.0 mg, or 0.9 mg to 1.1 mg; e.g., about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.75 mg, about 2.0 mg, about 2.25 mg, about 2.5 mg, about 2.75 mg, or about 3.0 mg), the Cl D2 is between 1.0 mg to 6.0 mg (e.g., 1.5 mg to 6.0 mg, 2.0 mg to 6.0 mg, 2.5 mg to 6.0 mg, 3.0 mg to 6.0 mg, 3.5 mg to 6.0 mg, 4.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 5.0 mg to 6.0 mg, 1.0 mg to 5.0 mg, 1.0 mg to 4.5 mg, 1.0 mg to 4.0 mg, 1.0 mg to 3.5 mg, 1.0 mg to 3.0 mg, 1.0 mg to 2.5 mg, 1.0 mg to 2.0 mg, 1.0 mg to 1.5 mg, 1.5 mg to 2.5 mg, 3.0 mg to 6.0 mg, 2.0 mg to 4.0 mg, 2.5 mg to 5.0 mg, or 2.5 mg to 3.5 mg;
e.g., about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about. 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, or about 6.0 mg), and the Cl D3 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg;
e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg); and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg (e.g., 4.0 mg to 45.0 mg, 5.0 mg to 45.0 mg, 10.0 mg to 45.0 mg, 15.0 mg to 45.0 mg, 20.0 mg to 45.0 mg, 25.0 mg to 45.0 mg, 30.0 mg to 45.0 mg, 35.0 mg to 45.0 mg, 40.0 mg to 45.0 mg, 3.0 mg to 40.0 mg, 3.0 mg to 35.0 mg, 3.0 mg to 30.0 mg, 3.0 mg to 25.0 mg, 3.0 mg to 20.0 mg, 3.0 mg to 15.0 mg, 3.0 mg to 10.0 mg, 3.0 mg to 5.0 mg, 10.0 mg to 20.0 mg, 20.0 mg to 30.0 mg, 30.0 mg to 40.0 mg, 5.0 mg to 25.0 mg, 4.0 mg to 4.5 mg, 4.0 mg to 5.0 mg, 25.0 mg to 35.0 mg, 28.0 mg to 32.0 mg, 10.0 mg to 30.0 mg, or 20.0 mg to 40.0 mg; e.g., about 3.0 mg, about 4.0 mg, about 4.2 mg, about 4.5 mg, about 5.0 mg, about 5.5 mg, about 6.0 mg, about 6.5 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10.0 mg, about 12.0 mg, about 15.0 mg, about 20.0 mg, about 25.0 mg, about 30.0 mg, about 35.0 mg, about 40.0 mg, or about 45.0 mg).
In some embodiments, the C1D1 and C1D2 are each less than the Cl D3. In some embodiments, the C1D2 is greater than the C1D1 by about 50% to about 250%
(e.g., the C1D2 is greater than the C1D1 by about 50% to about 225%, the C1D2 is greater than the C1D1 by about 50% to about 200%, the C1D2 is greater than the C1D1 by about 50% to about 175%, the C1D2 is greater than the C1D1 by about 50% to about 150%, the C1D2 is greater than the C1D1 by about 50% to about 125%, the C1D2 is greater than the C1D1 by about 50% to about 100%, or the C1D2 is greater than the C1D1 by about 50% to about 75%; e.g., the C1D2 is greater than the C1D1 by about 50%, the C1D2 is greater than the C1D1 by about 100%, the C1D2 is greater than the C1D1 by about 150%, the C1D2 is greater than the C1D1 by about 200%, or the C1D2 is greater than the C1D1 by about 250%).
In some embodiments, (a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, the Cl D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg; (b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
In some embodiments, the length of the first dosing cycle is 21 days ( 1 day). In some embodiments, the method comprises administering to the subject the C1D1, the C1D2, and the Cl D3 on or about Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle. In some embodiments, the length of each of the second to twelfth dosing cycles is 28 days ( 1 day).
In some embodiments, mosunetuzumab is administered intravenously.
In some embodiments, lenalidomide is administered during the second and subsequent cycles. In some embodiments, lenalidomide is not administered during the first cycle. In some embodiments, lenalidomide is administered daily. In some embodiments, lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide. In some embodiments, lenalidomide is administered at a dose of 20 mg. In some embodiments, lenalidomide is administered orally.
In some embodiments, the subject was previously treated with at least one anti-monoclonal antibody. In some embodiments, the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody. In some embodiments, the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day) , and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises administering 20 mg lenalidomide daily orally on Days 1-21 of the second dosing cycle.
In one aspect, the invention features a method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject: (i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included rituximab; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of each additional dose of mosunetuzumab.
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 80%-100%, between 85-100%, between 87-100%, between 90-100%, between 95-100%, between 80%-90%, between 80-85%, between 85-97%, between 85-95%, between 85-90%, between 85-87%, between 90-95%, or between 93-97%; e.g., about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more). In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 90%. In some embodiments, the overall response rate in a population of subjects having R/R
FL is at least 95%.
In some embodiments, the overall response rate in a population of subjects having R/R FL is at least 99%.
In some embodiments, the complete response rate in a population of subjects having R/R
FL is at least 65% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or more; e.g., between 65-100%, between 75-100%, between 85-100%, between 95-100%, between 65-90%, between 65-80%, between 65-70%, between 65-75%, or between 75-85%; e.g., about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 80%, about 85%, about 90%, or more). In some embodiments, the complete response rate in a population of subjects having R/R
FL is at least 75%.
In some embodiments, the complete response rate in a population of subjects having R/R FL is at least 85%.
In some embodiments, combination therapy with mosunetuzumab and lenalidomide exhibits synergistic effects in the efficacy of the therapy compared to therapy with mosunetuzumab or lenalidomide alone for treating subjects with R/R FL. In some embodiments, a population of subjects with R/R FL treated with a combination therapy with mosunetuzumab and lenalidomide exhibits a higher overall response rate compared to a population of subjects treated with monotherapy of mosunetuzumab or lenalidomide alone. In some embodiments, a population of subjects with R/R FL treated with a combination therapy with mosunetuzumab and lenalidomide exhibits a higher complete response rate compared to a population of subjects treated with monotherapy of mosunetuzumab or lenalidomide alone.
In some embodiments, the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT). In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40%
(e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, at least 45% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more;
e.g., between 45-100%, between 45-80%, between 45-60%, between 50-70%, between 55-65%, between 70-90%, between 70-80%, between 60-100%, between 80-100%; e.g., about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%) of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide. In some embodiments, the reduction in tumor burden is determined by computed tomography (CT).
In some embodiments, the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions. In some embodiments, the decrease in SPD is at least 40% (e.g., at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more; e.g., between 40-100%, between 40-80%, between 40-60%, between 50-70%, between 70-90%, between 75-85%, between 60-100%, between 55-65%, between 80-100%; e.g., about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%). In some embodiments, the decrease in SPD is at least 60%. In some embodiments, the decrease in SPD is at least 80%.
In some embodiments, the subject is human. In some embodiments, each subject in the population is human.
B. Dosing Strategies for Mitigating Adverse Events The present invention relates to methods of treating a subject having a relapsed and/or refractory (RIR) follicular lymphoma (FL) by administration of mosunetuzumab and lenalidornide as a combination therapy. In particular, the present invention relates to methods of treating a subject having a RIR FL that is RiR to at least one prior systemic therapy (e.g., one prior treatment with a chemo-imrnunotherapy regimen) which included an anti-0D20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituximab or obinuturumab) or other treatment. The therapies and dosing regimens described herein provide acceptable safety profiles in subjects with RIR FL treated with the described dosing regimens.
1. CRS Symptoms and Grading Any of the methods described herein may involve monitoring a subject for cytokine release syndrome (CRS), e.g., a CRS event following commencement of any of the methods described above.
Current clinical management focuses on treating the individual signs and symptoms, providing supportive care, and attempting to dampen the inflammatory response using a high dose of corticosteroids.
However, this approach is not always successful, especially in the case of late intervention. The CRS
grading criteria used by the methods described herein are published by the American Society for Transplantation and Cellular Therapy (ASTCT) to define mild, moderate, severe, or life-threatening CRS
and harmonize reporting across clinical trials to allow rapid recognition and treatment of CRS (Lee et al.
Biol Blood Marrow Transplantation. 25(4): 625-638, 2019). The ASTCT criteria is intended to be objective, easy to apply, and more accurately categorize the severity of CRS.
This CRS grading system is shown below in Table 1.
Table 1. CRS Grading System CRS
Parameter Grade 1 Grade 2 Grade 3 Grade 4 Fever Temperature Temperature Temperature Temperature with Hypotension None Not requiring Requiring a Requiring multiple vasopressors vasopressor with or vasopressors without vasopressin (excluding vasopressin) and/or Hypoxia None Requiring low-glow Requiring high-flow Requiring positive nasal cannula or nasal cannula, pressure blow-by facemask, (e.g., CRAP, BiPAP, nonrebreather mask intubation and or Venturi mask mechanical ventilation) ASTCT = American Society for Transplantation and Cellular Therapy; BiPAP =
bilevel positive airway pressure; CRAP = continuous positive airway pressure; CRS = cytokine release syndrome; CTCAE =
Common Terminology Criteria for Adverse Events.
Fever is defined as a temperature 38 00 not attributable to any other cause.
In subjects who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is determined by hypotension and/or hypoxia.
CRS grade is determined by the more severe event, hypotension or hypoxia not attributable to any other cause. For example, a subject with temperature of 39.5 C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as Grade 3 CRS.
Low-flow nasal cannula is defined as oxygen delivered at 6 L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics. High-flow nasal cannula is defined as oxygen delivered at >6 L/minute.
CRS is associated with elevations in a wide array of cytokines, including marked elevations in IFN-y, IL-6, and TNF-oc levels. Emerging evidence implicates IL-6, in particular, as a central mediator in CRS. IL-6 is a proinflammatory, multi-functional cytokine produced by a variety of cell types, which has been shown to be involved in a diverse array of physiological processes, including T cell activation.
Regardless of the inciting agent, CRS is associated with high IL-6 levels (Nagorsen et al. Cytokine. 25(1):
31-5, 2004; Lee et al. Blood. 124(2): 188-95, 2014); Doesegger et al. Clin.
Transl. Immunology. 4(7): e39, 2015), and IL-6 correlates with the severity of CRS, with subjects who experience a Grade 4 or 5 CRS
event having much higher IL-6 levels compared to subjects who do not experience CRS or experience milder CRS (Grades 0-3) (Chen et al. J. lmmunol. Methods. 434:1-8, 2016).
Therefore, blocking the inflammatory action of IL-6 using an agent that inhibits IL-6-mediated signaling to manage CRS observed in subjects during the double-step fractionated, dose-escalation dosing regimen is an alternative to steroid treatment that would not be expected to negatively impact T
cell function or diminish the efficacy or clinical benefit of mosunetuzumab therapy in the treatment of CD20-positive cell proliferative disorders (e.g., a B cell proliferative disorders).
If the subject has a CRS event that does not resolve or worsens within 24 hours of administering the IL-6R antagonist to treat the symptoms of the CRS event, and the method may further comprise administering to the subject one or more additional doses of the IL-6R
antagonist to manage the CRS
event. The subject may be administered a corticosteroid, such as methylprednisolone or dexamethasone if CRS event is not managed through administration of the IL-6R antagonist.
2. Other Adverse Events and Grading Any of the methods described herein may involve monitoring a subject for additional non-CRS
adverse events. Incidence, nature, and severity of physical findings and adverse events, with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v5.0). Other than CRS, one of the most common adverse events reported in patients undergoing treatment with mosunetuzumab and/or lenalidomide is neutropenia (e.g., febrile neutropenia).
Neutropenia is characterized by an abnormally low blood count of neutrophils, which are a type of white blood cells. Neutropenia may lead to an increased risk of infection. The generally accepted reference range for absolute neutrophil count (ANC) in adult humans is 1,500 to 8,000 cells/p1 of blood.
Mild neutropenia is characterized by ANC between 1,000-1,500 cells/p.L (Grade 1-2); moderate neutropenia is characterized by ANC between 500 and 1,000 cells/pt (Grade 3), and severe neutropenia is characterized by ANC below 500 cells/4 (Grade 4). Febrile neutropenia (Grade 3+ neutropenia) is characterized by ANC below 1,000 cells/.LL in addition to either a single temperature measurement greater than 38.3 C or sustained temperature measurements greater than 38 C
for more than one hour.
3. Dosing Regimens with Acceptable Safety Profiles In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day ( 1 day) dosing cycle and a second 28-day ( 1 day) dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In one aspect, the invention features a method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject: (a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day ( 1 day) dosing cycle and eleven subsequent 28-day ( 1 day) dosing cycles, wherein: (a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (C1D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle. In some embodiments, at least one chemo-immunotherapy regimen included an anti-CD20 monoclonal antibody (e.g., rituximab or obinutuzumab).
In some embodiments, each subject has received only one prior line of systemic therapy and either: (a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.
Blood. 2004; 104 (5): 1258-1265.) score of 2-5 (e.g., a score of 2, 3, 4, or 5), (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
In some embodiments, the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
In some embodiments, each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks (e.g., 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, or more) prior to being administered the effective amount of mosunetuzumab and lenalidomide.
In some embodiments, mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL. In some embodiments, the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Onco/ 2014; 32:1-9). In some embodiments, the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
In one aspect, the methods of the invention features premedication with corticosteroids to reduce adverse effects of mosunetuzumab administration. In some embodiments, premedication with corticosteroids reduces the rate of cytokine release syndrome (CRS) in subjects treated with mosunetuzumab (e.g., subjects administered a combination of mosunetuzumab and lenalidomide).
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subject during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subject on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab. In some embodiments, the corticosteroid used is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg). In some embodiments, dexamethasone is administered intravenously.
In some embodiments, the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subject on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab. In some embodiments, the C2D1 of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, the dosing regimen further comprises administration of a corticosteroid. In some embodiments, the corticosteroid is administered to the subjects during the first dosing cycle. In some embodiments, the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid. In some embodiments, the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered to the subjects on Days 1, 8 ( 1 day), and 15 ( 1 day), respectively, of the first dosing cycle. In some embodiments, each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the Cl Dl-C1D3, respectively, of mosunetuzumab. In some embodiments, each single dose Cl Dl-Cl D3 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
In some embodiments, the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
In some embodiments, the corticosteroid is administered to the subjects on the second dosing cycle. In some embodiments, the second dosing cycle comprises a single dose (C2D1) of the corticosteroid. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle. In some embodiments, the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
In some embodiments, the C2D1 of the corticosteroid is administered to the subjects 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of the C2D1 of mosunetuzumab.
In some embodiments, each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid. In some embodiments, each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle. In some embodiments, each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab. In some embodiments, each additional dose of the corticosteroid is administered to the subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of each additional dose of mosunetuzumab.
In some embodiments, the corticosteroid is administered intravenously. In some embodiments, the corticosteroid is dexamethasone. In some embodiments, each dose of dexamethasone is about 10 mg (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, or 20 mg).
In some embodiments, the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects having R/R
FL. In some embodiments, the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects. In some embodiments, the incidence rate of an adverse event is not significantly higher in a population of subjects having R/R FL
when treated with a combination therapy of mosunetuzumab and lenalidomide in comparison to a population of subjects having R/R FL treated with a monotherapy of mosunetuzumab or lenalidomide alone.
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45% (e.g., less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0%
to about 50%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 45%, between about 30% to about 40%, between about 20% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 45%, or between about 25% to about 45%; e.g., about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 1%, or about 0%).
In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 35%. In some embodiments, the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%. In some embodiments, the incidence rate of CRS is about 30%.
In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10% (e.g., less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%; e.g., between 0% and 10%, between 0% and 9%, between 0% and 8%, between 0% and 7%, between 0% and 6%, between 0% and 5%, between 0% and 4%, between 0%
and 3%, between 0% and 2%, between 0% and 1%, between 1% and 3%, between 1%
and 5%, between 1% and 10%, between 3% and 5%, between 5% and 8%, between 5% and 10%, or between 8% and 10%). In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 5%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%. In some embodiments, the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%. In some embodiments, the incidence rate of CRS having a grade of 3 or higher is about 0%.
In some embodiments, the incidence rate of neutropenia in a population of patients having R/R FL and treated with combination therapy of mosunetuzumab and lenalidomide is less than 40%
(e.g., less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 5%, less than 3%, or less than 1%; e.g., between about 0% to about 40%, between about 5% to about 40%, between about 5% to about 20%, between about 5% to about 10%, between about 20% to about 40%, between about 30% to about 40%, between about 15% to about 35%, between about 15% to about 25%, between about 35% to about 40%, or between about 25% to about 40%;
e.g., about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 3%, about 1%, or about 0%). In some embodiments, the incidence rate of neutropenia is less than 30%. In some embodiments, the incidence rate of neutropenia is less than 20%. In some embodiments, the incidence rate of neutropenia having Grade of 3 or 4 is about 19%. In some embodiments, the incidence rate of febrile neutropenia is about 0%.
The methods described herein may result in an acceptable safety profile for subjects having R/R
mosunetuzumab being treated with combination therapy of mosunetuzumab and lenalidomide. In some instances, treatment using the methods described herein that result in intravenously administering mosunetuzumab in the context of a fractionated, dose-escalation dosing regimen and oral administration of lenalidomide results in a reduction (e.g., by 20% or greater, 25% or greater, 30% or greater, 35% or greater, 40% or greater, 45% or greater, 50% or greater, 55% or greater, 60%
or greater, 65% or greater, 70% or greater, 75% or greater, BO% or greater, 85% or greater, 90% or greater, 95% or greater, 96% or greater, 97% or greater, 98% or greater, or 99% or greater; e.g., between 20%
and 100%, between 20%
and 90%, between 20% and 80%, between 20% and 70%, between 20% and 60%, between 20% and 50%, between 20% and 40%, between 20% and 30%, between 40% and 100%, between 60% and 100%, between 80% and 100%, between 30% and 70%, between 40% and 60%, between 30%
and 50%, between 50% and 80%, or between 90% and 100%; e.g., about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 97%, about 99%, or about 100%) or complete inhibition (100% reduction) of undesirable adverse events, such as cytokine-driven toxicities (e.g., cytokine release syndrome (CRS)), infusion-related reactions (IRRs), macrophage activation syndrome (MAS), neurologic toxicities, severe tumor lysis syndrome (TLS), neutropenia, thrombocytopenia, elevated liver enzymes, and/or hepatotoxicities, following treatment with mosunetuzurnab using the fractionated, dose-escalation dosing regimen of the invention relative to treatment with mosunetuzurnab using a non-fractioned dosing regimen.
IV. THERAPEUTIC AGENTS
A. Mosunetuzumab The invention provides mosunotuzumab, a bispecific antibody that binds to CD20 and CD3, useful for treating relapsed and/or refractory (R/R) follicular lymphoma (FL).
The FL may be of Grades 1, 2, or 3a, but not Grade 3b.
In some instances, the invention provides mosunetuzumab that includes an anti-CD20 arm having a first binding domain comprising at least one, two, three, four, five, or six hypervariable regions (HVRs) selected from (a) an HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID
NO: 1); (b) an HVR-H2 comprising the amino acid sequence of AlYPGNGDTSYNQKFKG
(SEQ ID NO:
2); (c) an HVR-H3 comprising the amino acid sequence of VVYYSNSYWYFDV (SEQ ID
NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) an comprising the amino acid sequence of APSNLAS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6). In some instances, rnosunetuzumab comprises at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 17-20, respectively, and/or at least one (e.g., 1, 2,3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID
NOs: 21-24, respectively. In some instances, mesunetuzumab comprises an anti-CD20 arm comprising a first binding domain comprising (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 7; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 8;
or (c) a VH domain as in (a) and a VL domain as in (b). Accordingly, in some instances, the first binding domain comprises a VH domain comprising an amino acid sequence of SEQ ID NO: 7 and a VL domain comprising an amino acid sequence of SEQ ID NO: 8.
In some instances, the invention provides mosunetuzurnab that includes an anti-CD3 arm having a second binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) an HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) an HVR-H3 comprising the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11); (d) an HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) an HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and (f) an HVR-L3 comprising the amino acid sequence of TQSFILRT (SEQ ID NO: 14). In some instances, mosunetuzumab comprises at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 25-28, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs:
29-32, respectively.
In some instances, mesunetuzurnab comprises an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 15; (b) a VL domain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 16; or (c) a VH domain as in (a) and a VL
domain as in (b).
Accordingly, in some instances, the second binding domain comprises a VH
domain comprising an amino acid sequence of SEQ ID NO: 15 and a VL domain comprising an amino acid sequence of SEQ ID NO:
16.
In some instances, the invention provides mosunetuzumab that includes (1) an anti-CD20 arm having a first binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of GYTFTSYNMH (SEQ ID NO: 1); (b) an HVR-H2 comprising the amino acid sequence of AlYPGNGDTSYNQKFKG (SEQ ID NO: 2); (c) an comprising the amino acid sequence of VVYYSNSYWYFDV (SEQ ID NO: 3); (d) an HVR-L1 comprising the amino acid sequence of RASSSVSYMH (SEQ ID NO: 4); (e) an HVR-L2 comprising the amino acid sequence of APSNLAS (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence of QQWSFNPPT (SEQ ID NO: 6); and (2) an anti-CD3 arm having a second binding domain comprising at least one, two, three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid sequence of NYYIH (SEQ ID NO: 9); (b) an HVR-H2 comprising the amino acid sequence of WIYPGDGNTKYNEKFKG (SEQ ID NO: 10); (c) an HVR-H3 comprising the amino acid sequence of DSYSNYYFDY (SEQ ID NO: 11); (d) an HVR-L1 comprising the amino acid sequence of KSSQSLLNSRTRKNYLA (SEQ ID NO: 12); (e) an HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 13); and (f) an HVR-L3 comprising the amino acid sequence of TQSFILRT
(SEQ ID NO: 14). In some instances, mosunetuzumab comprises (1) at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID
NOs: 17-20, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-Li, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID NOs: 21-24, respectively, and (2) at least one (e.g., 1, 2, 3, or 4) of heavy chain framework regions FR-H1, FR-H2, FR-H3, and FR-H4 comprising the sequences of SEQ ID NOs: 25-28, respectively, and/or at least one (e.g., 1, 2, 3, or 4) of the light chain framework regions FR-L1, FR-L2, FR-L3, and FR-L4 comprising the sequences of SEQ ID
NOs: 29-32, respectively. In some instances, mosunetuzumab comprises (1) an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
sequence identity) to, or the sequence of, SEQ ID NO: 7; (b) a VL domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 8; or (c) a VH domain as in (a) and a VL domain as in (b), and (2) an anti-CD3 arm comprising a second binding domain comprising (a) a VH
domain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO:
15; (b) a VL domain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 16; or (c) a VH domain as in (a) and a VL domain as in (b). In some instances, mosuretuzumab comprises (1) a first binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 7 and a VL domain comprising an amino acid sequence of SEQ ID NO: 8 and (2) a second binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID
NO: 15 and a VL domain comprising an amino acid sequence of SEQ ID NO: 16.
In some instances, rnosunetuzurnab has the International Nonproprietary Names for Pharmaceutical Substances (INN) List 117 (WHO Drug Information, Vol. 31, No.
2, 2017, p. 303), or CAS
Registry No. 1905409-39-3, and having (1) an anti-CD20 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 33 and 34 , respectively; and (2) an anti-CD3 arm comprising the heavy chain and light chain sequences of SEQ ID NOs: 35 and 36, respectively. In some instances, mosunetuzumab comprises (1) an anti-CD20 arm comprising a first binding domain comprising (a) a heavy chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ
ID NO: 33; (b) a light chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO:
34; or (c) a heavy chain as in (a) and a light chain as in (b), and (2) an anti-CD3 arm comprising a second binding domain comprising (a) a heavy chain comprising an amino acid sequence having at least 90%
sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 35; (b) a light chain comprising an amino acid sequence having at least 90% sequence identity (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
sequence identity) to, or the sequence of, SEQ ID NO: 36; or (c) a heavy chain as in (a) and a light chain as in (b). In some instances, rflosunetuzurnab comprises (1) an anti-CD20 arm comprising a first binding domain comprising a heavy chain comprising an amino acid sequence of SEQ ID
NO: 33 and a light chain comprising an amino acid sequence of SEQ ID NO: 34 and (2) an anti-CD3 arm comprising a second binding domain comprising a heavy chain comprising an amino acid sequence of SEQ ID NO: 35 and a light chain comprising an amino acid sequence of SEQ ID NO: 36.
Amino acid sequences of mosunetuzumab are summarized in Table 2 below.
Table 2. Sequence 113s for Mosunetuzumab CD3 Arm CD20 Arm SEQ ID NO: Description SEQ ID NO: Description
14 CD3 HVR-L3 6 CD20 HVR-L3
15 CD3 VH 7 CD20 VH
16 CD3 VL 8 CD20 VL
35 CD3 heavy chain 33 CD20 heavy chain 36 CD3 light chain 34 CD20 light chain Mosunetuzumab may be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567.
B. Lenalidomide Lenalidomide is an immunomodulatory (IMiD) imide drug that binds to cereblon, an E3 ubiquitin ligase protein (Gribben et al. 2015). The immunomodulatory activity of lenalidomide is not completely understood; however, lenalidomide has been shown to enhance CD4+ and CD8+ T-cell co-stimulation, induce T-cell proliferation, and enhance IL-2 and IFN-y (Haslett et al. 1998;
Davies et al. 2001).
Lenalidomide has the CAS Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindo1-2-Apiperidine-2,6-dione. Lenalidomide is also known by tradenames including REVLIMID , linamid, and lenalid. Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula Ci3F1,3N303. The present invention describes additive/synergistic efficacy in the combination of a mosunetuzumab with lenalidomide, as well as potential overlapping toxicity, for which patients are carefully monitored and managed by the dosing regimens and treatment described herein.
C. Additional Therapeutic Agents In some instances, the methods described herein include administering mosunetuzumab and lenalidomide in combination with one or more additional therapeutic agents.
In some instances, the one or more additional therapeutic agents may reduce the rate or the severity of cytokine release syndrome (CRS). In some instances, the one or more additional therapeutic agents may prevent symptoms associated with CRS. In particular instances, the additional therapeutic agent used to reduce the rate or severity of CRS or prevent symptoms associated with CRS is a corticosteroid (e.g., dexamethasone (CAS#: 50-02-2), prednisone (CAS#: 53-03-2), prednisolone (CAS#
50-42-8), or methylprednisolone (CAS#: 83-43-2)) or an IL-6R antagonist (e.g., tocilizumab, sarilumab, vobarilizumab (ALX-0061), satralizumab (SA-237), and variants thereof). In some instances, the additional therapeutic agent is tocilizunnab. In some instances, the additional therapeutic agent is a corticosteroid. In some instances, a corticosteroid is administered prior to administration of mosunetuzumab. In some instances, the corticosteroid is administered 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of mosunetuzumab. In some instances, the corticosteroid is administered intravenously. In some instances, the corticosteroid is dexamethasone. In some instances, 10 mg of dexamethasone is administered to a subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of mosunetuzumab to the subject. In some instances, the corticosteroid is methylprednisolone. In some instances, the corticosteroid is prednisone.
In some instances, the one or more additional therapeutic agents may be used in the treatment of neutropenia. In some instances, the additional therapeutic agents may be prevent symptoms associated with neutropenia. In some instances, the additional therapeutic agents may reduce the rate or severity of neutropenia. In particular instances, the additional therapeutic agent is granulocyte colony-stimulating factor (G-CSF or GCSF) or colony-stimulating factor 3 (CSF 3). The mRNA
sequence of human G-CSF/CSF 3 includes, e.g., NCB! RefSeq No. NM 000759, NM 001178147, NM 172219, and NM 172220, and the protein amino acid sequence of human G-CSF/CSF 3 includes, e.g., NCB! RefSeq No. NP 000750, NP_001171618, NP 757373, and NP_757374.
For all the methods described herein, rnosunetuzurnab and lenalidomide are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
Mosunetuzumab and lenalidomide need not be, but are optionally formulated with, one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of mosunetuzumab and/or lenalidomide present in the formulation, the type of disorder or treatment, and other factors discussed above. Mosunetuzumab and lenalidomide may be suitably administered to the subject over a series of treatments. When mosunetuzumab and lenalidomide are administered on the same day, mosunetuzumab may be administered before, simultaneously with, or after administration of lenalidomide.
In some instances, additional therapeutic agents useful in the present invention include therapeutic antibodies, such as alemtuzumab (CAM PATH ), bevacizumab (AVASTINO, Genentech);
cetuximab (ERBITUXO, Imclone); panitumumab (VECTIBIXO, Amgen), rituximab (RITUXANO, Genentech/Biogen ldec), pertuzumab (OMNITARGO, 2C4, Genentech), trastuzumab (HERCEPTINO, Genentech), tositumomab (BEXXARG, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARGO, Wyeth). Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizunnab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, inotuzumab ozogamicin, ipilimunnab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzunnab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, tafasitamab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, urnavizumab, urtoxazumab, ustekinumab, visilizumab, and briakinumab.
IV. PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS
Mosunetuzurnab and/or lenalidomide described herein can be used in pharmaceutical compositions and formulations. Pharmaceutical compositions and formulations of mosunetuzumab, lenalidomide, and/or other agents describe herein (e.g., dexamethasone) can be prepared by mixing one, two, or all three agents having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Lenalidomide may also be formulated according to standard formulation and/or manufacturing practices. Dexamethasone may also be formulated according to standard formulation and/or manufacturing practices. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX , Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
Exemplary lyophilized antibody formulations are described in U.S. Patent No.
6,267,958.
Aqueous antibody formulations include those described in U.S. Patent No.
6,171,586 and W02006/044908, the latter formulations including a histidine-acetate buffer.
The formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an additional therapeutic agent (e.g., a chemotherapeutic agent, a cytotoxic agent, a growth inhibitory agent, and/or an anti-hormonal agent, such as those recited herein above). Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, for example, films, or microcapsules.
The formulations to be used for in vivo administration are generally sterile.
Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
In some embodiments, mosunetuzumab is formulated for administration intravenously. In some embodiments, lenalidomide is formulated for administration orally. In some embodiments, dexamethasone is formulated for administration intravenously.
V. KITS AND ARTICLES OF MANUFACTURE
In another aspect of the invention, a kit or an article of manufacture containing materials useful for the treatment, prevention, and/or diagnosis of the disorders described above is provided. The kit or article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic.
The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is mosunetuzumab or lenalidomide described herein. The label or package insert indicates that the composition is used for treating relapsed and/or refractory (R/R) follicular lymphoma (FL) and further includes information related to at least one of the dosing regimens described herein. In some embodiments, the label or package insert indicates that the composition is used for treating R/R FL in a patient who is R/R to at least one prior treatment (e.g., a chemo-immunotherapy) that comprised an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituximab or obinutuzumab). Moreover, the kit or article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises mosunetuzumab, lenalidomide, or both mosunetuzumab and lenalidomide; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. Alternatively, or additionally, the kit or article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
EXAMPLES
The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.
Example 1. A Phase lb, Open-Label, Non-Randomized, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab in Combination with Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma Study Design Study C041942 is an ongoing Phase lb, open-label, multicenter study evaluating the safety, pharmacokinetics, and efficacy of mosunetuzumab in combination with lenalidomide in patients with relapsed and/or refractory (e.g., R/R or r/r) follicular lymphoma (FL).
Patients with r/r FL after at least one prior systemic therapy are eligible to enter the study. As of CCOD, mosunetuzumab in combination with lenalidonnide is the only active treatment combination in Study 0041942, therefore this study focuses on the mosunetuzumab plus lenalidomide combination only.
The study design is summarized in FIGS. lA and 1B.
The study includes an initial dose-escalation phase, comprising a dose-escalation cohort, designed to determine the recommended Phase 2 dose (RP2D) of mosunetuzumab.
The initial dose-escalation phase is followed by an expansion phase in which the RP2D for mosunetuzumab is given.
Study treatment is administered for 12 cycles; the duration of Cycle 1 is 21 days, and the duration of Cycle 2-12 is 28 days. Mosunetuzumab is administered intravenously: in Cycle 1 (21-day cycle), patients receive 1 mg on Day 1 (Cl Dl dose); 2 mg on Day 8 (Cl D2 dose); and 30 mg on Day 15 (Cl D3 dose). In Cycles 2-12 (28-day cycles), patients receive 30 mg on Day 1 (C2D1-C12D1 doses). Lenalidomide is administered orally (PO) 20 mg once daily on Days 1-21 of Cycles 2-12 (28-day cycles). Lenalidomide is not administered on the last 7 days of each of the 28-day Cycles 2-12.
Study Population and Treatment Received As of CCOD (April 5, 2021), all patients (N = 16) were enrolled in the mosunetuzumab in combination with lenalidomide (IV) arm and received at least one dose of mosunetuzumab. Ten patients completed the DLT assessment window and reached D28 of Cycle 2. The 1/2/30 mg dose for mosunetuzumab was used for all patients. Lenalidomide 20 mg was the dose for all patients.
Overall, 9 patients (56.3%) had a duration on study of 0 to 3 months; 4 patients (25.0%) had a duration of 3 to 6 months; 3 patients (18.8%) had a duration of 6 to 9 months.
Patient demographics for the safety-evaluable population (N ¨ 16) are presented in Table 3.
The majority of patients were female (62.5%; 10/16 patients) and had a median age of 61.5 years.
Patient Eastern Cooperative Oncology Group (ECOG) status was 0 for 81.3%
(13/16 patients) and 1 for 18.8% (3/16 patients).
Table 3. Demographic and baseline characteristics of the safety-evaluable patients.
Patients treated with Mosunetuzumab 1/2/30 mg (N = 16) Age (year) Mean (SD) 60.8 (13.2) Median 61.5 Min-Max 31-79 Sex Male 6 (37.5%) Female 10 (62.5%) Ethnicity Hispanic or Latino 1 (6.3%) Not Hispanic or Latino 7 (43.8%) Not stated 8 (50%) Race White 8 (50%) Unknown 8 (50%) Weight (kg) Mean 78.68 (13.05) Median 75.15 Min-Max 58.3-100.5 Height (cm) Mean 167.78 (11.65) Median 165.50 Min-Max 153.0-190.0 Body Mass Index (kg/m2) at baseline Mean 27.92 (3.37) Median 29.12 Min-Max 20.8-33.1 ECOG Status at Baseline 0 13(81.3%) 1 3(18.8%) CCOD: April 5, 2021 As of CCOD, all 16 patients in the safety-evaluable population had received at least one dose of study treatment. Sixteen patients entered Cycle 1, Day 1 (and received the Cl Dl dose); 14 patients entered Cycle 1, Day 8 (and received the Cl D2 dose) 14 patients entered Cycle 1, Day 15 (and received the Cl D3 dose); 13 patients entered Cycle 2 (C2); and 8 patients entered Cycle 3 of treatment.
For mosunetuzumab, the median duration of treatment was 1.8 months (range: 0-7 months).
The median number of treatment cycles was 3 (range: 1-9); the median number of doses received was 5 (range: 1-11); and the median cumulative dose received was 93 mg (range:
1.0-273.0).
For lenalidomide, the median duration of treatment was 1.9 months (range: 0-6 months).
The median number of treatment cycles was 3 (range: 1-5); the median number of doses received was 37 (range: 1-151); and the median of cumulative dose received was 740 mg (range: 20.0-3020.0).
Safety Results The safety-evaluable population (N = 16) included all patients who were enrolled in the study and received at least one dose of study treatment. An overview of key safety results obtained by the CCOD (April 5, 2021) is summarized below and further described in Table 4.
= The percentage of patients who reported at least one adverse event (AE) was 81.3%
(13/16 patients), with a total of 83 AEs reported overall.
= The most commonly reported AEs by PT were CRS; 31.3%; 5/16 patients);
constipation, and neutropenia (both 25.0%; 4/16 patients).
= The percentage of patients who reported at least one event considered related to study treatment was 81.3% (13/16 patients). The percentage of patients who reported at least one event considered related to mosunetuzumab or lenalidomide treatment was 81.3% and 50.0%, respectively.
= As of CCOD, no fatal (Grade 5) AEs were reported in the study.
= The percentage of patients who reported at least one serious adverse event (SAE) was 12.5% (2/16 patients), of which three events were related to mosunetuzumab treatment (by PT, CRS [2 events]; rash maculo-papular).
= The percentage of patients who reported at least one Grade 3 AE was 31.3%
(5/16 patients).
= No AEs were reported that led to study treatment discontinuation.
= The percentage of patients who reported at least one event that led to dose modification/interruption of study treatment was 37.5% (6/16 patients). Of these, 2 patients had dose interruption of rnosunetuzumab and 6 patients had dose interruption of lenalidomide treatment.
= The percentage of patients who reported at least one adverse event of special interest (AESI) was 31.3% (5/16 patients).
The incidence and frequency of AEs, including AEs considered related to rnosunetuzumab, SAEs and AESIs were similar in this study as a related study with monotherapy mosunetuzumab administered with similar doses.
Table 4. Safety Summary for Safety-Evaluable Patients as of CCOD of April 5, 2021.
Mosunetuzumab + Mosunetuzumab Lenalidomide (IV) (IV) (N = 16) (N
= 213) N(%) N(%) Patients who experienced at least one adverse event 13 (81.3) 207 (97.2) (AE) Total number of AEs 83 Deaths 0 64 (30.0) Fatal AEsa 0 5 (2.3) Serious AEs 2(12.5) 107 (50.2) Grade 3-5 AEs 5 (31.3) 141 (66.2) Treatment-related AEs 13 (81.3) 183 (85.9) Mosunetuzumab 13 (81.3) 183 (85.9) Lenalidomide 8 (50.0) AEs leading to treatment withdrawal 0 7 (3.3) Mosunetuzumab 0 7 (3.3) Lenalidomide 0 AEs leading to dose modification/interruption 6(37.5) 29 (13.6) Mosunetuzumab 2(12.5) 29 (13.6) Lenalidomide 6 (37.5) Patients who experienced at least one AESI
Cytokine release syndromeh 5 (31.3) 79 (37.1) Neutropenia/neutrophil count decrease 4 (25.0) 56 (26.3) Febrile neutropenia 0 6 (2.8) Thrombocytopenia 1 (6.3) 14 (6.6) Tumor lysis syndrome 0 3 (1.4) Tumor flare 1 (6.3)c 4 (1.9) AST increased 1 (6.3) 14 (6.6) ALT increased 1 (6.3) 22 (10.3) AE = adverse event, AESI = adverse event of special interest a Does not include events of "death due to progressive disease"
b per ASTCT criteria Subject had worsening pleural effusion. Tumor flare based on Medical Dictionary for Regulatory Activities (Med DRA) preferred terms (PT) of "tumor flare, tumor inflammation, tumor pain and new or worsening pleural effusion".
Most Frequently Reported Adverse Events:
Overall, the percentage of patients who reported at least one AE was 81.3%
(13/16 patients), with a total of 83 AEs reported overall.
The most commonly reported AEs by System Organ Class (SOC) were skin and subcutaneous tissue disorders (43.8%; 7/16 patients); gastrointestinal disorders (37.5%; 6/16 patients); blood and lymphatic system disorders; general disorders and administration site conditions, immune system disorders, and nervous system disorders (all 31.3%;
5/16 patients).
The most commonly reported AEs by MedDRA Preferred Term (PT) were CRS (31.3%;
patients); constipation and neutropenia (both 25.0%; 4/16 patients). A summary of AEs 10%) is presented in Table 5.
Table 5. Summary of Adverse Events with 10% by patient, as of April 5, 2021.
MedDRA System Organ Class Mosun + Len MedDRA Preferred Term (N = 16) Skin and subcutaneous tissue disorders Dry skin 3(18.8%) Pruritus 3 (18.8%) Erythema 2(12.5%) Rash 2(12.5%) Rash maculo-papular 2 (12.5%) Gastrointestinal disorders Constipation 4 (25.0%) Dry mouth 2 (12.5%) Blood and lymphatic system disorders Neutropenia 4 (25.0%) General disorders and administration site conditions Asthenia 2(12.5%) Immune system disorders Cytokine release syndrome 5 (31.3%) Nervous system disorders headache 2(12.5%) Musculoskeletal and connective tissue disorders Bone pain 2(12.5%) Metabolism and nutrition disorders Decreased appetite 2 (12.5%) Based on MedDRA version 23.1. Percentages are based on N in the column headings. Only treatment emergent AEs are displayed. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. CCOD of April 5, 2021.
Adverse Events Related to Treatment Overall, the percentage of patients who reported at least one event considered related to study treatment was 81.3% (13/16 patients; Table 4). The most commonly reported adverse events relating to treatment were CRS (31.3%; 5/16 patients) and neutropenia (25.0%;
4/16 patients). AEs 10%) considered related to study treatment (e.g., related to mosunetuzumab or lenalidomide) are shown in FIG. 2.
Overall, the percentage of patients who reported at least one AE considered related to mosunetuzumab treatment was 81.3% (13/16 patients; Table 4). The most commonly reported AE
by PT considered related to mosunetuzumab treatment was CRS (31.3%; 5/16 patients). AEs 10%) considered related to mosunetuzumab are shown in FIG. 3.
Overall, the percentage of patients who reported at least one AE considered related to lenalidomide treatment was 50.0% (8/16 patients; Table 4). The most commonly reported AE by PT
considered related to lenalidomide treatment was neutropenia (25.0%; 4/16 patients). AEs 10%) considered related to lenalidomide are shown in FIG. 4.
Adverse Events by Intensity Overall, the percentage of patients who reported at least one Grade 3 AE was 31.3% (5/16 patients; Table 4). The most commonly reported AE by PT was neutropenia (25.0%; 4/16 patients;
Table 6).
Table 6. Summary of Adverse Events (AE) with Grades 3-5, as of April 5, 2021.
MedDRA System Organ Class Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Total number of patients with at least one Grade 3-5 AE 5 (31.3%) Overall total number of events 13 Blood and lymphatic system disorders Total number of patients with at least one Grade 3-5 4 (25.0%) AE
Total number of events 9 Neutropenia 4 (25.0%) Skin and subcutaneous tissue disorders Total number of patients with at least one Grade 3-5 2 (12.5%) AE
Total number of events 2 Erythema 1 (6.3%) Rash maculo-papular 1 (6.3%) Investigations Total number of patients with at least one Grade 3-5 1 (6.3%) AE
Total number of events 2 Erythema 1 (6.3%) Rash maculo-papular 1 (6.3%) Based on MedDRA version 23.1. Percentages are based on N in the column headings.
Only treatment emergent AEs are displayed. For frequency counts of "Total number of events"
rows, multiple occurrences of the same AE in an individual are counted separately.
Deaths As of the CCOD, no deaths have been reported in Study C041942.
Serious Adverse Events Overall, the percentage of patients who reported at least one SAE was 12.5%
(2/16 patients;
Table 4). A summary of serious adverse events reported is provided in Table 7.
One patient (6.3%) experienced an SAE (by PT, rash maculo-papular) considered related to mosunetuzumab by the Investigator. This event was of Grade 3 severity and resolved after 9 days, following a dose interruption of mosunetuzumab. Two other events (by PT, pleural effusion;
atrial flutter) led to dose interruption of treatment (lenalidomide and mosunetuzumab, respectively); both events were Grade 2 severity and had resolved by Day 8 of onset. All other SAEs reported were of Grade 1 or Grade 2 severity, and resolved on or by Day 9 of onset without dose interruption/modification of study treatment. No SAEs of Grade 4 or 5 severity were reported.
Table 7. Summary of Serious Adverse Events (SAE), as of April 5, 2021.
MedDRA System Organ Class Grade Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Any serious adverse events Any Grade 2 (12.5%) 1 (6.3%) 1 (6.3%) Cardiac disorders Overall Any Grade 1 (6.3%) 1 (6.3%) Atrial Flutter Any Grade 1 (6.3%) 1 (6.3%) General disorders and administration site conditions Overall Any Grade 1 (6.3%) 1 (6.3%) Adverse Drug Reaction Any Grade 1 (6.3%) 1 (6.3%) Immune system disorders Overall Any Grade 1 (6.3%) 1 (6.3%) Cytokine release syndrome Any Grade 1 (6.3%) 1 (6.3%) Respiratory, thoracic, and mediastinal disorders Overall Any Grade 1 (6.3%) (6.3%) Pleural effusion Any Grade 1 (6.3%) (6.3%) Skin and subcutaneous disorders Overall Any Grade 1 (6.3%) (6.3%) Rash maculo-papular Any Grade 1 (6.3%) (6.3%) Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same SAE in an individual are counted only once.
For frequency counts of "Total number of events" rows, multiple occurrences of the same SAE in an individual are counted separately. Adverse Events with missing Common Terminology Criteria for Adverse Events 5 (CTCAE) grades are excluded.
Adverse Events that led to Study Treatment Dose Modification or Interruption Overall, the percentage of patients who reported at least one event that led to dose modification/interruption of study treatment was 37.5% (6/16 patients; Table 4). Of these, 2 patients had dose interruption of mosunetuzurnab and 6 patients had dose interruption of lenalidomide treatment.
Two patients (12.5%) experienced events (by PT, rash maculo-papular [Grade 3];
neutropenia [Grade 4]; atrial flutter [Grade 2]) reported by the Investigator that led to dose interruption of mosunetuzumab. All events resolved within 9 days of onset following treatment for the AE.
Six patients (37.5%) experienced events (by PT, pleural effusion [Grade 2];
neutropenia, [Grade 3 and Grade 4, 3 events each]; erythema [Grade 3]; pruritus [Grade 2];
rash maculo-papular [Grade 3]) that led to dose interruption of lenalidomide. Two patients (12.5%) experienced an event (by PT, neutropenia [Grade 3 and Grade 4]) that led to dose reduction of lenalidomide. All events resolved, except for two events of neutropenia (both Grade 3 severity), which were still ongoing as of the CCOD.
Adverse Events of Special Interest (AESI) AESIs include events that are considered to be of overlapping toxicities between the study treatments, and are summarized in Table 8. Overall, the percentage of patients who reported at least one AESI was 43.8%(7/16 patients). The most commonly reported AESIs were CRS (31.3%;
5/16 patients), and neutropenia (25.0%; 4/16 patients). One patient (6.3%) reported an event of Grade 1 thrombocytopenia that had not resolved at the time of CCOD; no intervention was taken.
Table 8. Summary of Adverse Events of Special Interest (AESI), as of April 5, 2021.
MedDRA System Organ Class Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Total number of patients with at least one AESI 7 (43.8) Overall total number of events 20 Immune system disorders Total number of patients with at least one AESI 5 (31.3%) Total number of events 7 Cytokine release syndrome 5 (31.3%) Blood and lymphatic system disorders Total number of patients with at least one AESI 4 (25.0%) Total number of events 10 Neutropenia 4 (25.0%) Thrombocytopenia 1 (6.3%) Investigations Total number of patients with at least one AESI 1 (6.3%) Total number of events 2 Alanine aminotransferase increased 1 (6.3%) Aspartate aminotransferase increased 1 (6.3%) Respiratory, thoracic, and mediastinal disorders Total number of patients with at least one AESI 1 (6.3%) Total number of events 1 Pleural effusion 1 (6.3%) Percentages are based on N in the column headings.
Overall, the most commonly reported AESI was CRS (31.3%; 5/16 patients; 7 events). Of the patients who experienced an event, 4 patients (25.0%) reported an event of Grade 1 severity, and one patient (6.3%) reported an event of Grade 2 severity; all events were considered related to mosunetuzumab treatment. The majority of events were reported in patients on study day 1, all of which resolved within 3 days of onset. Two patients (12.5%) reported subsequent events: one patient on study day 15 and another on study day 29, which resolved within 2 and 7 days, respectively. Of the 5 patients who reported CRS, 4 patients (25.0%) received interventional treatment for this event.
Five patients (31.3%) had a CRS event, considered related to mosunetuzumab treatment, as assessed by the Investigator, including 4 patients (25.0%) with ASTCT Grade 1, and one patient (6.3%) with Grade 2 (Table 9). All 5 patients had onset of first CRS event between Day 1 of Cycle 1 and Day 7 of Cycle 1 (FIG. 5). One patient (6.3%; 1/14) had a subsequent Grade 1 event between Day 15 of Cycle 1 and Day 21 of Cycle 1 during mosunetuzumab monotherapy treatment, and another patient (6.3%; 1/14) had a subsequent Grade 1 event in 02 during mosunetuzumab and lenalidomide combination treatment.
Table 9. CRS Events by Dose Cycle for Safety-Evaluable Patients as of CCOD of April 5, 2021.
CRS Grade Cycle 1 Cycle 1 Cycle 1 Cycle 2 Cycle 3 Days 1-7 Days 8-14 Days 15-21 N . 13 N . 8 N . 16 N . 14 N . 14 Any Grade 5(31.3%) 0 1 (7.1%) 1(7.1%) 1 4 (25.0%) 0 1 (7.1%) 1 (7.1%) 2 1(6.3%) 0 0 0 Overall, fever was the most frequent symptom of CRS, of which 7 events were reported in 5 patients who reported an event of CRS. Other signs and symptoms reported concurrently CRS
5 included chills, hypoxia, tachycardia, elevated liver enzyme (AST), elevated liver enzyme (ALT), hyperuricemia and lactate dehydrogenase (LDH) increased. One patient (6.3%) received low-flow oxygen for the treatment of Grade 2 CRS. No Grade 3 CRS events were observed and no patient required tocilizumab, ICU management, high flow oxygen or vasopressor support.
Four patients (25.0%) reported 9 events of neutropenia (Table 4). Of these, 2 patients experienced 5 events considered related to mosunetuzumab and lenalidomide treatment, and 2 patients experienced 4 events considered related to lenalidomide treatment only, as assessed by the Investigator. Two patients reported events of Grade 4 severity, all of which resolved, one patient without any treatment and one patient following treatment with G-CSF.
Two patients reported 5 events of Grade 3 severity, of which 2 events (one in each patient) did not resolve as of the CCOD, following treatment with G-CSF for the event and dose interruption of lenalidomide.
Events of neutropenia occurred between Day 42 and Day 155, and had a duration of between 8 and 16 days.
Preliminary Efficacy The efficacy evaluable population included all patients who had been assessed for response at any time on study, who had withdrawn from treatment or study prior to reaching their first response assessment, or who had been on study long enough to have reached their first scheduled response assessment, planned per protocol for Cycle 3, D15-21. The response was assessed by the Investigator per Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
No formal efficacy data analysis was performed. Upon review of the electronic database, as of CCOD, 8 patients enrolled in Study 0041942 had at least one response assessment. Of these 8 patients, 2 patients had a partial response, and 6 patients had a complete response (i.e., an overall response rate (OR) of 100% and a complete response rate (CR) of 75%. No patients had progression of the disease or withdrew from the study.
Pharmacokinetics Preliminary mosunetuzumab pharmacokinetic data (N = 13) in patients who received the 1/2/30 mg 04W dose of mosunetuzumab in Study 0041942 are summarized in FIG. 6.
Observed pharmacokinetics of mosunetuzumab at 1/2/30 mg (IV) in combination with lenalidomide in R/R FL
patients were similar to predictions of mosunetuzumab pharmacokinetics of mosunetuzumab monotherapy in R/R NHL patients at the same dose. Preliminary results indicate that mosunetuzumab PK is similar when administered in combination with lenalidomide as compared to monotherapy, where the observed concentration measurements fell generally within the popPK
model simulated 5th to 95th prediction intervals.
No lenalidomide PK data were available at the time of this report.
Mosunetuzumab is not expected to impact the PK of lenalidomide which is primarily excreted in the urine (Chen N et al.
Clin Pharmacokinet 2017; 56(2):139-152).
Conclusion The safety profile for mosunetuzumab, in combination with lenalidomide, at the tested dose and schedule (1/2/30 mg, 04W) was acceptable, with no unexpected safety signals.
The overall frequency and severity of CRS events (7 events of Grade 1-2 severity, in 5 patients) observed with mosunetuzumab in combination with lenalidomide in this study was comparable to CRS events observed with mosunetuzumab monotherapy. All CRS
events were Grade 1, except in one patient who experienced a Grade 2 event in Cycle 1 with mosunetuzumab (1 mg) monotherapy. This patient was the only patient who experienced a CRS event in Cycle 2, which was Grade 1. Four patients (25.0%) reported events of Grade 3-4 neutropenia. Of the 9 events reported, 7 events resolved and 2 events (Grade 3 severity) had not resolved as of CCOD.
One patient (6.3%) reported an event of Grade 1 thrombocytopenia that had not resolved at the time of CCOD. No patients discontinued study treatment due to AEs.
Mosunetuzumab PK exposures observed in Study C041942 were consistent with what was expected based on PK observed with mosunetuzumab monotherapy, suggesting that the combination of mosunetuzumab with lenalidomide does not appear to affect mosunetuzumab exposure. The proposed dosing regimen was supported by the totality of data and the exposure-response characterizations based on mosunetuzumab monotherapy and mosunetuzumab in combination with lenalidomide, suggesting an adequate balance of clinical benefit/risk in the patient population.
In summary, the available data from Study G041942 demonstrated an acceptable safety profile and preliminary efficacy for patients with R/R FL, thus supporting the continued use of 1/2/30 mg step-up dosing regimen of mosunetuzumab in combination with lenalidomide.
Example 2. Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase lb Study Presented here are initial data from an ongoing Phase lb study (N0T04246086) evaluating the safety and activity of combination therapy of mosunetuzumab and lenalidomide in R/R FL
patients who have received at least one prior line of therapy.
Methods Patients with R/R FL (Grade 1-3a) and at least one prior systemic anti-cancer therapy were enrolled to receive 12 cycles of combination therapy of mosunetuzumab and lenalidomide (cycle duration: Cycle 1,21 days; Cycles 2-12,28 days). In Cycle 1, step-up doses of mosunetuzumab (IV
infusion) were given on Day 1 of Cycle 1 (the Cl Dl dose; 1 mg) and Day 2 of Cycle 1 (the Cl D2 dose; 2 mg), with the target dose given on Day 3 of Cycle 1 (the Cl D3 dose;
30 mg) and on Day 1 of Cycles 2-12 (the C2D1-C12D1 doses). Lenalidomide (20 mg orally) was administered on Days 1-21 of Cycles 2-12. No hospitalization was mandated by the protocol. The primary objective was to evaluate the safety of combination therapy of mosunetuzumab and lenalidomide;
secondary objectives include assessment of response and long-term efficacy outcomes.
Cytokine release syndrome (CRS) was reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019).
Responses are assessed by investigators with PET-CT using Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
Results At data cut-off (May 31, 2021), 27 patients had been enrolled. Median age was 59 years (range: 31-79 years); 12 patients (44%) were male. All patients had an ECOG
(Eastern Cooperative Oncology Group) performance status of 0 (18 patients, 67%) or 1 (9 patients, 33%). Median number of prior lines of therapy was 1 (range: 1-4), and 3 patients (11%) had disease progression (PD) < 24 months from the start of first-line therapy. At data cut-off, 16 patients (59%) had been on study for 0-3 months, 8 (30%) for 3-6 months, 2 (7%) for 6-9 months, and 1 (4%) for > 9 months.
All 27 patients were safety evaluable at data cut-off. Twenty patients (74%) experienced 1 adverse event (AE) of any Grade (GO; the most common AE was CRS (8 patients, 30%). Grade 3-4 AEs occurred in 8 patients (30%) and serious AEs in 8 patients (30%). No Grade 5 (fatal) AEs were observed. AEs relating to mosunetuzumab occurred in 20 patients (74%) and AEs relating to lenalidomide occurred in 10 patients (37%). There were no AEs leading to withdrawal of mosunetuzumab or lenalidomide; 2 patients had mosunetuzurnab-related AEs leading to mosunetuzumab dose delays, 6 patients (22%) had lenalidomide-related AEs leading to lenalidomide dose interruption and/or reduction.
In all patients, CRS events were Grade 1 (7/8 patients) or Grade 2 (1/8 patients). For most patients (6/8), CRS events occurred in Cycle 1; 2 patients experienced Grade 1 CRS events in Cycle 2. Median time to CRS onset was 1 day after first study drug administration (range: 1-28 days), median CRS duration was 3 days (range: 2-5 days). All CRS events resolved without sequelae. No patient required tocilizumab, ICU admission, high flow oxygen, or vasopressor support. Five patients (19%) reported 14 events of Grade 3-4 neutropenia; all neutropenia events occurred between Day 41 and Day 218, with a duration of 6-16 days. All neutropenia events resolved, with 1 patient receiving primary granulocyte colony-stimulating factor (G-CSF) prophylaxis and 2 patients receiving G-CSF treatment. No febrile neutropenia events occurred.
The efficacy-evaluable population included all patients who had been assessed for response at any time on study, who had withdrawn from treatment or study prior to reaching their first response assessment, or who had been on study long enough to have reached their first scheduled response assessment, planned per protocol for Days 15-21 of Cycle 3. Objective response rate in the 13 patients who were efficacy evaluable at data cut-off was 92%, with complete metabolic response observed in 10 patients (77%), partial metabolic response (PMR) in 2 patients (15%), and stable disease in 1 patient (8%). One patient who initially achieved PMR
experienced PD after 8 cycles of treatment.
Conclusion Combination treatment of mosunetuzumab and lenalidomide appeared to have an acceptable safety profile in patients with R/R FL who had received at least one prior line of therapy, with encouraging preliminary anti-lymphoma activity observed.
Example 3. Preliminary Safety and Efficacy for Mosunetuzumab in Combination with Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase lb Study Presented here are additional data from an ongoing Phase lb study (NCT04246086) (described in Example 2 above) evaluating the safety and activity of combination therapy of mosunetuzumab and lenalidomide in R/R FL patients who have received at least one prior line of therapy.
Methods Patients with R/R FL (Grade 1-3a) and at least one prior systemic anti-cancer therapy were enrolled to receive 12 dosing cycles of combination therapy of mosunetuzumab and lenalidomide (cycle duration: Cycle 1, 21 days; Cycles 2-12, 28 days). In Cycle 1, step-up doses of mosunetuzumab (IV infusion) were given on Day 1 of Cycle 1 (the Cl Dl dose; 1 mg) and Day 2 of Cycle 1 (the Cl D2 dose; 2 mg), with the target dose given on Day 3 of Cycle 1 (the Cl D3 dose; 30 mg) and on Day 1 of Cycles 2-12 (the C2D1-C12D1 doses). Lenalidomide (20 mg orally) was administered on Days 1-21 of Cycles 2-12. Corticosteroid pre-medication was administered to the patients during Cycles 1 and 2 and was optional from Cycle 3 onwards. For corticosteroid premedication, 10 mg of dexarnethasone was administered intravenously to the patients prior to each dose of mosunetuzumab. Corticosteroid pre-medication may additionally be deemed optional on Cycle 2 depending on further safety data evaluation. No hospitalization was mandated by the protocol. The primary objective was to evaluate the safety of combination therapy of mosunetuzumab and lenalidomide; secondary objectives include assessment of response and long-term efficacy outcomes. Cytokine release syndrome (CRS) was reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019). Responses are assessed by investigators with PET-CT
using Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
Results At data cut-off (September 13, 2021), 29 patients had been enrolled. Median age was 59 years (range: 30-79 years); 13 patients (44.8%) were male. All patients had an ECOG (Eastern Cooperative Oncology Group) performance status of 0-2. Two (6.8%) patients were Ann Arbor stage I-II at study entry and 27 (93.1%) patients were Ann Arbor stage III-IV
at study entry (see Carbone et al., Cancer Res. 1971, 31(11): 1860-1861). Seven (24.1%) patients had 0-1 FLIP! risk factors at study entry, eight (27.6%) patients had 2 FLIP! risk factors at study entry, and 14 (48.3%) patients had 3-5 FLIP! risk factors at study entry. 18(62.1%) patients had FL
Grade 1-2, 5 (17.2%) patients had FL Grade 3a, and six (20.7%) patients had FL of an unknown Grade.
Median number of prior lines of therapy was 1 (range: 1-6), and 3 patients (10.3%) had disease progression (PD) <
24 months from the start of first-line therapy (P0D24). Nine (31%) patients were refractory to at least one prior therapy comprising an anti-CD20 monoclonal antibody. Seven (24.1%) patients were double refractory to both a therapy comprising an anti-CD20 monoclonal antibody and a therapy comprising an alkylating agent. At data cut-off, 1 patient (3.4%) had been on study for 0-3 months, 14(48.3%) for 3-6 months, 7(24.1%) for 6-9 months, and 7 (24.1%) for > 9 months. Median duration of mosunetuzumab treatment was 4.9 months (range 2-11) and median duration of lenalidomide treatment was 4.3 months (range 2-10). Median duration of follow-up was 5.4 months (range 3-12).
All 29 patients were safety evaluable at data cut-off (September 13, 2021).
Adverse events are summarized below in Table 10.
Table 10. Adverse Events in Safety Evaluable Patients (data cut-off: September 13, 2021) N = 29 ( /0) Any AE
29 (100) Related to mosunetuzumab / lenalidomide 27 (93.1) / 23 (79.3) Grade 3-4 AE
13 (44.8) Related to mosunetuzumab / lenalidomide 1 (3.4) / 1 (3.4) Serious AE
9 (31.0) Related to mosunetuzumab / lenalidomide 6 (20.7) / 1 (3.4) Grade 5 (fatal) AE 0 AE leading to mosunetuzumab / lenalidomide withdrawal 0 / 1 (3.4) AE leading to mosunetuzumab / lenalidomide dose modification/ interruption 6 (20.7) / 12 (41.4) AE = adverse event Twenty-nine patients (100%) experienced 1 adverse event (AE) of any Grade.
Common adverse events, experienced by at least 10% of patients, are summarized in FIG. 7. Grade 3-4 AEs occurred in 13 patients (44.8%) and serious AEs in 9 patients (31%). No Grade 5 (fatal) AEs were observed. AEs relating to mosunetuzumab occurred in 27 patients (93.2%) and AEs relating to lenalidomide occurred in 23 patients (79.3%%). There were no AEs leading to withdrawal of mosunetuzumab and one AE (3.4%) leading to withdrawal of lenalidomide; 6 patients (20.7%) had mosunetuzumab-related AEs leading to mosunetuzumab dose modification and/or interruption; 12 patients (41.4%) had lenalidomide-related AEs leading to lenalidomide dose modification and/or interruption.
Cytokine release syndrome (CRS) events observed in the safety-evaluable patients are summarized below in Table 11.
Table 11. CRS Events in Safety Evaluable Patients (data cut-off: September 13, 2021) N = 29 (%) Any CRS (all Grades 1-2) 8 (27.6) Grade 1 7(24.1) Grade 2a 1 (3.4) Median time to CRS onset, days (range) 1 (1-28) Median duration of CRS, days (range) 3 (2-5) apatient had fever and hypoxia that required 2L nasal cannula oxygen In all patients who experienced at least one CRS event (8/29 total patients), CRS events were Grade 1 (7/8 patients) or Grade 2 (1/8 patients). For most patients (6/8), CRS events occurred in Cycle 1; 2 patients experienced Grade 1 CRS events in Cycle 2. Median time to CRS onset was 1 day after first study drug administration (range: 1-28 days), median CRS
duration was 3 days (range: 2-5 days). All CRS events resolved by data cut-off date (September 13, 2021). No patient received tocilizumab, and no patient required ICU admission, high flow oxygen, or vasopressor support. No immune effector cell-associated neurotoxicity syndrome (ICANS) events occurred. A
summary of CRS events by dosing cycle and dose is shown in FIG. 8.
Neutropenia and febrile neutropenia events observed in the safety-evaluable patients are summarized below in Table 12.
Table 12. Neutropenia and Febrile Neutropenia Events in Safety Evaluable Patients (data cut-off:
September 13, 2021) N = 29 (/0) Any neutropenia (all Grade 3-4) 7(24.1) Grade 3 4(13.4) Grade 4 3(10.3) Median time to neutropenia onset, days (range) 86 (41-189) Median duration of neutropenia, days (range) 9 (4-29) Seven patients (24.1%) reported neutropenia or febrile neutropenia events of Grade 3-4; all neutropenia events occurred between Day 41 and Day 189 (median 86 days), with a median duration of 9 days (range 4-29). All neutropenia events resolved by data cut-off date. Febrile neutropenia (Grade 3) occurred in 1 patient (duration: 5 days) and was considered treatment-related. A summary of neutropenia events reported by dosing cycle and Grade and granulocyte colony-stimulating factor (G-CSF) use by dosing cycle is shown in FIG. 9.
Anti-tumor activity in evaluable patients is shown in FIG. 10. In particular, objective response rate in the 29 patients at data cut-off was 89.7%, with complete metabolic response observed in 65.5% of patients (see FIG. 11). Notably, 3/3 patients with history of P0D24, 9/9 patients with anti-CD20 refractory disease, and 7/7 patients with double-refractory disease all exhibited responses as measured by PET-CT. Duration of response in all 29 patients as of the data cut-off date of September 13, 2021, is summarized in FIG. 12.
Conclusion Combination treatment of mosunetuzumab and lenalidomide appeared to have an acceptable safety profile in patients with R/R FL who had received at least one prior line of therapy, with encouraging anti-lymphoma activity and anti-tumor activity observed. No increase in CRS and neutropenia events was observed compared with mosunetuzumab monotherapy.
EMBODIMENTS
Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments:
1. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
2. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
3. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
4. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
5. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
6. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
7. The method, mosunetuzumab for use, or use of any one of embodiments 1-6, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
8. The method, mosunetuzumab for use, or use of any one of embodiments 1-7, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
9. The method of any one of embodiment 7 or 8, wherein the subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
10. The mosunetuzumab for use or use of embodiment 7 or 8, wherein mosunetuzumab and lenalidomide are not to be administered to the subject for at least 4 weeks after the subject has received treatment with an anti-CD20 monoclonal antibody.
11. The method, mosunetuzumab for use, or use of any one of embodiments 1-6, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
12. The method, mosunetuzumab for use, or use of embodiment 11, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
13. The method, mosunetuzumab for use, or use of embodiment 11, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
14. The method of any one of embodiments 1 and 7-9, and 11-13, wherein administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg: and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
15. The mosunetuzumab for use or use of any one of embodiments 2-8 and 10-14, wherein the mosunetuzumab is to be administered to the subject according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
16. The method, mosunetuzumab for use, or use of embodiment 14 or 15, wherein:
(a) the Cl Dl is between 0.4 mg to 4.0 mg, the Cl D2 is between 1.0 mg to 20.0 mg, and the Cl D3 is between 3.0 mg to 50.0 mg; and (b) the C2D1 is between 3.0 mg to 50.0 mg.
35 CD3 heavy chain 33 CD20 heavy chain 36 CD3 light chain 34 CD20 light chain Mosunetuzumab may be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567.
B. Lenalidomide Lenalidomide is an immunomodulatory (IMiD) imide drug that binds to cereblon, an E3 ubiquitin ligase protein (Gribben et al. 2015). The immunomodulatory activity of lenalidomide is not completely understood; however, lenalidomide has been shown to enhance CD4+ and CD8+ T-cell co-stimulation, induce T-cell proliferation, and enhance IL-2 and IFN-y (Haslett et al. 1998;
Davies et al. 2001).
Lenalidomide has the CAS Registry Number 191732-72-6 and IUPAC name (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindo1-2-Apiperidine-2,6-dione. Lenalidomide is also known by tradenames including REVLIMID , linamid, and lenalid. Lenalidomide has the DrugBank Accession Number DB00480, PubChem CID 216326, and chemical formula Ci3F1,3N303. The present invention describes additive/synergistic efficacy in the combination of a mosunetuzumab with lenalidomide, as well as potential overlapping toxicity, for which patients are carefully monitored and managed by the dosing regimens and treatment described herein.
C. Additional Therapeutic Agents In some instances, the methods described herein include administering mosunetuzumab and lenalidomide in combination with one or more additional therapeutic agents.
In some instances, the one or more additional therapeutic agents may reduce the rate or the severity of cytokine release syndrome (CRS). In some instances, the one or more additional therapeutic agents may prevent symptoms associated with CRS. In particular instances, the additional therapeutic agent used to reduce the rate or severity of CRS or prevent symptoms associated with CRS is a corticosteroid (e.g., dexamethasone (CAS#: 50-02-2), prednisone (CAS#: 53-03-2), prednisolone (CAS#
50-42-8), or methylprednisolone (CAS#: 83-43-2)) or an IL-6R antagonist (e.g., tocilizumab, sarilumab, vobarilizumab (ALX-0061), satralizumab (SA-237), and variants thereof). In some instances, the additional therapeutic agent is tocilizunnab. In some instances, the additional therapeutic agent is a corticosteroid. In some instances, a corticosteroid is administered prior to administration of mosunetuzumab. In some instances, the corticosteroid is administered 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of mosunetuzumab. In some instances, the corticosteroid is administered intravenously. In some instances, the corticosteroid is dexamethasone. In some instances, 10 mg of dexamethasone is administered to a subject 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, or 12 hours before administration of mosunetuzumab to the subject. In some instances, the corticosteroid is methylprednisolone. In some instances, the corticosteroid is prednisone.
In some instances, the one or more additional therapeutic agents may be used in the treatment of neutropenia. In some instances, the additional therapeutic agents may be prevent symptoms associated with neutropenia. In some instances, the additional therapeutic agents may reduce the rate or severity of neutropenia. In particular instances, the additional therapeutic agent is granulocyte colony-stimulating factor (G-CSF or GCSF) or colony-stimulating factor 3 (CSF 3). The mRNA
sequence of human G-CSF/CSF 3 includes, e.g., NCB! RefSeq No. NM 000759, NM 001178147, NM 172219, and NM 172220, and the protein amino acid sequence of human G-CSF/CSF 3 includes, e.g., NCB! RefSeq No. NP 000750, NP_001171618, NP 757373, and NP_757374.
For all the methods described herein, rnosunetuzurnab and lenalidomide are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
Mosunetuzumab and lenalidomide need not be, but are optionally formulated with, one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of mosunetuzumab and/or lenalidomide present in the formulation, the type of disorder or treatment, and other factors discussed above. Mosunetuzumab and lenalidomide may be suitably administered to the subject over a series of treatments. When mosunetuzumab and lenalidomide are administered on the same day, mosunetuzumab may be administered before, simultaneously with, or after administration of lenalidomide.
In some instances, additional therapeutic agents useful in the present invention include therapeutic antibodies, such as alemtuzumab (CAM PATH ), bevacizumab (AVASTINO, Genentech);
cetuximab (ERBITUXO, Imclone); panitumumab (VECTIBIXO, Amgen), rituximab (RITUXANO, Genentech/Biogen ldec), pertuzumab (OMNITARGO, 2C4, Genentech), trastuzumab (HERCEPTINO, Genentech), tositumomab (BEXXARG, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARGO, Wyeth). Additional humanized monoclonal antibodies with therapeutic potential as agents in combination with the compounds of the invention include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab mertansine, cantuzumab mertansine, cedelizunnab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, inotuzumab ozogamicin, ipilimunnab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzunnab, pectuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab tetraxetan, tadocizumab, tafasitamab, talizumab, tefibazumab, tocilizumab, toralizumab, tucotuzumab celmoleukin, tucusituzumab, urnavizumab, urtoxazumab, ustekinumab, visilizumab, and briakinumab.
IV. PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS
Mosunetuzurnab and/or lenalidomide described herein can be used in pharmaceutical compositions and formulations. Pharmaceutical compositions and formulations of mosunetuzumab, lenalidomide, and/or other agents describe herein (e.g., dexamethasone) can be prepared by mixing one, two, or all three agents having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Lenalidomide may also be formulated according to standard formulation and/or manufacturing practices. Dexamethasone may also be formulated according to standard formulation and/or manufacturing practices. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX , Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in U.S. Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
Exemplary lyophilized antibody formulations are described in U.S. Patent No.
6,267,958.
Aqueous antibody formulations include those described in U.S. Patent No.
6,171,586 and W02006/044908, the latter formulations including a histidine-acetate buffer.
The formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an additional therapeutic agent (e.g., a chemotherapeutic agent, a cytotoxic agent, a growth inhibitory agent, and/or an anti-hormonal agent, such as those recited herein above). Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, for example, films, or microcapsules.
The formulations to be used for in vivo administration are generally sterile.
Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
In some embodiments, mosunetuzumab is formulated for administration intravenously. In some embodiments, lenalidomide is formulated for administration orally. In some embodiments, dexamethasone is formulated for administration intravenously.
V. KITS AND ARTICLES OF MANUFACTURE
In another aspect of the invention, a kit or an article of manufacture containing materials useful for the treatment, prevention, and/or diagnosis of the disorders described above is provided. The kit or article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic.
The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is mosunetuzumab or lenalidomide described herein. The label or package insert indicates that the composition is used for treating relapsed and/or refractory (R/R) follicular lymphoma (FL) and further includes information related to at least one of the dosing regimens described herein. In some embodiments, the label or package insert indicates that the composition is used for treating R/R FL in a patient who is R/R to at least one prior treatment (e.g., a chemo-immunotherapy) that comprised an anti-CD20 antibody (e.g., an anti-CD20 monoclonal antibody; e.g., rituximab or obinutuzumab). Moreover, the kit or article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises mosunetuzumab, lenalidomide, or both mosunetuzumab and lenalidomide; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. Alternatively, or additionally, the kit or article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
EXAMPLES
The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.
Example 1. A Phase lb, Open-Label, Non-Randomized, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab in Combination with Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma Study Design Study C041942 is an ongoing Phase lb, open-label, multicenter study evaluating the safety, pharmacokinetics, and efficacy of mosunetuzumab in combination with lenalidomide in patients with relapsed and/or refractory (e.g., R/R or r/r) follicular lymphoma (FL).
Patients with r/r FL after at least one prior systemic therapy are eligible to enter the study. As of CCOD, mosunetuzumab in combination with lenalidonnide is the only active treatment combination in Study 0041942, therefore this study focuses on the mosunetuzumab plus lenalidomide combination only.
The study design is summarized in FIGS. lA and 1B.
The study includes an initial dose-escalation phase, comprising a dose-escalation cohort, designed to determine the recommended Phase 2 dose (RP2D) of mosunetuzumab.
The initial dose-escalation phase is followed by an expansion phase in which the RP2D for mosunetuzumab is given.
Study treatment is administered for 12 cycles; the duration of Cycle 1 is 21 days, and the duration of Cycle 2-12 is 28 days. Mosunetuzumab is administered intravenously: in Cycle 1 (21-day cycle), patients receive 1 mg on Day 1 (Cl Dl dose); 2 mg on Day 8 (Cl D2 dose); and 30 mg on Day 15 (Cl D3 dose). In Cycles 2-12 (28-day cycles), patients receive 30 mg on Day 1 (C2D1-C12D1 doses). Lenalidomide is administered orally (PO) 20 mg once daily on Days 1-21 of Cycles 2-12 (28-day cycles). Lenalidomide is not administered on the last 7 days of each of the 28-day Cycles 2-12.
Study Population and Treatment Received As of CCOD (April 5, 2021), all patients (N = 16) were enrolled in the mosunetuzumab in combination with lenalidomide (IV) arm and received at least one dose of mosunetuzumab. Ten patients completed the DLT assessment window and reached D28 of Cycle 2. The 1/2/30 mg dose for mosunetuzumab was used for all patients. Lenalidomide 20 mg was the dose for all patients.
Overall, 9 patients (56.3%) had a duration on study of 0 to 3 months; 4 patients (25.0%) had a duration of 3 to 6 months; 3 patients (18.8%) had a duration of 6 to 9 months.
Patient demographics for the safety-evaluable population (N ¨ 16) are presented in Table 3.
The majority of patients were female (62.5%; 10/16 patients) and had a median age of 61.5 years.
Patient Eastern Cooperative Oncology Group (ECOG) status was 0 for 81.3%
(13/16 patients) and 1 for 18.8% (3/16 patients).
Table 3. Demographic and baseline characteristics of the safety-evaluable patients.
Patients treated with Mosunetuzumab 1/2/30 mg (N = 16) Age (year) Mean (SD) 60.8 (13.2) Median 61.5 Min-Max 31-79 Sex Male 6 (37.5%) Female 10 (62.5%) Ethnicity Hispanic or Latino 1 (6.3%) Not Hispanic or Latino 7 (43.8%) Not stated 8 (50%) Race White 8 (50%) Unknown 8 (50%) Weight (kg) Mean 78.68 (13.05) Median 75.15 Min-Max 58.3-100.5 Height (cm) Mean 167.78 (11.65) Median 165.50 Min-Max 153.0-190.0 Body Mass Index (kg/m2) at baseline Mean 27.92 (3.37) Median 29.12 Min-Max 20.8-33.1 ECOG Status at Baseline 0 13(81.3%) 1 3(18.8%) CCOD: April 5, 2021 As of CCOD, all 16 patients in the safety-evaluable population had received at least one dose of study treatment. Sixteen patients entered Cycle 1, Day 1 (and received the Cl Dl dose); 14 patients entered Cycle 1, Day 8 (and received the Cl D2 dose) 14 patients entered Cycle 1, Day 15 (and received the Cl D3 dose); 13 patients entered Cycle 2 (C2); and 8 patients entered Cycle 3 of treatment.
For mosunetuzumab, the median duration of treatment was 1.8 months (range: 0-7 months).
The median number of treatment cycles was 3 (range: 1-9); the median number of doses received was 5 (range: 1-11); and the median cumulative dose received was 93 mg (range:
1.0-273.0).
For lenalidomide, the median duration of treatment was 1.9 months (range: 0-6 months).
The median number of treatment cycles was 3 (range: 1-5); the median number of doses received was 37 (range: 1-151); and the median of cumulative dose received was 740 mg (range: 20.0-3020.0).
Safety Results The safety-evaluable population (N = 16) included all patients who were enrolled in the study and received at least one dose of study treatment. An overview of key safety results obtained by the CCOD (April 5, 2021) is summarized below and further described in Table 4.
= The percentage of patients who reported at least one adverse event (AE) was 81.3%
(13/16 patients), with a total of 83 AEs reported overall.
= The most commonly reported AEs by PT were CRS; 31.3%; 5/16 patients);
constipation, and neutropenia (both 25.0%; 4/16 patients).
= The percentage of patients who reported at least one event considered related to study treatment was 81.3% (13/16 patients). The percentage of patients who reported at least one event considered related to mosunetuzumab or lenalidomide treatment was 81.3% and 50.0%, respectively.
= As of CCOD, no fatal (Grade 5) AEs were reported in the study.
= The percentage of patients who reported at least one serious adverse event (SAE) was 12.5% (2/16 patients), of which three events were related to mosunetuzumab treatment (by PT, CRS [2 events]; rash maculo-papular).
= The percentage of patients who reported at least one Grade 3 AE was 31.3%
(5/16 patients).
= No AEs were reported that led to study treatment discontinuation.
= The percentage of patients who reported at least one event that led to dose modification/interruption of study treatment was 37.5% (6/16 patients). Of these, 2 patients had dose interruption of rnosunetuzumab and 6 patients had dose interruption of lenalidomide treatment.
= The percentage of patients who reported at least one adverse event of special interest (AESI) was 31.3% (5/16 patients).
The incidence and frequency of AEs, including AEs considered related to rnosunetuzumab, SAEs and AESIs were similar in this study as a related study with monotherapy mosunetuzumab administered with similar doses.
Table 4. Safety Summary for Safety-Evaluable Patients as of CCOD of April 5, 2021.
Mosunetuzumab + Mosunetuzumab Lenalidomide (IV) (IV) (N = 16) (N
= 213) N(%) N(%) Patients who experienced at least one adverse event 13 (81.3) 207 (97.2) (AE) Total number of AEs 83 Deaths 0 64 (30.0) Fatal AEsa 0 5 (2.3) Serious AEs 2(12.5) 107 (50.2) Grade 3-5 AEs 5 (31.3) 141 (66.2) Treatment-related AEs 13 (81.3) 183 (85.9) Mosunetuzumab 13 (81.3) 183 (85.9) Lenalidomide 8 (50.0) AEs leading to treatment withdrawal 0 7 (3.3) Mosunetuzumab 0 7 (3.3) Lenalidomide 0 AEs leading to dose modification/interruption 6(37.5) 29 (13.6) Mosunetuzumab 2(12.5) 29 (13.6) Lenalidomide 6 (37.5) Patients who experienced at least one AESI
Cytokine release syndromeh 5 (31.3) 79 (37.1) Neutropenia/neutrophil count decrease 4 (25.0) 56 (26.3) Febrile neutropenia 0 6 (2.8) Thrombocytopenia 1 (6.3) 14 (6.6) Tumor lysis syndrome 0 3 (1.4) Tumor flare 1 (6.3)c 4 (1.9) AST increased 1 (6.3) 14 (6.6) ALT increased 1 (6.3) 22 (10.3) AE = adverse event, AESI = adverse event of special interest a Does not include events of "death due to progressive disease"
b per ASTCT criteria Subject had worsening pleural effusion. Tumor flare based on Medical Dictionary for Regulatory Activities (Med DRA) preferred terms (PT) of "tumor flare, tumor inflammation, tumor pain and new or worsening pleural effusion".
Most Frequently Reported Adverse Events:
Overall, the percentage of patients who reported at least one AE was 81.3%
(13/16 patients), with a total of 83 AEs reported overall.
The most commonly reported AEs by System Organ Class (SOC) were skin and subcutaneous tissue disorders (43.8%; 7/16 patients); gastrointestinal disorders (37.5%; 6/16 patients); blood and lymphatic system disorders; general disorders and administration site conditions, immune system disorders, and nervous system disorders (all 31.3%;
5/16 patients).
The most commonly reported AEs by MedDRA Preferred Term (PT) were CRS (31.3%;
patients); constipation and neutropenia (both 25.0%; 4/16 patients). A summary of AEs 10%) is presented in Table 5.
Table 5. Summary of Adverse Events with 10% by patient, as of April 5, 2021.
MedDRA System Organ Class Mosun + Len MedDRA Preferred Term (N = 16) Skin and subcutaneous tissue disorders Dry skin 3(18.8%) Pruritus 3 (18.8%) Erythema 2(12.5%) Rash 2(12.5%) Rash maculo-papular 2 (12.5%) Gastrointestinal disorders Constipation 4 (25.0%) Dry mouth 2 (12.5%) Blood and lymphatic system disorders Neutropenia 4 (25.0%) General disorders and administration site conditions Asthenia 2(12.5%) Immune system disorders Cytokine release syndrome 5 (31.3%) Nervous system disorders headache 2(12.5%) Musculoskeletal and connective tissue disorders Bone pain 2(12.5%) Metabolism and nutrition disorders Decreased appetite 2 (12.5%) Based on MedDRA version 23.1. Percentages are based on N in the column headings. Only treatment emergent AEs are displayed. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. CCOD of April 5, 2021.
Adverse Events Related to Treatment Overall, the percentage of patients who reported at least one event considered related to study treatment was 81.3% (13/16 patients; Table 4). The most commonly reported adverse events relating to treatment were CRS (31.3%; 5/16 patients) and neutropenia (25.0%;
4/16 patients). AEs 10%) considered related to study treatment (e.g., related to mosunetuzumab or lenalidomide) are shown in FIG. 2.
Overall, the percentage of patients who reported at least one AE considered related to mosunetuzumab treatment was 81.3% (13/16 patients; Table 4). The most commonly reported AE
by PT considered related to mosunetuzumab treatment was CRS (31.3%; 5/16 patients). AEs 10%) considered related to mosunetuzumab are shown in FIG. 3.
Overall, the percentage of patients who reported at least one AE considered related to lenalidomide treatment was 50.0% (8/16 patients; Table 4). The most commonly reported AE by PT
considered related to lenalidomide treatment was neutropenia (25.0%; 4/16 patients). AEs 10%) considered related to lenalidomide are shown in FIG. 4.
Adverse Events by Intensity Overall, the percentage of patients who reported at least one Grade 3 AE was 31.3% (5/16 patients; Table 4). The most commonly reported AE by PT was neutropenia (25.0%; 4/16 patients;
Table 6).
Table 6. Summary of Adverse Events (AE) with Grades 3-5, as of April 5, 2021.
MedDRA System Organ Class Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Total number of patients with at least one Grade 3-5 AE 5 (31.3%) Overall total number of events 13 Blood and lymphatic system disorders Total number of patients with at least one Grade 3-5 4 (25.0%) AE
Total number of events 9 Neutropenia 4 (25.0%) Skin and subcutaneous tissue disorders Total number of patients with at least one Grade 3-5 2 (12.5%) AE
Total number of events 2 Erythema 1 (6.3%) Rash maculo-papular 1 (6.3%) Investigations Total number of patients with at least one Grade 3-5 1 (6.3%) AE
Total number of events 2 Erythema 1 (6.3%) Rash maculo-papular 1 (6.3%) Based on MedDRA version 23.1. Percentages are based on N in the column headings.
Only treatment emergent AEs are displayed. For frequency counts of "Total number of events"
rows, multiple occurrences of the same AE in an individual are counted separately.
Deaths As of the CCOD, no deaths have been reported in Study C041942.
Serious Adverse Events Overall, the percentage of patients who reported at least one SAE was 12.5%
(2/16 patients;
Table 4). A summary of serious adverse events reported is provided in Table 7.
One patient (6.3%) experienced an SAE (by PT, rash maculo-papular) considered related to mosunetuzumab by the Investigator. This event was of Grade 3 severity and resolved after 9 days, following a dose interruption of mosunetuzumab. Two other events (by PT, pleural effusion;
atrial flutter) led to dose interruption of treatment (lenalidomide and mosunetuzumab, respectively); both events were Grade 2 severity and had resolved by Day 8 of onset. All other SAEs reported were of Grade 1 or Grade 2 severity, and resolved on or by Day 9 of onset without dose interruption/modification of study treatment. No SAEs of Grade 4 or 5 severity were reported.
Table 7. Summary of Serious Adverse Events (SAE), as of April 5, 2021.
MedDRA System Organ Class Grade Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Any serious adverse events Any Grade 2 (12.5%) 1 (6.3%) 1 (6.3%) Cardiac disorders Overall Any Grade 1 (6.3%) 1 (6.3%) Atrial Flutter Any Grade 1 (6.3%) 1 (6.3%) General disorders and administration site conditions Overall Any Grade 1 (6.3%) 1 (6.3%) Adverse Drug Reaction Any Grade 1 (6.3%) 1 (6.3%) Immune system disorders Overall Any Grade 1 (6.3%) 1 (6.3%) Cytokine release syndrome Any Grade 1 (6.3%) 1 (6.3%) Respiratory, thoracic, and mediastinal disorders Overall Any Grade 1 (6.3%) (6.3%) Pleural effusion Any Grade 1 (6.3%) (6.3%) Skin and subcutaneous disorders Overall Any Grade 1 (6.3%) (6.3%) Rash maculo-papular Any Grade 1 (6.3%) (6.3%) Percentages are based on N in the column headings. For frequency counts by preferred term, multiple occurrences of the same SAE in an individual are counted only once.
For frequency counts of "Total number of events" rows, multiple occurrences of the same SAE in an individual are counted separately. Adverse Events with missing Common Terminology Criteria for Adverse Events 5 (CTCAE) grades are excluded.
Adverse Events that led to Study Treatment Dose Modification or Interruption Overall, the percentage of patients who reported at least one event that led to dose modification/interruption of study treatment was 37.5% (6/16 patients; Table 4). Of these, 2 patients had dose interruption of mosunetuzurnab and 6 patients had dose interruption of lenalidomide treatment.
Two patients (12.5%) experienced events (by PT, rash maculo-papular [Grade 3];
neutropenia [Grade 4]; atrial flutter [Grade 2]) reported by the Investigator that led to dose interruption of mosunetuzumab. All events resolved within 9 days of onset following treatment for the AE.
Six patients (37.5%) experienced events (by PT, pleural effusion [Grade 2];
neutropenia, [Grade 3 and Grade 4, 3 events each]; erythema [Grade 3]; pruritus [Grade 2];
rash maculo-papular [Grade 3]) that led to dose interruption of lenalidomide. Two patients (12.5%) experienced an event (by PT, neutropenia [Grade 3 and Grade 4]) that led to dose reduction of lenalidomide. All events resolved, except for two events of neutropenia (both Grade 3 severity), which were still ongoing as of the CCOD.
Adverse Events of Special Interest (AESI) AESIs include events that are considered to be of overlapping toxicities between the study treatments, and are summarized in Table 8. Overall, the percentage of patients who reported at least one AESI was 43.8%(7/16 patients). The most commonly reported AESIs were CRS (31.3%;
5/16 patients), and neutropenia (25.0%; 4/16 patients). One patient (6.3%) reported an event of Grade 1 thrombocytopenia that had not resolved at the time of CCOD; no intervention was taken.
Table 8. Summary of Adverse Events of Special Interest (AESI), as of April 5, 2021.
MedDRA System Organ Class Patients treated with MedDRA Preferred Term 1/2/30 mg Mosun (N = 16) Total number of patients with at least one AESI 7 (43.8) Overall total number of events 20 Immune system disorders Total number of patients with at least one AESI 5 (31.3%) Total number of events 7 Cytokine release syndrome 5 (31.3%) Blood and lymphatic system disorders Total number of patients with at least one AESI 4 (25.0%) Total number of events 10 Neutropenia 4 (25.0%) Thrombocytopenia 1 (6.3%) Investigations Total number of patients with at least one AESI 1 (6.3%) Total number of events 2 Alanine aminotransferase increased 1 (6.3%) Aspartate aminotransferase increased 1 (6.3%) Respiratory, thoracic, and mediastinal disorders Total number of patients with at least one AESI 1 (6.3%) Total number of events 1 Pleural effusion 1 (6.3%) Percentages are based on N in the column headings.
Overall, the most commonly reported AESI was CRS (31.3%; 5/16 patients; 7 events). Of the patients who experienced an event, 4 patients (25.0%) reported an event of Grade 1 severity, and one patient (6.3%) reported an event of Grade 2 severity; all events were considered related to mosunetuzumab treatment. The majority of events were reported in patients on study day 1, all of which resolved within 3 days of onset. Two patients (12.5%) reported subsequent events: one patient on study day 15 and another on study day 29, which resolved within 2 and 7 days, respectively. Of the 5 patients who reported CRS, 4 patients (25.0%) received interventional treatment for this event.
Five patients (31.3%) had a CRS event, considered related to mosunetuzumab treatment, as assessed by the Investigator, including 4 patients (25.0%) with ASTCT Grade 1, and one patient (6.3%) with Grade 2 (Table 9). All 5 patients had onset of first CRS event between Day 1 of Cycle 1 and Day 7 of Cycle 1 (FIG. 5). One patient (6.3%; 1/14) had a subsequent Grade 1 event between Day 15 of Cycle 1 and Day 21 of Cycle 1 during mosunetuzumab monotherapy treatment, and another patient (6.3%; 1/14) had a subsequent Grade 1 event in 02 during mosunetuzumab and lenalidomide combination treatment.
Table 9. CRS Events by Dose Cycle for Safety-Evaluable Patients as of CCOD of April 5, 2021.
CRS Grade Cycle 1 Cycle 1 Cycle 1 Cycle 2 Cycle 3 Days 1-7 Days 8-14 Days 15-21 N . 13 N . 8 N . 16 N . 14 N . 14 Any Grade 5(31.3%) 0 1 (7.1%) 1(7.1%) 1 4 (25.0%) 0 1 (7.1%) 1 (7.1%) 2 1(6.3%) 0 0 0 Overall, fever was the most frequent symptom of CRS, of which 7 events were reported in 5 patients who reported an event of CRS. Other signs and symptoms reported concurrently CRS
5 included chills, hypoxia, tachycardia, elevated liver enzyme (AST), elevated liver enzyme (ALT), hyperuricemia and lactate dehydrogenase (LDH) increased. One patient (6.3%) received low-flow oxygen for the treatment of Grade 2 CRS. No Grade 3 CRS events were observed and no patient required tocilizumab, ICU management, high flow oxygen or vasopressor support.
Four patients (25.0%) reported 9 events of neutropenia (Table 4). Of these, 2 patients experienced 5 events considered related to mosunetuzumab and lenalidomide treatment, and 2 patients experienced 4 events considered related to lenalidomide treatment only, as assessed by the Investigator. Two patients reported events of Grade 4 severity, all of which resolved, one patient without any treatment and one patient following treatment with G-CSF.
Two patients reported 5 events of Grade 3 severity, of which 2 events (one in each patient) did not resolve as of the CCOD, following treatment with G-CSF for the event and dose interruption of lenalidomide.
Events of neutropenia occurred between Day 42 and Day 155, and had a duration of between 8 and 16 days.
Preliminary Efficacy The efficacy evaluable population included all patients who had been assessed for response at any time on study, who had withdrawn from treatment or study prior to reaching their first response assessment, or who had been on study long enough to have reached their first scheduled response assessment, planned per protocol for Cycle 3, D15-21. The response was assessed by the Investigator per Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
No formal efficacy data analysis was performed. Upon review of the electronic database, as of CCOD, 8 patients enrolled in Study 0041942 had at least one response assessment. Of these 8 patients, 2 patients had a partial response, and 6 patients had a complete response (i.e., an overall response rate (OR) of 100% and a complete response rate (CR) of 75%. No patients had progression of the disease or withdrew from the study.
Pharmacokinetics Preliminary mosunetuzumab pharmacokinetic data (N = 13) in patients who received the 1/2/30 mg 04W dose of mosunetuzumab in Study 0041942 are summarized in FIG. 6.
Observed pharmacokinetics of mosunetuzumab at 1/2/30 mg (IV) in combination with lenalidomide in R/R FL
patients were similar to predictions of mosunetuzumab pharmacokinetics of mosunetuzumab monotherapy in R/R NHL patients at the same dose. Preliminary results indicate that mosunetuzumab PK is similar when administered in combination with lenalidomide as compared to monotherapy, where the observed concentration measurements fell generally within the popPK
model simulated 5th to 95th prediction intervals.
No lenalidomide PK data were available at the time of this report.
Mosunetuzumab is not expected to impact the PK of lenalidomide which is primarily excreted in the urine (Chen N et al.
Clin Pharmacokinet 2017; 56(2):139-152).
Conclusion The safety profile for mosunetuzumab, in combination with lenalidomide, at the tested dose and schedule (1/2/30 mg, 04W) was acceptable, with no unexpected safety signals.
The overall frequency and severity of CRS events (7 events of Grade 1-2 severity, in 5 patients) observed with mosunetuzumab in combination with lenalidomide in this study was comparable to CRS events observed with mosunetuzumab monotherapy. All CRS
events were Grade 1, except in one patient who experienced a Grade 2 event in Cycle 1 with mosunetuzumab (1 mg) monotherapy. This patient was the only patient who experienced a CRS event in Cycle 2, which was Grade 1. Four patients (25.0%) reported events of Grade 3-4 neutropenia. Of the 9 events reported, 7 events resolved and 2 events (Grade 3 severity) had not resolved as of CCOD.
One patient (6.3%) reported an event of Grade 1 thrombocytopenia that had not resolved at the time of CCOD. No patients discontinued study treatment due to AEs.
Mosunetuzumab PK exposures observed in Study C041942 were consistent with what was expected based on PK observed with mosunetuzumab monotherapy, suggesting that the combination of mosunetuzumab with lenalidomide does not appear to affect mosunetuzumab exposure. The proposed dosing regimen was supported by the totality of data and the exposure-response characterizations based on mosunetuzumab monotherapy and mosunetuzumab in combination with lenalidomide, suggesting an adequate balance of clinical benefit/risk in the patient population.
In summary, the available data from Study G041942 demonstrated an acceptable safety profile and preliminary efficacy for patients with R/R FL, thus supporting the continued use of 1/2/30 mg step-up dosing regimen of mosunetuzumab in combination with lenalidomide.
Example 2. Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase lb Study Presented here are initial data from an ongoing Phase lb study (N0T04246086) evaluating the safety and activity of combination therapy of mosunetuzumab and lenalidomide in R/R FL
patients who have received at least one prior line of therapy.
Methods Patients with R/R FL (Grade 1-3a) and at least one prior systemic anti-cancer therapy were enrolled to receive 12 cycles of combination therapy of mosunetuzumab and lenalidomide (cycle duration: Cycle 1,21 days; Cycles 2-12,28 days). In Cycle 1, step-up doses of mosunetuzumab (IV
infusion) were given on Day 1 of Cycle 1 (the Cl Dl dose; 1 mg) and Day 2 of Cycle 1 (the Cl D2 dose; 2 mg), with the target dose given on Day 3 of Cycle 1 (the Cl D3 dose;
30 mg) and on Day 1 of Cycles 2-12 (the C2D1-C12D1 doses). Lenalidomide (20 mg orally) was administered on Days 1-21 of Cycles 2-12. No hospitalization was mandated by the protocol. The primary objective was to evaluate the safety of combination therapy of mosunetuzumab and lenalidomide;
secondary objectives include assessment of response and long-term efficacy outcomes.
Cytokine release syndrome (CRS) was reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019).
Responses are assessed by investigators with PET-CT using Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
Results At data cut-off (May 31, 2021), 27 patients had been enrolled. Median age was 59 years (range: 31-79 years); 12 patients (44%) were male. All patients had an ECOG
(Eastern Cooperative Oncology Group) performance status of 0 (18 patients, 67%) or 1 (9 patients, 33%). Median number of prior lines of therapy was 1 (range: 1-4), and 3 patients (11%) had disease progression (PD) < 24 months from the start of first-line therapy. At data cut-off, 16 patients (59%) had been on study for 0-3 months, 8 (30%) for 3-6 months, 2 (7%) for 6-9 months, and 1 (4%) for > 9 months.
All 27 patients were safety evaluable at data cut-off. Twenty patients (74%) experienced 1 adverse event (AE) of any Grade (GO; the most common AE was CRS (8 patients, 30%). Grade 3-4 AEs occurred in 8 patients (30%) and serious AEs in 8 patients (30%). No Grade 5 (fatal) AEs were observed. AEs relating to mosunetuzumab occurred in 20 patients (74%) and AEs relating to lenalidomide occurred in 10 patients (37%). There were no AEs leading to withdrawal of mosunetuzumab or lenalidomide; 2 patients had mosunetuzurnab-related AEs leading to mosunetuzumab dose delays, 6 patients (22%) had lenalidomide-related AEs leading to lenalidomide dose interruption and/or reduction.
In all patients, CRS events were Grade 1 (7/8 patients) or Grade 2 (1/8 patients). For most patients (6/8), CRS events occurred in Cycle 1; 2 patients experienced Grade 1 CRS events in Cycle 2. Median time to CRS onset was 1 day after first study drug administration (range: 1-28 days), median CRS duration was 3 days (range: 2-5 days). All CRS events resolved without sequelae. No patient required tocilizumab, ICU admission, high flow oxygen, or vasopressor support. Five patients (19%) reported 14 events of Grade 3-4 neutropenia; all neutropenia events occurred between Day 41 and Day 218, with a duration of 6-16 days. All neutropenia events resolved, with 1 patient receiving primary granulocyte colony-stimulating factor (G-CSF) prophylaxis and 2 patients receiving G-CSF treatment. No febrile neutropenia events occurred.
The efficacy-evaluable population included all patients who had been assessed for response at any time on study, who had withdrawn from treatment or study prior to reaching their first response assessment, or who had been on study long enough to have reached their first scheduled response assessment, planned per protocol for Days 15-21 of Cycle 3. Objective response rate in the 13 patients who were efficacy evaluable at data cut-off was 92%, with complete metabolic response observed in 10 patients (77%), partial metabolic response (PMR) in 2 patients (15%), and stable disease in 1 patient (8%). One patient who initially achieved PMR
experienced PD after 8 cycles of treatment.
Conclusion Combination treatment of mosunetuzumab and lenalidomide appeared to have an acceptable safety profile in patients with R/R FL who had received at least one prior line of therapy, with encouraging preliminary anti-lymphoma activity observed.
Example 3. Preliminary Safety and Efficacy for Mosunetuzumab in Combination with Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase lb Study Presented here are additional data from an ongoing Phase lb study (NCT04246086) (described in Example 2 above) evaluating the safety and activity of combination therapy of mosunetuzumab and lenalidomide in R/R FL patients who have received at least one prior line of therapy.
Methods Patients with R/R FL (Grade 1-3a) and at least one prior systemic anti-cancer therapy were enrolled to receive 12 dosing cycles of combination therapy of mosunetuzumab and lenalidomide (cycle duration: Cycle 1, 21 days; Cycles 2-12, 28 days). In Cycle 1, step-up doses of mosunetuzumab (IV infusion) were given on Day 1 of Cycle 1 (the Cl Dl dose; 1 mg) and Day 2 of Cycle 1 (the Cl D2 dose; 2 mg), with the target dose given on Day 3 of Cycle 1 (the Cl D3 dose; 30 mg) and on Day 1 of Cycles 2-12 (the C2D1-C12D1 doses). Lenalidomide (20 mg orally) was administered on Days 1-21 of Cycles 2-12. Corticosteroid pre-medication was administered to the patients during Cycles 1 and 2 and was optional from Cycle 3 onwards. For corticosteroid premedication, 10 mg of dexarnethasone was administered intravenously to the patients prior to each dose of mosunetuzumab. Corticosteroid pre-medication may additionally be deemed optional on Cycle 2 depending on further safety data evaluation. No hospitalization was mandated by the protocol. The primary objective was to evaluate the safety of combination therapy of mosunetuzumab and lenalidomide; secondary objectives include assessment of response and long-term efficacy outcomes. Cytokine release syndrome (CRS) was reported using ASTCT criteria (Lee et al. Biol Blood Marrow Transplant 2019). Responses are assessed by investigators with PET-CT
using Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
Results At data cut-off (September 13, 2021), 29 patients had been enrolled. Median age was 59 years (range: 30-79 years); 13 patients (44.8%) were male. All patients had an ECOG (Eastern Cooperative Oncology Group) performance status of 0-2. Two (6.8%) patients were Ann Arbor stage I-II at study entry and 27 (93.1%) patients were Ann Arbor stage III-IV
at study entry (see Carbone et al., Cancer Res. 1971, 31(11): 1860-1861). Seven (24.1%) patients had 0-1 FLIP! risk factors at study entry, eight (27.6%) patients had 2 FLIP! risk factors at study entry, and 14 (48.3%) patients had 3-5 FLIP! risk factors at study entry. 18(62.1%) patients had FL
Grade 1-2, 5 (17.2%) patients had FL Grade 3a, and six (20.7%) patients had FL of an unknown Grade.
Median number of prior lines of therapy was 1 (range: 1-6), and 3 patients (10.3%) had disease progression (PD) <
24 months from the start of first-line therapy (P0D24). Nine (31%) patients were refractory to at least one prior therapy comprising an anti-CD20 monoclonal antibody. Seven (24.1%) patients were double refractory to both a therapy comprising an anti-CD20 monoclonal antibody and a therapy comprising an alkylating agent. At data cut-off, 1 patient (3.4%) had been on study for 0-3 months, 14(48.3%) for 3-6 months, 7(24.1%) for 6-9 months, and 7 (24.1%) for > 9 months. Median duration of mosunetuzumab treatment was 4.9 months (range 2-11) and median duration of lenalidomide treatment was 4.3 months (range 2-10). Median duration of follow-up was 5.4 months (range 3-12).
All 29 patients were safety evaluable at data cut-off (September 13, 2021).
Adverse events are summarized below in Table 10.
Table 10. Adverse Events in Safety Evaluable Patients (data cut-off: September 13, 2021) N = 29 ( /0) Any AE
29 (100) Related to mosunetuzumab / lenalidomide 27 (93.1) / 23 (79.3) Grade 3-4 AE
13 (44.8) Related to mosunetuzumab / lenalidomide 1 (3.4) / 1 (3.4) Serious AE
9 (31.0) Related to mosunetuzumab / lenalidomide 6 (20.7) / 1 (3.4) Grade 5 (fatal) AE 0 AE leading to mosunetuzumab / lenalidomide withdrawal 0 / 1 (3.4) AE leading to mosunetuzumab / lenalidomide dose modification/ interruption 6 (20.7) / 12 (41.4) AE = adverse event Twenty-nine patients (100%) experienced 1 adverse event (AE) of any Grade.
Common adverse events, experienced by at least 10% of patients, are summarized in FIG. 7. Grade 3-4 AEs occurred in 13 patients (44.8%) and serious AEs in 9 patients (31%). No Grade 5 (fatal) AEs were observed. AEs relating to mosunetuzumab occurred in 27 patients (93.2%) and AEs relating to lenalidomide occurred in 23 patients (79.3%%). There were no AEs leading to withdrawal of mosunetuzumab and one AE (3.4%) leading to withdrawal of lenalidomide; 6 patients (20.7%) had mosunetuzumab-related AEs leading to mosunetuzumab dose modification and/or interruption; 12 patients (41.4%) had lenalidomide-related AEs leading to lenalidomide dose modification and/or interruption.
Cytokine release syndrome (CRS) events observed in the safety-evaluable patients are summarized below in Table 11.
Table 11. CRS Events in Safety Evaluable Patients (data cut-off: September 13, 2021) N = 29 (%) Any CRS (all Grades 1-2) 8 (27.6) Grade 1 7(24.1) Grade 2a 1 (3.4) Median time to CRS onset, days (range) 1 (1-28) Median duration of CRS, days (range) 3 (2-5) apatient had fever and hypoxia that required 2L nasal cannula oxygen In all patients who experienced at least one CRS event (8/29 total patients), CRS events were Grade 1 (7/8 patients) or Grade 2 (1/8 patients). For most patients (6/8), CRS events occurred in Cycle 1; 2 patients experienced Grade 1 CRS events in Cycle 2. Median time to CRS onset was 1 day after first study drug administration (range: 1-28 days), median CRS
duration was 3 days (range: 2-5 days). All CRS events resolved by data cut-off date (September 13, 2021). No patient received tocilizumab, and no patient required ICU admission, high flow oxygen, or vasopressor support. No immune effector cell-associated neurotoxicity syndrome (ICANS) events occurred. A
summary of CRS events by dosing cycle and dose is shown in FIG. 8.
Neutropenia and febrile neutropenia events observed in the safety-evaluable patients are summarized below in Table 12.
Table 12. Neutropenia and Febrile Neutropenia Events in Safety Evaluable Patients (data cut-off:
September 13, 2021) N = 29 (/0) Any neutropenia (all Grade 3-4) 7(24.1) Grade 3 4(13.4) Grade 4 3(10.3) Median time to neutropenia onset, days (range) 86 (41-189) Median duration of neutropenia, days (range) 9 (4-29) Seven patients (24.1%) reported neutropenia or febrile neutropenia events of Grade 3-4; all neutropenia events occurred between Day 41 and Day 189 (median 86 days), with a median duration of 9 days (range 4-29). All neutropenia events resolved by data cut-off date. Febrile neutropenia (Grade 3) occurred in 1 patient (duration: 5 days) and was considered treatment-related. A summary of neutropenia events reported by dosing cycle and Grade and granulocyte colony-stimulating factor (G-CSF) use by dosing cycle is shown in FIG. 9.
Anti-tumor activity in evaluable patients is shown in FIG. 10. In particular, objective response rate in the 29 patients at data cut-off was 89.7%, with complete metabolic response observed in 65.5% of patients (see FIG. 11). Notably, 3/3 patients with history of P0D24, 9/9 patients with anti-CD20 refractory disease, and 7/7 patients with double-refractory disease all exhibited responses as measured by PET-CT. Duration of response in all 29 patients as of the data cut-off date of September 13, 2021, is summarized in FIG. 12.
Conclusion Combination treatment of mosunetuzumab and lenalidomide appeared to have an acceptable safety profile in patients with R/R FL who had received at least one prior line of therapy, with encouraging anti-lymphoma activity and anti-tumor activity observed. No increase in CRS and neutropenia events was observed compared with mosunetuzumab monotherapy.
EMBODIMENTS
Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments:
1. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
2. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
3. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
4. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
5. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
6. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen.
7. The method, mosunetuzumab for use, or use of any one of embodiments 1-6, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
8. The method, mosunetuzumab for use, or use of any one of embodiments 1-7, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
9. The method of any one of embodiment 7 or 8, wherein the subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
10. The mosunetuzumab for use or use of embodiment 7 or 8, wherein mosunetuzumab and lenalidomide are not to be administered to the subject for at least 4 weeks after the subject has received treatment with an anti-CD20 monoclonal antibody.
11. The method, mosunetuzumab for use, or use of any one of embodiments 1-6, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
12. The method, mosunetuzumab for use, or use of embodiment 11, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
13. The method, mosunetuzumab for use, or use of embodiment 11, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
14. The method of any one of embodiments 1 and 7-9, and 11-13, wherein administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg: and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
15. The mosunetuzumab for use or use of any one of embodiments 2-8 and 10-14, wherein the mosunetuzumab is to be administered to the subject according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the Cl D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the Cl D3 and is between 0.2 mg to 50 mg.
16. The method, mosunetuzumab for use, or use of embodiment 14 or 15, wherein:
(a) the Cl Dl is between 0.4 mg to 4.0 mg, the Cl D2 is between 1.0 mg to 20.0 mg, and the Cl D3 is between 3.0 mg to 50.0 mg; and (b) the C2D1 is between 3.0 mg to 50.0 mg.
17. The method, mosunetuzumab for use, or use of any one of embodiments 14-16, wherein:
(a) the Cl Dl is between 0.8 mg to 3.0 mg, the Cl D2 is between 1.0 mg to 6.0 mg, and the Cl D3 is between 3.0 mg to 45.0 mg; and (b) the C2D1 is between 3.0 mg to 45.0 mg.
(a) the Cl Dl is between 0.8 mg to 3.0 mg, the Cl D2 is between 1.0 mg to 6.0 mg, and the Cl D3 is between 3.0 mg to 45.0 mg; and (b) the C2D1 is between 3.0 mg to 45.0 mg.
18. The method, mosunetuzumab for use, or use of any one of embodiments 14-17, wherein the Cl Dl and Cl D2 are each less than the Cl D3.
19. The method, mosunetuzumab for use, or use of any one of embodiments 14-17, wherein the Cl D2 is greater than the Cl Dl by about 50% to about 250%.
20. The method, mosunetuzumab for use, or use of any one of embodiments 14-17, wherein:
(a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 4.2 mg, and the is 4.2 mg;
(b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the Cl D3 is 3.0 mg, and the is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
(a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 4.2 mg, and the is 4.2 mg;
(b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the Cl D3 is 3.0 mg, and the is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and the C2D1 is 30.0 mg.
21. The method, mosunetuzumab for use, or use of any one of embodiments 14-20, wherein the length of the first dosing cycle is 21 days.
22. The method of embodiment 21, wherein the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
23. The mosunetuzumab for use or use of embodiment 21, wherein the Cl Dl, the Cl D2, and the Cl D3 are to be administered to the subject on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
24. The method, mosunetuzumab for use, or use of any one of embodiments 14-23, wherein the length of the second dosing cycle is 28 days.
25. The method of embodiment 24, wherein the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
26. The mosunetuzumab for use or use of embodiment 24, wherein the C2D1 is to be administered to the subject on Day 1 of the second dosing cycle.
27. The method, mosunetuzumab for use, or use of any one of embodiments 24-26, wherein the dosing regimen comprises one or more additional dosing cycles.
28. The method, mosunetuzumab for use, or use of embodiment 27, wherein the dosing regimen comprises one to ten additional dosing cycles.
29. The method, mosunetuzumab for use, or use of embodiment 27 or 28, wherein the dosing regimen comprises ten additional dosing cycles.
30. The method, mosunetuzumab for use, or use of any one of embodiments 27-29, wherein the length of each of the one or more additional dosing cycles is 28 days.
31. The method, mosunetuzumab for use, or use of any one of embodiments 27-30, wherein each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab.
32. The method of embodiment 31, wherein each additional dose of mosunetuzumab is administered on Day 1 of each of the one or more additional dosing cycles.
33. The mosunetuzumab for use or use of embodiment 31, wherein each additional dose of mosunetuzumab is to be administered on Day 1 of each of the one or more additional dosing cycles.
34. The method of any one of embodiments 1-13, wherein administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (C1D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (C1D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
35. The mosunetuzumab for use or use of any one of embodiments 1-13, wherein the mosunetuzumab is to be administered to the subject according to a dosing regimen comprising twelve dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (C1D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (C1D3) of mosunetuzumab, wherein the Cl Dl and the Cl D2 are each no greater than the C1D3, and wherein the Cl Dl is between 0.02 mg to 4.0 mg, the Cl D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
36. The method, mosunetuzumab for use, or use of embodiment 34 or 35, wherein:
(a) the Cl Dl is between 0.4 mg to 4.0 mg, the Cl D2 is between 1.0 mg to 20.0 mg, and the C1D3 is between 3.0 mg to 50.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg.
(a) the Cl Dl is between 0.4 mg to 4.0 mg, the Cl D2 is between 1.0 mg to 20.0 mg, and the C1D3 is between 3.0 mg to 50.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg.
37. The method, mosunetuzumab for use, or use of any one of embodiments 34-36, wherein:
(a) the Cl Dl is between 0.8 mg to 3.0 mg, the Cl D2 is between 1.0 mg to 6.0 mg, and the C1D3 is between 3.0 mg to 45.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg.
(a) the Cl Dl is between 0.8 mg to 3.0 mg, the Cl D2 is between 1.0 mg to 6.0 mg, and the C1D3 is between 3.0 mg to 45.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 45.0 mg.
38. The method, mosunetuzumab for use, or use of any one of embodiments 34-37, wherein the Cl D1 and Cl D2 are each less than the Cl D3.
39. The method, mosunetuzumab for use, or use of any one of embodiments 34-38, wherein the Cl D2 is greater than the Cl Dl by about 50% to about 250%.
40. The method, mosunetuzumab for use, or use of any one of embodiments 34-37, wherein:
(a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the C1D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg;
(b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
(a) the Cl Dl is 0.8 mg, the Cl D2 is 2.0 mg, and the C1D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg;
(b) the Cl Dl is 1.0 mg, the Cl D2 is 1.0 mg, and the C1D3 is 3.0 mg, and each single dose C2D1-C12D1 is 30.0 mg; or (c) the Cl Dl is 1.0 mg, the Cl D2 is 2.0 mg, and the Cl D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
41. The method, mosunetuzumab for use, or use of any one of embodiments 34-40, wherein the length of the first dosing cycle is 21 days.
42. The method of embodiment 41, wherein the method comprises administering to the subject the Cl Dl, the Cl D2, and the Cl D3 on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
43. The mosunetuzumab for use or use of embodiment 41, wherein the Cl Dl, the Cl D2, and the Cl D3 are to be administered to the subject on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
44. The method, mosunetuzumab for use, or use of any one of embodiments 34-43, wherein the length of each of the second to twelfth dosing cycles is 28 days.
45. The method of embodiment 44, wherein the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle.
46. The method of any one of embodiments 34-45, wherein the length of each of the second to twelfth dosing cycles is 28 days.
47. The method of any one of embodiments 34-43, wherein the length of each of the second to twelfth dosing cycles is 21 days.
48. The method of any of the preceding embodiments, wherein mosunetuzumab is administered intravenously.
49. The mosunetuzumab for use or use of any of the preceding embodiments, wherein mosunetuzumab is to be administered intravenously.
50. The method of any one of embodiments 14-49, wherein lenalidomide is administered during the second and subsequent cycles.
51. The mosunetuzumab for use or use of any one of embodiments 14-49, wherein lenalidomide is to be administered during the second and subsequent cycles.
52. The method of any one of embodiments 14-51, wherein lenalidomide is not administered during the first cycle.
53. The mosunetuzumab for use or use of any one of embodiments 14-51, wherein lenalidomide is not to be administered during the first cycle.
54. The method of any one of embodiments 14-53, wherein lenalidomide is administered daily.
55. The mosunetuzumab for use or use of any one of embodiments 14-53, wherein lenalidomide is to be administered daily.
56. The method of any one of embodiments 46 and 48-55, wherein lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide.
57. The mosunetuzumab for use or use of any one of embodiments 46 and 48-55, wherein lenalidomide is to be administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide.
58. The method of any one of embodiments 47-55, wherein lenalidomide is administered daily on the first 14 days of each dosing cycle comprising administration of lenalidomide.
59. The mosunetuzumab for use or use of any one of embodiments 47-55, wherein lenalidomide is to be administered daily on the first 14 days of each dosing cycle comprising administration of lenalidomide.
60. The method of any one of embodiments 56-59, wherein lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide.
61. The mosunetuzumab for use or use of any one of embodiments 56-59, wherein lenalidomide is not to be administered on the last 7 days of each dosing cycle comprising administration of lenalidomide.
62. The method of any one of embodiments 14-61, wherein lenalidomide is administered at a dose of 20 mg.
63. The mosunetuzumab for use or use of any one of embodiments 14-61, wherein lenalidomide is to be administered at a dose of 20 mg.
64. The method of any of the preceding embodiments, wherein lenalidomide is administered orally.
65. The mosunetuzumab for use or use of any of the preceding embodiments, wherein lenalidomide is to be administered orally.
66. The method, mosunetuzumab for use, or use of any of the preceding embodiments, wherein the subject was previously treated with at least one anti-CD20 monoclonal antibody.
67. The method, mosunetuzumab for use, or use of embodiment 66, wherein the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody.
68. The method, mosunetuzumab for use, or use of embodiment 66 or 67, wherein the anti-CD20 monoclonal antibody is obinutuzumab or rituxirnab.
69. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
70. Mosunetuzumab for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
71. Use of mosunetuzumab in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
72. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
73. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
30 74. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
75. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
76. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
77. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
78. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
79. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
BO. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
81. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of the second dosing cycle.
82. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
83. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
84. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
85. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
86. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
87. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzurnab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of each dosing cycle.
88. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
89. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
90. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
91. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-012D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
92. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
93, The method, mosunetuzumab for use, or use of any one of embodiments 69-92, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
94. The method, mosunetuzumab for use, or use of embodiment 93, wherein the anti-CD20 monoclonal antibody is rituximab or obinutuzumab.
95. The method, mosunetuzumab for use, or use of any one of embodiments 69-94, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior obinutuzumab treatment, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy.
96. The method of any one of embodiments 93-95, wherein the subject has not been treated with obinutuzumab or rituximab for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
97. The mosunetuzumab for use or use of any one of embodiments 93-95, wherein mosunetuzumab and lenalidomide are not to be administered to the subject for at least 4 weeks after the subject has received treatment with an anti-CD20 monoclonal antibody.
98. The method, mosunetuzumab for use, or use of any one of embodiments 69-92, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
99. The method, mosunetuzumab for use, or use of embodiment 98, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
100. The method, mosunetuzumab for use, or use of embodiment 98, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014; 32:1-9).
101. The method, mosunetuzumab for use, or use of any of the preceding embodiments, wherein the FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al.
Blood 2016; 127:2375-90).
102. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
103. Mosunetuzumab for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
104. Use of mosunetuzumab in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
105. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
106. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
30 107. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
108. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
109. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
110. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
111. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
112. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
113. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
30 114. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of the second dosing cycle.
115. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
116. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
117. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
118. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
119. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
120. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single 30 dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of each dosing cycle.
121. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
122. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and 25 (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
123. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and 30 (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
124. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
125. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
126. The method, mosunetuzumab for use, or use of any one of embodiments 102-125, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
127. The method, mosunetuzumab for use, or use of embodiment 126, wherein the anti-CD20 monoclonal antibody is rituximab or obinutuzumab.
128. The method, mosunetuzumab for use, or use of any one of embodiments 102-127, wherein each subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIP!) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
129. The method, mosunetuzumab for use, or use of any one of embodiments 102-128, wherein the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
130. The method of any one of embodiments 102-129, wherein each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
131. The mosunetuzumab for use or use of any one of embodiments 102-129, wherein mosunetuzumab and lenalidomide are not to be administered to each subject for at least 4 weeks after said subject has received treatment with an anti-CD20 monoclonal antibody.
132. The method of any one of embodiments 102-125, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
133. The method of embodiment 132, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
134. The method of embodiment 132, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
135. The method, mosunetuzumab for use, or use of any one of embodiments 102-134, wherein the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects.
136. The method, mosunetuzumab for use, or use of any one of embodiments 102-134, wherein the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects.
137. The method, mosunetuzumab for use, or use of any one of embodiments 102-136, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45%.
138. The method, mosunetuzumab for use, or use of embodiment 137, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 35%.
139. The method, mosunetuzumab for use, or use of embodiment 138, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%.
140. The method, mosunetuzumab for use, or use of any one of embodiments 102-139, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10%.
141. The method, mosunetuzumab for use, or use of embodiment 140, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 5%.
142. The method, mosunetuzumab for use, or use of embodiment 141, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%.
143. The method, mosunetuzumab for use, or use of embodiment 142, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%.
144. The method, mosunetuzumab for use, or use of any one of embodiments 102-143, wherein the incidence rate of neutropenia is less than 40%.
145. The method, mosunetuzumab for use, or use of embodiment 144, wherein the incidence rate of neutropenia is less than 30%.
146. The method, mosunetuzumab for use, or use of embodiment 145, wherein the incidence rate of neutropenia is less than 20%.
147. The method, mosunetuzumab for use, or use of any one of embodiments 102-146, wherein the overall response rate is at least 80%.
148. The method, mosunetuzumab for use, or use of embodiment 147, wherein the overall response rate is at least 90%.
149. The method, mosunetuzumab for use, or use of embodiment 148, wherein the overall response rate is at least 95%.
150. The method, mosunetuzumab for use, or use of embodiment 149, wherein the overall response rate is at least 99%.
151. The method, mosunetuzumab for use, or use of any one of embodiments 102-146, wherein the complete response rate is at least 65%.
152. The method, mosunetuzumab for use, or use of embodiment 151, wherein the complete response rate is at least 75%.
153. The method, mosunetuzumab for use, or use of embodiment 152, wherein the complete response rate is at least 85%.
154. The method, mosunetuzumab for use, or use of any one of embodiments 102-153, wherein the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
155. The method, mosunetuzumab for use, or use of any one of embodiments 1-101, wherein the subject is human.
156. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein each subject in the population is human.
157. The method of any one of embodiments 1-101, wherein the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
158. The mosunetuzumab for use or use of any one of embodiments 1-101, wherein the subject exhibits a reduction in tumor burden after being treated with mosunetuzumab and lenalidomide.
159. The method, mosunetuzumab for use, or use of embodiment 157 or 158, wherein the reduction in tumor burden is determined by computed tomography (CT).
160. The method, mosunetuzumab for use, or use of any one of embodiments 157-159, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
161. The method, mosunetuzumab for use, or use of embodiment 160, wherein the decrease in SPD is at least 40%.
162. The method, mosunetuzumab for use, or use of embodiment 161, wherein the decrease in SPD is at least 60%.
163. The method, mosunetuzumab for use, or use of embodiment 162, wherein the decrease in SPD is at least 80%.
164. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein at least 45% of subjects in the population exhibit a reduction in tumor burden after being administered mosunetuzumab and lenalidomide.
165. The method, mosunetuzumab for use, or use of embodiment 164, wherein at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered mosunetuzumab and lenalidomide.
166. The method, mosunetuzumab for use, or use of embodiment 165, wherein at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
167. The method, mosunetuzumab for use, or use of any one of embodiments 164-166, wherein the reduction in tumor burden is determined by computed tomography (CT).
168. The method, mosunetuzumab for use, or use of any one of embodiments 164-167, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
169. The method, mosunetuzumab for use, or use of embodiment 168, wherein the decrease in SPD is at least 40%.
170. The method, mosunetuzumab for use, or use of embodiment 169, wherein the decrease in SPD is at least 60%.
171. The method, mosunetuzumab for use, or use of embodiment 170, wherein the decrease in SPD is at least 80%.
172. The method, mosunetuzumab for use, or use of any one of embodiments 8-54, wherein the dosing regimen further comprises administration of a corticosteroid.
173. The method, mosunetuzumab for use, or use of embodiment 172, wherein the corticosteroid is administered or is to be administered to the subject during the first dosing cycle.
174. The method, mosunetuzumab for use, or use of embodiment 173, wherein the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid.
175. The method, mosunetuzumab for use, or use of embodiment 174, wherein the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered or are to be administered to the subject on Days 1, 8, and 15, respectively, of the first dosing cycle.
176. The method, mosunetuzumab for use, or use of embodiment 175, wherein each single dose C1D1-C1D3 of the corticosteroid is administered or is to be administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
177. The method, mosunetuzumab for use, or use of any one of embodiments 172-176, wherein the corticosteroid is administered or is to be administered to the subject on the first dosing cycle and not on the second dosing cycle.
178. The method, mosunetuzumab for use, or use of any one of embodiments 172-176, wherein the corticosteroid is administered or is to be administered to the subject on the second dosing cycle.
179. The method, mosunetuzumab for use, or use of embodiment 178, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
180. The method, mosunetuzumab for use, or use of embodiment 179, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subject on Day 1 of the second dosing cycle.
181. The method, mosunetuzumab for use, or use of embodiment 180, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subject before administration of the C2D1 of mosunetuzumab.
182. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein the dosing regimen further comprises administration of a corticosteroid.
183. The method, mosunetuzumab for use, or use of embodiment 182, wherein the corticosteroid is administered or is to be administered to the subjects during the first dosing cycle.
184. The method, mosunetuzumab for use, or use of embodiment 183, wherein the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid.
185. The method, mosunetuzumab for use, or use of embodiment 184, wherein the Cl D1, the Cl D2, and the Cl D3 of the corticosteroid are administered or are to be administered to the subjects on Days 1, 8, and 15, respectively, of the first dosing cycle.
186. The method, mosunetuzumab for use, or use of embodiment 185, wherein each single dose C1D1-C1D3 of the corticosteroid is administered or is to be administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
187. The method, mosunetuzumab for use, or use of any one of embodiments 182-186, wherein the corticosteroid is administered or is to be administered to the subjects on the first dosing cycle and not on the second dosing cycle.
188. The method, mosunetuzumab for use, or use of any one of embodiments 182-186, wherein the corticosteroid is administered or is to be administered to the subjects on the second dosing cycle.
189. The method, mosunetuzumab for use, or use of embodiment 188, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
190. The method, mosunetuzumab for use, or use of embodiment 189, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subjects on Day 1 of the second dosing cycle.
191. The method, mosunetuzumab for use, or use of embodiment 190, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subjects before administration of the C2D1 of mosunetuzumab.
192. The method, mosunetuzumab for use, or use of any one of embodiments 31-33, wherein each additional dosing cycle comprises administration of an additional dose of the corticosteroid.
193. The method, mosunetuzumab for use, or use of embodiment 192, wherein each additional dose of the corticosteroid is administered or is to be administered on Day 1 of each additional dosing cycle.
194. The method, mosunetuzumab for use, or use of embodiment 193, wherein each additional dose of the corticosteroid is administered or is to be administered to the subject before administration of each additional dose of mosunetuzumab.
195. The method, mosunetuzumab for use, or use of any one of embodiments 172-194, wherein the corticosteroid is administered or is to be administered intravenously.
196. The method, mosunetuzumab for use, or use of any one of embodiments 172-195, wherein the corticosteroid is dexamethasone.
197. The method, mosunetuzumab for use, or use of embodiment 196, wherein each dose of dexamethasone is 10 mg.
OTHER EMBODIMENTS
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
30 74. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
75. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
76. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
77. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
78. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
79. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
BO. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
81. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of the second dosing cycle.
82. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
83. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
84. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
85. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
86. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
87. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen that included obinutuzumab; and wherein administering the effective amount of mosunetuzurnab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of each dosing cycle.
88. Mosunetuzumab for use in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
89. Use of mosunetuzumab in combination with lenalidomide in treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
90. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
91. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-012D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
92. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a subject, wherein the subject:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the subject according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
93, The method, mosunetuzumab for use, or use of any one of embodiments 69-92, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
94. The method, mosunetuzumab for use, or use of embodiment 93, wherein the anti-CD20 monoclonal antibody is rituximab or obinutuzumab.
95. The method, mosunetuzumab for use, or use of any one of embodiments 69-94, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Celigny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior obinutuzumab treatment, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy.
96. The method of any one of embodiments 93-95, wherein the subject has not been treated with obinutuzumab or rituximab for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
97. The mosunetuzumab for use or use of any one of embodiments 93-95, wherein mosunetuzumab and lenalidomide are not to be administered to the subject for at least 4 weeks after the subject has received treatment with an anti-CD20 monoclonal antibody.
98. The method, mosunetuzumab for use, or use of any one of embodiments 69-92, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
99. The method, mosunetuzumab for use, or use of embodiment 98, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
100. The method, mosunetuzumab for use, or use of embodiment 98, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J
Clin Oncol 2014; 32:1-9).
101. The method, mosunetuzumab for use, or use of any of the preceding embodiments, wherein the FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al.
Blood 2016; 127:2375-90).
102. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
103. Mosunetuzumab for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
104. Use of mosunetuzumab in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
105. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
106. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
30 107. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of the second dosing cycle.
108. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
109. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
110. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
111. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
112. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
113. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 25 (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-21 of each dosing cycle.
30 114. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of the second dosing cycle.
115. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl D1 is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
116. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
117. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl D1), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
118. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, 30 (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
119. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 21-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab to be administered intravenously on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises daily doses of 20 mg lenalidomide to be administered orally on Days 1-14 of the second dosing cycle.
120. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen that included an anti-CD20 monoclonal antibody; and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single 30 dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-14 of each dosing cycle.
121. Mosunetuzumab for use in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
122. Use of mosunetuzumab in combination with lenalidomide in treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and 25 (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
123. Use of mosunetuzumab in the manufacture of a medicament for use in combination with lenalidomide for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and 30 (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
124. Use of lenalidomide in the manufacture of a medicament for use in combination with mosunetuzumab for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
125. Use of mosunetuzumab and lenalidomide in the manufacture of a medicament for treating a population of subjects, wherein each subject in the population:
(i) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one cherno-immunotherapy regimen;
and wherein mosunetuzumab and lenalidomide are to be administered to the population of subjects according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 21-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of mosunetuzumab to be administered intravenously on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the Cl Dl is 1 mg, the Cl D2 is 2 mg, and the Cl D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzumab to be administered intravenously on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises daily doses of 20 mg lenalidomide to be administered on Days 1-14 of each dosing cycle.
126. The method, mosunetuzumab for use, or use of any one of embodiments 102-125, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
127. The method, mosunetuzumab for use, or use of embodiment 126, wherein the anti-CD20 monoclonal antibody is rituximab or obinutuzumab.
128. The method, mosunetuzumab for use, or use of any one of embodiments 102-127, wherein each subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIP!) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
129. The method, mosunetuzumab for use, or use of any one of embodiments 102-128, wherein the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
130. The method of any one of embodiments 102-129, wherein each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
131. The mosunetuzumab for use or use of any one of embodiments 102-129, wherein mosunetuzumab and lenalidomide are not to be administered to each subject for at least 4 weeks after said subject has received treatment with an anti-CD20 monoclonal antibody.
132. The method of any one of embodiments 102-125, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
133. The method of embodiment 132, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
134. The method of embodiment 132, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
135. The method, mosunetuzumab for use, or use of any one of embodiments 102-134, wherein the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects.
136. The method, mosunetuzumab for use, or use of any one of embodiments 102-134, wherein the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects.
137. The method, mosunetuzumab for use, or use of any one of embodiments 102-136, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading;" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45%.
138. The method, mosunetuzumab for use, or use of embodiment 137, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 35%.
139. The method, mosunetuzumab for use, or use of embodiment 138, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 25%.
140. The method, mosunetuzumab for use, or use of any one of embodiments 102-139, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 10%.
141. The method, mosunetuzumab for use, or use of embodiment 140, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 5%.
142. The method, mosunetuzumab for use, or use of embodiment 141, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%.
143. The method, mosunetuzumab for use, or use of embodiment 142, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%.
144. The method, mosunetuzumab for use, or use of any one of embodiments 102-143, wherein the incidence rate of neutropenia is less than 40%.
145. The method, mosunetuzumab for use, or use of embodiment 144, wherein the incidence rate of neutropenia is less than 30%.
146. The method, mosunetuzumab for use, or use of embodiment 145, wherein the incidence rate of neutropenia is less than 20%.
147. The method, mosunetuzumab for use, or use of any one of embodiments 102-146, wherein the overall response rate is at least 80%.
148. The method, mosunetuzumab for use, or use of embodiment 147, wherein the overall response rate is at least 90%.
149. The method, mosunetuzumab for use, or use of embodiment 148, wherein the overall response rate is at least 95%.
150. The method, mosunetuzumab for use, or use of embodiment 149, wherein the overall response rate is at least 99%.
151. The method, mosunetuzumab for use, or use of any one of embodiments 102-146, wherein the complete response rate is at least 65%.
152. The method, mosunetuzumab for use, or use of embodiment 151, wherein the complete response rate is at least 75%.
153. The method, mosunetuzumab for use, or use of embodiment 152, wherein the complete response rate is at least 85%.
154. The method, mosunetuzumab for use, or use of any one of embodiments 102-153, wherein the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
155. The method, mosunetuzumab for use, or use of any one of embodiments 1-101, wherein the subject is human.
156. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein each subject in the population is human.
157. The method of any one of embodiments 1-101, wherein the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
158. The mosunetuzumab for use or use of any one of embodiments 1-101, wherein the subject exhibits a reduction in tumor burden after being treated with mosunetuzumab and lenalidomide.
159. The method, mosunetuzumab for use, or use of embodiment 157 or 158, wherein the reduction in tumor burden is determined by computed tomography (CT).
160. The method, mosunetuzumab for use, or use of any one of embodiments 157-159, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
161. The method, mosunetuzumab for use, or use of embodiment 160, wherein the decrease in SPD is at least 40%.
162. The method, mosunetuzumab for use, or use of embodiment 161, wherein the decrease in SPD is at least 60%.
163. The method, mosunetuzumab for use, or use of embodiment 162, wherein the decrease in SPD is at least 80%.
164. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein at least 45% of subjects in the population exhibit a reduction in tumor burden after being administered mosunetuzumab and lenalidomide.
165. The method, mosunetuzumab for use, or use of embodiment 164, wherein at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered mosunetuzumab and lenalidomide.
166. The method, mosunetuzumab for use, or use of embodiment 165, wherein at least 75% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
167. The method, mosunetuzumab for use, or use of any one of embodiments 164-166, wherein the reduction in tumor burden is determined by computed tomography (CT).
168. The method, mosunetuzumab for use, or use of any one of embodiments 164-167, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
169. The method, mosunetuzumab for use, or use of embodiment 168, wherein the decrease in SPD is at least 40%.
170. The method, mosunetuzumab for use, or use of embodiment 169, wherein the decrease in SPD is at least 60%.
171. The method, mosunetuzumab for use, or use of embodiment 170, wherein the decrease in SPD is at least 80%.
172. The method, mosunetuzumab for use, or use of any one of embodiments 8-54, wherein the dosing regimen further comprises administration of a corticosteroid.
173. The method, mosunetuzumab for use, or use of embodiment 172, wherein the corticosteroid is administered or is to be administered to the subject during the first dosing cycle.
174. The method, mosunetuzumab for use, or use of embodiment 173, wherein the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid.
175. The method, mosunetuzumab for use, or use of embodiment 174, wherein the Cl Dl, the Cl D2, and the Cl D3 of the corticosteroid are administered or are to be administered to the subject on Days 1, 8, and 15, respectively, of the first dosing cycle.
176. The method, mosunetuzumab for use, or use of embodiment 175, wherein each single dose C1D1-C1D3 of the corticosteroid is administered or is to be administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
177. The method, mosunetuzumab for use, or use of any one of embodiments 172-176, wherein the corticosteroid is administered or is to be administered to the subject on the first dosing cycle and not on the second dosing cycle.
178. The method, mosunetuzumab for use, or use of any one of embodiments 172-176, wherein the corticosteroid is administered or is to be administered to the subject on the second dosing cycle.
179. The method, mosunetuzumab for use, or use of embodiment 178, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
180. The method, mosunetuzumab for use, or use of embodiment 179, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subject on Day 1 of the second dosing cycle.
181. The method, mosunetuzumab for use, or use of embodiment 180, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subject before administration of the C2D1 of mosunetuzumab.
182. The method, mosunetuzumab for use, or use of any one of embodiments 102-154, wherein the dosing regimen further comprises administration of a corticosteroid.
183. The method, mosunetuzumab for use, or use of embodiment 182, wherein the corticosteroid is administered or is to be administered to the subjects during the first dosing cycle.
184. The method, mosunetuzumab for use, or use of embodiment 183, wherein the first dosing cycle comprises a first dose (Cl Dl), a second dose (Cl D2), and a third dose (Cl D3) of the corticosteroid.
185. The method, mosunetuzumab for use, or use of embodiment 184, wherein the Cl D1, the Cl D2, and the Cl D3 of the corticosteroid are administered or are to be administered to the subjects on Days 1, 8, and 15, respectively, of the first dosing cycle.
186. The method, mosunetuzumab for use, or use of embodiment 185, wherein each single dose C1D1-C1D3 of the corticosteroid is administered or is to be administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
187. The method, mosunetuzumab for use, or use of any one of embodiments 182-186, wherein the corticosteroid is administered or is to be administered to the subjects on the first dosing cycle and not on the second dosing cycle.
188. The method, mosunetuzumab for use, or use of any one of embodiments 182-186, wherein the corticosteroid is administered or is to be administered to the subjects on the second dosing cycle.
189. The method, mosunetuzumab for use, or use of embodiment 188, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
190. The method, mosunetuzumab for use, or use of embodiment 189, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subjects on Day 1 of the second dosing cycle.
191. The method, mosunetuzumab for use, or use of embodiment 190, wherein the C2D1 of the corticosteroid is administered or is to be administered to the subjects before administration of the C2D1 of mosunetuzumab.
192. The method, mosunetuzumab for use, or use of any one of embodiments 31-33, wherein each additional dosing cycle comprises administration of an additional dose of the corticosteroid.
193. The method, mosunetuzumab for use, or use of embodiment 192, wherein each additional dose of the corticosteroid is administered or is to be administered on Day 1 of each additional dosing cycle.
194. The method, mosunetuzumab for use, or use of embodiment 193, wherein each additional dose of the corticosteroid is administered or is to be administered to the subject before administration of each additional dose of mosunetuzumab.
195. The method, mosunetuzumab for use, or use of any one of embodiments 172-194, wherein the corticosteroid is administered or is to be administered intravenously.
196. The method, mosunetuzumab for use, or use of any one of embodiments 172-195, wherein the corticosteroid is dexamethasone.
197. The method, mosunetuzumab for use, or use of embodiment 196, wherein each dose of dexamethasone is 10 mg.
OTHER EMBODIMENTS
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.
Claims (125)
1 . A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one cherno-immunotherapy regimen.
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one cherno-immunotherapy regimen.
2. The method of claim 1, wherein at least one cherno-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
3. The method of claim 1 or 2, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Céligny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI; Solal-Céligny et al.. Blood. 2004; 104 (5): 1258-1265.) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatment, or (c) has disease progression within 24 months after initiation of prior therapy.
4. The method of claim 2 or 3, wherein the subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
5. The method of claim 1, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
6. The method of claim 5, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
7. The method of claim 5, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
8. The method of any of the preceding claims, wherein administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising at least a first dosing cycle and a second dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab, wherein the C1D1 and the C1D2 are each no greater than the C1D3, and wherein the C1D1 is between 0.02 mg to 4.0 mg, the C1D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the C1D3 and is between 0.2 mg to 50 mg.
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab, wherein the C1D1 and the C1D2 are each no greater than the C1D3, and wherein the C1D1 is between 0.02 mg to 4.0 mg, the C1D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab, wherein the C2D1 is equal to or greater than the C1D3 and is between 0.2 mg to 50 mg.
9. The method of claim 8, wherein:
(a) the C1D1 is between 0.4 mg to 4.0 mg, the C1D2 is between 1.0 mg to 20.0 mg, and the 01D3 is between 3.0 mg to 50.0 mg; and (b) the C2D1 is between 3.0 mg to 50.0 mg.
(a) the C1D1 is between 0.4 mg to 4.0 mg, the C1D2 is between 1.0 mg to 20.0 mg, and the 01D3 is between 3.0 mg to 50.0 mg; and (b) the C2D1 is between 3.0 mg to 50.0 mg.
10. The method of claim 8 or 9, wherein:
(a) the C1D1 is between 0.8 mg to 3.0 mg, the C1D2 is between 1.0 mg to 6.0 mg, and the 01D3 is between 3.0 mg to 45.0 mg; and (b) the C2D1 is between 3.0 mg to 45.0 mg.
(a) the C1D1 is between 0.8 mg to 3.0 mg, the C1D2 is between 1.0 mg to 6.0 mg, and the 01D3 is between 3.0 mg to 45.0 mg; and (b) the C2D1 is between 3.0 mg to 45.0 mg.
11. The method of any one of claims 8-10, wherein the 01D1 and 01D2 are each less than the C1D3.
12. The method of any one of claims 8-10, wherein the C1D2 is greater than the C1D1 by about 50% to about 250%.
13. The method of any one of claims 8-10, wherein:
(a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, and the 01D3 is 4.2 mg, and the is 4.2 mg;
(b) the C1D1 is 1.0 mg, the 01D2 is 1.0 mg, and the 01D3 is 3.0 mg, and the is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, and the 01D3 is 30.0 mg, and the is 30.0 mg.
(a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, and the 01D3 is 4.2 mg, and the is 4.2 mg;
(b) the C1D1 is 1.0 mg, the 01D2 is 1.0 mg, and the 01D3 is 3.0 mg, and the is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, and the 01D3 is 30.0 mg, and the is 30.0 mg.
14. The method of any one of claims 8-13, wherein the length of the first dosing cycle is 21 days.
15. The method of claim 14, wherein the method comprises administering to the subject the C1D1, the C1D2, and the C1D3 on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
16. The method of any one of claims 8-15, wherein the length of the second dosing cycle is 28 days.
17. The method of claim 16, wherein the method comprises administering to the subject the C2D1 on Day 1 of the second dosing cycle.
18. The method of any one of claims 8-17, wherein the dosing regimen comprises one or more additional dosing cycles.
19. The method of claim 18, wherein the dosing regimen comprises one to ten additional dosing cycles.
20. The method of claim 18 or 19, wherein the dosing regimen comprises ten additional dosing cycles.
21. The method of any one of claims 18-20, wherein the length of each of the one or more additional dosing cycles is 28 days.
22. The method of any one of claims 18-21, wherein each of the one or more additional dosing cycles comprises an additional dose of mosunetuzumab.
23. The method of claim 22, wherein the method comprises administering to the subject each additional dose of mosunetuzumab on Day 1 of each of the one or more additional dosing cycles.
24. The method of any one of claims 1-7, wherein administering the effective amount of mosunetuzumab comprises administering mosunetuzumab according to a dosing regimen comprising twelve dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (01D1), a second dose (C1D2), and a third dose (01D3) of mosunetuzumab, wherein the 01D1 and the C1D2 are each no greater than the C1D3, and wherein the 01D1 is between 0.02 mg to 4.0 mg, the 01D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
(a) the first dosing cycle comprises a first dose (01D1), a second dose (C1D2), and a third dose (01D3) of mosunetuzumab, wherein the 01D1 and the C1D2 are each no greater than the C1D3, and wherein the 01D1 is between 0.02 mg to 4.0 mg, the 01D2 is between 0.05 mg to 20.0 mg, and the C1D3 is between 0.2 mg to 50.0 mg; and (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-C12D1) of mosunetuzumab, wherein each single dose C2D1-C12D1 are equivalent in amount, is equal to or greater than the C1D3, and is between 0.2 mg to 50 mg.
25. The method of claim 24, wherein:
(a) the C1D1 is between 0.4 mg to 4.0 mg, the 01D2 is between 1.0 mg to 20.0 mg, and the 01D3 is between 3.0 mg to 50.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg.
(a) the C1D1 is between 0.4 mg to 4.0 mg, the 01D2 is between 1.0 mg to 20.0 mg, and the 01D3 is between 3.0 mg to 50.0 mg; and (b) each single dose C2D1-C12D1 is between 3.0 mg to 50.0 mg.
26. The method of claim 24 or 25, wherein:
(a) the C1D1 is between 0.8 mg to 3.0 mg, the C1D2 is between 1.0 mg to 6.0 mg, and the 01D3 is between 3.0 mg to 45.0 mg; and (b) each single dose C2D1-012D1 is between 3.0 mg to 45.0 mg.
(a) the C1D1 is between 0.8 mg to 3.0 mg, the C1D2 is between 1.0 mg to 6.0 mg, and the 01D3 is between 3.0 mg to 45.0 mg; and (b) each single dose C2D1-012D1 is between 3.0 mg to 45.0 mg.
27. The method of any one of claims 24-26, wherein the 01D1 and 01D2 are each less than the C1D3.
28. The method of any one of claims 24-26, wherein the 01D2 is greater than the 01D1 by about 50% to about 250%.
29. The method of any one of claims 24-26, wherein:
(a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, and the 01D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg;
(b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, and the C1D3 is 3.0 mg, and each single dose 02D1-012D1 is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, and the C1D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
(a) the C1D1 is 0.8 mg, the C1D2 is 2.0 mg, and the 01D3 is 4.2 mg, and each single dose C2D1-C12D1 is 4.2 mg;
(b) the C1D1 is 1.0 mg, the C1D2 is 1.0 mg, and the C1D3 is 3.0 mg, and each single dose 02D1-012D1 is 30.0 mg; or (c) the C1D1 is 1.0 mg, the C1D2 is 2.0 mg, and the C1D3 is 30.0 mg, and each single dose C2D1-C12D1 is 30.0 mg.
30. The method of any one of claims 24-29, wherein the length of the first dosing cycle is 21 days.
31. The method of claim 30, wherein the method comprises administering to the subject the 01D1, the 01D2, and the C1D3 on or about Days 1, 8, and 15, respectively, of the first dosing cycle.
32. The method of any one of claims 24-31, wherein the length of each of the second to twelfth dosing cycles is 28 days.
33. The method of claim 32, wherein the method comprises administering to the subject each of the C2D1-C12D1 on Day 1 of each respective dosing cycle.
34. The method of any one of claims 24-33, wherein the length of each of the second to twelfth dosing cycles is 28 days.
35. The method of any of the preceding claims, wherein mosunetuzumab is administered intravenously.
36. The method of any one of claims 8-35, wherein lenalidomide is administered during the second and subsequent cycles.
37. The method of any one of claims 8-36, wherein lenalidomide is not administered during the first cycle.
38. The method of any one of claims 8-37, wherein lenalidomide is administered daily.
39. The method of any one of claims 36-38, wherein lenalidomide is administered daily on the first 21 days of each dosing cycle comprising administration of lenalidomide.
40. The method of claim 39, wherein lenalidomide is not administered on the last 7 days of each dosing cycle comprising administration of lenalidomide.
41. The method of any one of claims 8-40, wherein lenalidomide is administered at a dose of 20 rng.
42. The method of any of the preceding claims, wherein lenalidomide is administered orally.
43. The method of any of the preceding claims, wherein the subject was previously treated with at least one anti-CD20 monoclonal antibody.
44. The method of claim 43, wherein the subject is relapsed or refractory to the treatment comprising the anti-CD20 monoclonal antibody.
45. The method of claim 43 or 44, wherein the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
46. A rnethod of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphorna (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (01D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
(i) has relapsed or refractory follicular lymphorna (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (01D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
47. A method of treating a subject, comprising administering to the subject an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein the subject:
(i) has relapsed or refractory follicular lymphorna (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzurnab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the 01D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzurnab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
(i) has relapsed or refractory follicular lymphorna (R/R FL) that expresses CD20, and (ii) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzurnab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the 01D3 is 30 mg, (b) the second to twelfth dosing cycles each comprise a single dose (C2D1-C12D1) of mosunetuzurnab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
48. The method of any one of claims 45-47, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
49. The method of any one of claims 45-48, wherein the subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic index (FLIPI) score of 2-5, (b) has been refractory to prior obinutuzumab treatrnent, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy.
(a) has a Follicular Lymphoma International Prognostic index (FLIPI) score of 2-5, (b) has been refractory to prior obinutuzumab treatrnent, (c) has been refractory to prior rituximab treatment, or (d) has disease progression within 24 months after initiation of prior therapy.
50. The method of any one of claims 45-49, wherein the subject has not been treated with obinutuzumab or rituximab for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
51. The method of any one of claims 45-49, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
52. The method of claim 51, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
53. The method of claim 51, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
54. The method of any of the preceding claims, wherein the FL is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al. Blood 2016; 127:2375-90).
55. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (01D1), a second dose (01D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising at least a first 21-day dosing cycle and a second 28-day dosing cycle, wherein:
(a) the first dosing cycle comprises a first dose (01D1), a second dose (01D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab intravenously administered on Day 1 of the second dosing cycle, wherein the C2D1 is 30 mg, and (c) the second dosing cycle further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
56. A method of treating a population of subjects, comprising administering to each subject in the population an effective amount of mosunetuzumab and an effective amount of lenalidomide, wherein each subject:
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (01D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-012D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
(a) has relapsed or refractory follicular lymphoma (R/R FL) that expresses CD20, and (b) has been previously treated with at least one chemo-immunotherapy regimen;
and wherein administering the effective amount of mosunetuzumab and lenalidomide comprises administering mosunetuzumab and lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and eleven subsequent 28-day dosing cycles, wherein:
(a) the first dosing cycle comprises a first dose (01D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab intravenously administered on Days 1, 8, and 15, respectively, of the first dosing cycle, wherein the C1D1 is 1 mg, the C1D2 is 2 mg, and the C1D3 is 30 mg, (b) the second to twelfth dosing cycles each comprises a single dose (C2D1-012D1) of mosunetuzumab intravenously administered on Day 1 of each dosing cycle, wherein each single dose C2D1-C12D1 is 30 mg, and (c) the second to twelfth dosing cycles each further comprises orally administering 20 mg lenalidomide daily on Days 1-21 of each dosing cycle.
57. The method of claim 55 or 56, wherein at least one chemo-immunotherapy regimen comprises an anti-CD20 monoclonal antibody.
58. The method of any one of claims 55-57, wherein each subject has received only one prior line of systemic therapy and either:
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatrnent, or (c) has disease progression within 24 months after initiation of prior therapy.
(a) has a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5, (b) has been refractory to prior anti-CD20 monoclonal antibody treatrnent, or (c) has disease progression within 24 months after initiation of prior therapy.
59. The method of any one of claims 55-58, wherein the FL of each subject is histologically documented as Grade 1, 2, or 3a, but not 3b according to the World Health Organization classification of lymphoid neoplasms (as referenced in Swerdlow SH, et al.
Blood 2016; 127:2375-90).
Blood 2016; 127:2375-90).
60. The method of any one of claims 57-59, wherein each subject has not been treated with the anti-CD20 monoclonal antibody for at least 4 weeks prior to being administered the effective amount of mosunetuzumab and lenalidomide.
61. The method of claim 60, wherein mosunetuzumab and lenalidomide have a synergistic effect on the R/R FL.
62. The method of claim 61, wherein the synergistic effect is a partial response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin 0nc012014; 32:1-9).
63. The method of claim 61, wherein the synergistic effect is a complete response, as defined by Lugano 2014 criteria (Cheson BD, et al. J Clin Oncol 2014; 32:1-9).
64. The method of any one of claims 55-63, wherein the incidence of an adverse event is not significantly higher than if mosunetuzumab was administered alone to the population of subjects.
65. The method of any one of claims 55-63, wherein the incidence of an adverse event is not significantly higher than if lenalidomide is not administered to the population of subjects.
66. The method of any one of claims 55-65, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading:" Lee et al., Biol Blood Marrow Transplant 2019) is less than 45%.
67. The method of claim 66, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 35%.
68. The method of claim 67, wherein the incidence rate of cytokine release syndrome as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 25%.
69. The method of any one of claims 55-68, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS
grading") is less than 10%.
grading") is less than 10%.
70. The method of claim 69, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 50/0.
71. The method of claim 70, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 3%.
72. The method of claim 71, wherein the incidence rate of cytokine release syndrome having a grade of 3 or higher as defined by the American Society of Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine-Release Syndrome ("ASTCT CRS grading") is less than 1%.
73. The method of any one of claims 55-72, wherein the incidence rate of neutropenia is less than 40%.
74. The method of claim 73, wherein the incidence rate of neutropenia is less than 30%.
75. The method of claim 74, wherein the incidence rate of neutropenia is less than 20%.
76. The method of any one of claims 55-75, wherein the overall response rate is at least 80%.
77. The method of claim 76, wherein the overall response rate is at least 90%.
78. The method of claim 77, wherein the overall response rate is at least 95%.
79. The method of claim 78, wherein the overall response rate is at least 99%.
80. The method of any one of claims 55-75, wherein the complete response rate is at least 65%.
81. The method of claim 80, wherein the complete response rate is at least 75%.
82. The method of claim 81, wherein the complete response rate is at least 85%.
83. The method of any one of claims 55-82, wherein the anti-CD20 monoclonal antibody is obinutuzumab or rituximab.
84. The method of any one of claims 1-54, wherein the subject is human.
85. The method of any one of claims 55-83, wherein each subject in the population is human.
86. The method of any one of claims 1-54, wherein the subject exhibits a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
87. The method of claim 86, wherein the reduction in tumor burden is determined by computed tomography (CT).
88. The method of claim 86 or 87, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
89. The method of claim 88, wherein the decrease in SPD is at least 40%.
90. The method of claim 89, wherein the decrease in SPD is at least 60%.
91. The method of claim 90, wherein the decrease in SPD is at least 80%.
92. The method of any one of claims 55-83, wherein at least 45% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
93. The method of claim 92, wherein at least 60% of subjects in the population exhibit a reduction in tumor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
94. The method of claim 93, wherein at least 75% of subjects in the population exhibit a reduction in turnor burden after being administered an effective amount of mosunetuzumab and an effective amount of lenalidomide.
95. The method of any one of claims 92-94, wherein the reduction in tumor burden is determined by computed tomography (CT).
96. The method of any one of claims 92-95, wherein the reduction in tumor burden is a decrease in the sum of the product of the diameters (SPD) of target lesions.
97. The method of claim 96, wherein the decrease in SPD is at least 40%.
98. The method of claim 97, wherein the decrease in SPD is at least 60%.
99. The method of claim 98, wherein the decrease in SPD is at least 80%.
100. The method of any one of claims 8-54, wherein the dosing regimen further comprises administration of a corticosteroid.
101. The method of claim 100, wherein the corticosteroid is administered to the subject during the first dosing cycle.
102. The method of claim 101, wherein the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of the corticosteroid.
103. The method of claim 102, wherein the C1D1, the 01D2, and the C1D3 of the corticosteroid are administered to the subject on Days 1, 8, and 15, respectively, of the first dosing cycle.
104. The method of claim 103, wherein each single dose C1D1-01D3 of the corticosteroid is administered to the subject before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
105. The method of any one of claims 100-104, wherein the corticosteroid is administered to the subject on the first dosing cycle and not on the second dosing cycle.
106. The method of any one of claims 100-104, wherein the corticosteroid is administered to the subject on the second dosing cycle.
107. The method of claim 106, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
108. The method of claim 107, wherein the C2D1 of the corticosteroid is administered to the subject on Day 1 of the second dosing cycle.
109. The method of claim 108, wherein the C2D1 of the corticosteroid is administered to the subject before administration of the C2D1 of mosunetuzumab.
110. The method of any one of claims 55-83, wherein the dosing regimen further comprises administration of a corticosteroid.
111. The method of claim 110, wherein the corticosteroid is administered to the subjects during the first dosing cycle.
112. The method of claim 111, wherein the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (01D3) of the corticosteroid.
113. The method of claim 112, wherein the C1D1, the C1D2, and the C1D3 of the corticosteroid are administered to the subjects on Days 1, 8, and 15, respectively, of the first dosing cycle.
114. The method of claim 113, wherein each single dose C1D1-C1D3 of the corticosteroid is administered to the subjects before administration of the C1D1-C1D3, respectively, of mosunetuzumab.
115. The method of any one of claims 110-114, wherein the corticosteroid is administered to the subjects on the first dosing cycle and not on the second dosing cycle.
116. The method of any one of claims 110-115, wherein the corticosteroid is administered to the subjects on the second dosing cycle.
117. The method of claim 116, wherein the second dosing cycle comprises a single dose (C2D1) of the corticosteroid.
118. The method of claim 117, wherein the C2D1 of the corticosteroid is administered to the subjects on Day 1 of the second dosing cycle.
119. The method of claim 118, wherein the C2D1 of the corticosteroid is administered to the subjects before administration of the C2D1 of mosunetuzumab.
120. The method of claim 22 or 23, wherein each additional dosing cycle comprises administering to the subject an additional dose of the corticosteroid.
121. The method of claim 120, wherein each additional dose of the corticosteroid is administered on Day 1 of each additional dosing cycle.
122. The method of claim 121, wherein each additional dose of the corticosteroid is administered to the subject before administration of each additional dose of mosunetuzumab.
123. The method of any one of claims 100-122, wherein the corticosteroid is administered intravenously.
124. The method of any one of claims 100-123, wherein the corticosteroid is dexamethasone.
125. The method of claim 124, wherein each dose of dexamethasone is 10 mg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/057439 WO2023075798A1 (en) | 2021-10-29 | 2021-10-29 | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3236111A1 true CA3236111A1 (en) | 2023-05-04 |
Family
ID=86158448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3236111A Pending CA3236111A1 (en) | 2021-10-29 | 2021-10-29 | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2021471006A1 (en) |
CA (1) | CA3236111A1 (en) |
WO (1) | WO2023075798A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202108178A (en) * | 2019-05-14 | 2021-03-01 | 美商建南德克公司 | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA |
-
2021
- 2021-10-29 AU AU2021471006A patent/AU2021471006A1/en active Pending
- 2021-10-29 WO PCT/US2021/057439 patent/WO2023075798A1/en active Application Filing
- 2021-10-29 CA CA3236111A patent/CA3236111A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023075798A1 (en) | 2023-05-04 |
AU2021471006A1 (en) | 2024-05-16 |
WO2023075798A9 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10544223B2 (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
US11583577B2 (en) | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens | |
US20200216542A1 (en) | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent | |
CN110636861A (en) | Synergistic therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer | |
KR20220020331A (en) | Combination therapy comprising an anti-CD25 antibody drug conjugate and an additional agent | |
US20220305132A1 (en) | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent | |
US20230190932A1 (en) | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide | |
CA3236111A1 (en) | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide | |
CA3196191A1 (en) | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates | |
TW202348626A (en) | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide | |
US20240043553A1 (en) | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide | |
US20220411528A1 (en) | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin | |
US20220380466A1 (en) | Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies | |
US20230416391A1 (en) | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patients | |
TW202409075A (en) | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide | |
CA3223534A1 (en) | Methods and compositions for treating cancer | |
WO2022074033A1 (en) | Combination therapy |